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 A physiologically – based pharmacokinetic model has been developed to examine 
the effects of organophosphates on the levels of acetylcholine in different tissues 
throughout the mammalian body.  Many organophosphate-like chemical and kinetic 
characteristics are tested without reference to a specific chemical.  Characteristics include 
partition coefficients, metabolic constants, the inhibition coefficient which determines the 
rate free AChE is bound by an organophosphate and becomes inhibited AChE, the aging 
rate which determines the rate in which the bond between AChE and the 
organophosphate become permanent, and the regeneration rate which determines the rate 
where the bound AChE is separated from the organophosphate and becomes free AChE 
once again.  Two separate exposure scenarios are tested and compared against a baseline.  
The baseline consists of a direct inhalation exposure which allows 100 percent of the 
organophosphate to enter into the blood stream via blood – gas exchange.  The first 
exposure scenario examines the effects of bronchial scrubbing (via inhalation) of a 
fraction of the inhaled agent with direct absorption into bronchial tissue under different 
exposure conditions and compares them with the inhalation exposures.  The second 
scenario is a study of dermal exposures and compares the levels of ACh in the different 
tissues with those in the inhalation (baseline) tests. 
 Organophosphates that are absorbed directly into the bronchial tissue exhibit little 
variation on the levels of ACh buildup in any of the tissue groups tested when compared 
to the inhalation exposures.  No matter what the scrubbing coefficient used, or the 
  v 
combination of the parameters (partition coefficients, inhibition coefficient, aging rate, 
and regeneration rate) values, the change in ACh was minimal.  This suggests that the 
scrubbing of the chemical as it passes through the airway does not help the individual 
being exposed.  The changes are so minor that the individual will experience the same 
symptoms whether bronchial scrubbing takes place or not. 
 The results showed different behavior between inhalation and dermal exposures.  
The levels of ACh present in the liver, kidneys, brain, slowly perfused tissue, richly 
perfused tissue, and diaphragm were lower with the dermal tests.  These results suggest 
that an individual may have additional time to don protective equipment before the levels 
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I.  Introduction 
Introduction 
 Organophosphates have been around for a long time.  Pesticides are the most 
commonly used organophosphates, both residentially and commercially.  In the 1940’s, 
chemists in Germany developed organophosphates that were much stronger than the 
everyday pesticide.  These chemists discovered that a country could use these 
organophosphates as a weapon to create a great deal of destruction, panic, and terror on 
an enemy.  Since that time, many countries have been looking at ways to defend 
themselves against these select organophosphates. 
Background 
In the 1900s, the understanding of chemistry exploded in Europe bringing about 
organophosphate compounds that could be used as effective military weapons. German 
chemists developed three different agents called tabun, sarin, and soman.  After World 
War II, NATO designated these agents GA, GB, and GD respectively (G standing for 
German).  Two other chemicals designated by initials are VX (V standing for venomous) 
and GF.  Great Britain developed the VX agent and the United States of America was 
able to weaponize it.  The world began stockpiling these deadly agents, or nerve agents, 
and they began to surface during military conflicts and terrorist attacks against civilian 
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populations (Costa, 2005, Cannard, 2006).  Nerve agents are a colorless, mostly odorless 
liquid, not a gas, as popular beliefs suggest.  A common delivery method is to use an 
explosion or crop duster to aerosolize or vaporize the liquid into the air (Cannard, 2006).  
By using this type of delivery method, the enemy can expose the highest number of 
people possible and create a much larger contamination zone.  Achieving the same affects 
in its liquid form is far more difficult.  Putting the agent into the air makes inhalation the 
most common route of entry to the body. 
Due to the adverse affects of organophosphates, human experiments are unethical 
to conduct.  However, there are several instances throughout history where nerve agents 
have been used on human populations, such as the subway bombing in Tokyo and 
Matsumoto, Japan.  Data can be and has been collected from those samples (Nishiwaki 
2001, Yanagisawa, 1995).  Currently, the best source showing the effects 
organophosphates have on mammals comes from experiments performed on laboratory 
animals.  Scientists can then scale those results to the human body (Aurbek, 2006) and 
make predictions as to how it will react.  To overcome the deficiency of human subjects 
in determining the effects of nerve agents, the use of modeling can be of great help.  
Physiologically-based pharmacokinetic (PBPK) models show a representation of how 
organophosphates react with different body tissues.  This type of modeling is valuable 
because it shows the hazards of the different routes of entry, such as inhalation, oral, or 
dermal (Shelley, 1996).  There are limitations to modeling in that, although rats, mice and 
pigs are all mammalian, their genetic makeup is different from humans.  This can cause 
problems in the scaling process from the animal tests to human kinetics (Cannard, 2006, 
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Gearhart, 1994).  Animal data, however, can give a good indication of how the agents 
decompose in the body by natural processes (metabolism), the levels of toxicity in the 
various tissues, and how fast they recover.  PBPK models can also overcome some of the 
scaling problems from one species to another. 
Surviving a nerve agent attack is possible.  Historical events have given us human 
experiences with these deadly agents.  A good example is the attack in Tokyo, Japan.  In 
this case, 1,050 humans were exposed and only 12 died.  The deaths were caused by 
either acute exposure or hypoxic injury prior to reaching the hospital.  The attack was not 
an ideal scenario; the sarin used was relatively diluted and dispersed in an ineffective 
manner.  This event may not accurately predict future attacks (Cannard, 2006), but does 
give a level of insight as to how the body will react in a real life situation. 
Problem Statement 
As service members fight for their country and for the freedom of those in other 
countries, it is imperative that they return home both mentally and physically healthy.  
Currently, the United States is fighting in places where the enemy is using more and more 
innovative weapons (dirty bombs or improvised explosive devices).  A soldier being able 
to protect himself from these types of weapons has become a high priority on today’s 
battlefields.  The likelihood that the enemy may obtain a crude type of nerve agent from 
the many rogue organizations (whether legitimate governments or terrorist cells) around 
the world is not inconceivable.  It is important that these soldiers know the best ways to 
protect themselves if the enemy obtains and attacks with these agents. 
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Organophosphates, particularly nerve agents, are some of the deadliest substances 
on earth.  Their effects to the body materialize very quickly, and, if the victim does not 
receive treatment in a timely manner, serious long-term effects or death can occur.  In 
this study, a physiologically-based pharmacokinetic model is developed to model the 
effects of exposure.  Once this is accomplished, exploration of the model to compare the 
different routes of entry into the body as well as looking at the levels of acetylcholine that 
is produced and accumulated in the different tissues groups. 
In the case of death, literature agrees that the cause is mainly from respiratory 
failure due to the paralysis of a combination of the respiratory muscles from acute 
exposure.  Therefore, the bulk of this research will be looking at lower doses of exposure 
and how they affect acetylcholine levels in specific tissues.  The different tissues groups 
that are incorporated into the model will be the brain, liver, kidney, fat, diaphragm, 
arterial blood, venous blood, bronchial passages, and the skin.  The remaining tissues will 
be lumped together as either slowly or richly perfused tissues. 
Research Question 
 The main purpose of this study is to answer the following question: How do the 
kinetics and the distribution of organophosphates affect the target tissue’s level of 




This study will investigate several questions.  These questions deal with how the 
organophosphate is absorbed into the body and what type of effects will be encountered. 
 Can a reasonable model concept be formulated to represent OP kinetics relevant 
to action and toxicological target tissues? 
 What are the levels of acetylcholine (ACh) in target tissues as a resulting from 
different exposure possibilities? 
 Does bronchial scrubbing have an effect on how fast the actual concentrations of 
the tissues reach maximum or steady state levels? 
 Does dermal absorption kinetics differ from those of inhalation and if so how 
fast/slow does it take for the concentrations of the tissues to reach the 
maximum/steady state levels? 
 What trends can be seen (if any) in the ACh levels with the different exposures? 
These questions are of particular importance because if answered, they can provide 
valuable information to those in the field who need decision tools for optimizing 
available treatments to avoid death and/or severe long-term effects. 
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II. Literature Review 
What are organophosphates 
 Organophosphates have been around since the 1800s.  It was not until the late 
1930s, early 1940s when organophosphates were developed and used as insecticides 
(Costa, 2005).  These agents were then further developed as a weapon, whose primary 
effect is on the central nervous system.  These agents are tabun, sarin, soman, and VX.  
They have been designated as “nerve agents” by NATO, which fall into the class of 
weapon of mass destruction.  Weapons of mass destruction are nothing new, they have 
been a threat and used since the early 1900s.  One of the earliest recordings in the modern 
era is in 1915 when German forces used chlorine gas on opposing French troops, causing 
anywhere from 5,000 to 10,000 casualties.  The general chemical makeup of an 
organophosphate or nerve agent (Figure 1 and Table 1) contains a central phosphorous 
atom bound to an oxygen (or sulfur) atom, two alkyl groups, and a leaving group 
(Cannard, 2006). 
 Compounds that contain a sulfur atom require a metabolic bioactivation whereas; 
compounds that contain a phosphorous – oxygen bond are effective inhibitors of 
acetylcholinesterase (Costa, 2005).  The carbon-phosphorous bond is fairly common to 
nerve agents but is rarely found in their pesticide cousins (Augerson, 2000). 
 
Figure 1.  Basic Structure of Nerve Agent.  R1 and 
R2 are the alkyl groups and X is the leaving group. 
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Table 1.  Nerve Agent Chemical Structure 
Agent X R1 R2 
Tabun (GA) CN N(CH3)2 C2H5 
Sarin (GB) F CH3 CH(CH3)2 
Soman (GD) F CH3 CH(CH3)C(CH)3 
VX SCH2CH2N[CH(CH3)2]2 CH3 C2H5 
Source: Augerson, 2000 
Note: Keyed to Figure 1 
 
 There are a variety of organophosphates that will be discussed throughout this 
study.  Each one of them varies in toxicity and properties.  Some of the properties are 
similar (all of the nerve agents are a liquid) and some of the properties vary widely across 
the spectrum (i.e. LD50 for each agent).  Table 2 summarizes the properties of nerve 
agents, which are highly toxic organophosphates.  One of the properties that make nerve 
agents so much deadlier than typical organophosphate insecticides is that the nerve agents 
do not allow the required time for bioactivation to take place, which in turn does not 
provide efficient protection from the endogenous mechanisms.  The organophosphate 
insecticides are much weaker than their nerve agent cousins and they allow enough time 
for bioactivation, which allows the body to utilize its defenses more effectively 
(Chambers, 2003). 
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Table 2.  Properties of Nerve Agents 
Property NA    
 Tabun (GA) Sarin (GB) Soman (GD) VX 
Description Clear, colorless and 
tasteless liquid 
Clear, colorless and 
tasteless liquid 
Pure liquid is clear, 
colorless, and tasteless; 
discolors with aging to 
dark brown 
Amber colored, 
tasteless, and odorless 
oily liquid 
Warning properties Although GA has a slight 
fruit odor, this cannot be 
relied on to provide 
sufficient warning against 
toxic exposure 
None Although GD has a slight 
fruity or camphor odor, 
this cannot be relied on to 
provide sufficient warning 
against toxic exposure 
None 
LD50 (mg) 1000 1700 50 6-10 
LCt50 (mg-min/m3) 400 100 50-70 10-50 
Aging half-time 
(approx.) 
14 5 h 2-6 min 48 
Vapor Density 5.6 (air = 1.0) 4.9 6.33 9.2 
Solubility in water 9.8g/100g Miscible 2.1g/100g 3g/100g (miscible 
below 48.9 ○F [9.4 ○C]) 
Volatility 490 mg/m3 at 77 ○F (25 
○C) 
22,000 mg/m3 at 77 ○F 
(25 ○C) 
3900 mg/m3 at 77 ○F (25 
○C) 
10.5 mg/m3 at 77 ○F 
(25 ○C) 
Source: Cannard, 2006 
Release Mechanisms 
 There are several different ways or methods that organophosphates can be 
delivered in order to cause an individual or group of individuals to become exposed.  
When an enemy is trying to target a few people, they may use such delivery methods as 
explosive shells, rockets, missiles, aircraft bombs, or mines (NATO, n.d.).  When these 
weapons are used, the contamination area will be rather small.  Depending on the type of 
munitions used, the agent will be concentrated within a certain radius of the impact point.  
The radius will have some variation due to wind speeds and how long it takes the agent to 
disperse into the atmosphere where it is diluted enough to no longer be toxic.  Another 
way to target a few people is by putting the nerve agent in a specific area in its liquid 
form.  This presents more of a dermal threat rather than an inhalation threat, but because 
of the nature of the agents, specifically VX, it can sit on a surface for hours, days or even 
weeks depending on the weather (Canard, 2006). 
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 If exposing as many people as possible is the ultimate goal, then the use of spray 
devices might be the weapon of choice.  This is because it can be used in an aircraft with 
spray nozzles (such as a crop duster) in order to cover people with a fine mist of the 
chemical.  Other ways that large amounts of people can be exposed is by contaminating a 
community’s water supply with chemicals that are water-soluble or miscible liquids or 
solids (NATO, n.d.).  Not only can these agents be delivered by spray in an aircraft, but 
they can also be spread using something as simple as an aerosol canister or sprayer that 
mounts to a trailer or bed of a truck.  This would allow someone to drive around an area 
while “pumping” the agent into the air. 
 It is important to know that because of the nature and makeup of the different 
agents, they tend to dissipate fairly quickly.  This allows rescue personnel the opportunity 
to reach victims, treat them and move them to a medical facility, giving most individuals 
an opportunity to get the treatment needed.  The successful recovery of patients largely 
depends on the treatment given in the first couple of hours (Canard, 2006). 
How do organophosphates work 
 Although there are different types of organophosphates and each one varies in its 
properties, they do have similar effects on the body.  Each agent is an 
acetylcholinesterase (AChE) inhibitor.  Once the nerve agent enters the body, the primary 
target is the body’s AChE, which hydrolyses ACh, a major neurotransmitter in the 
peripheral and central nervous system (Costa, 2005).  The inhibition of AChE causes a 
chain reaction that develops into symptoms, which can be easily seen throughout the 
body. 
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 Having a basic understanding of the cholinergic receptor types and their locations 
is needed to properly understand how the enzymes work naturally and to be able to 
distinguish the difference once an organophosphate (or nerve agent) attacks them.  The 
muscarinic and nicotinic receptors are the two primary types of cholinergic receptors.  
The muscarinic receptors are found on the targets of parasympathetic neurons, which 
primarily innervate smooth muscles and exocrine glands.  The tissue groups where the 
muscarinic receptors can be found are around the eye, tear ducts, nasal and salivary 
glands, the heart, gut, and the bladder (Cannard, 2006).  As the nerve cell releases ACh 
from its presynaptic side, the stimulation of the nicotinic receptors of the neuromuscular 
junction occurs on the post synaptic side of the next nerve cell “in line” (See Figure 2).  
The presynaptic release takes place when the potential for movement occurs.  These 
nerves branch out to innervate many muscle fibers and essentially contract at the same 
time causing the desired movement (Cannard, 2006). 
 The body uses ACh and AChE constantly and is essential for life to exist.  The 
brain sends an electrical pulse through the different nerve cells throughout the body.  
Each nerve cell is independent of each other (they do not touch).  Those cells are lined up 
and in order to send signals to each other, they must have a way to effectively 
communicate across the synaptic space (space between each cell).  As shown in Figure 2, 
once the cell receives the electrical pulse and this pulse reaches the presynaptic side, ACh 
is secreted into the cleft.  The ACh then quickly travels across the approximately 50nm of 
space to the postsynaptic side of the cleft.  Here it binds and within 100μs the pulse is 
past on to the next nerve cell.  In order to stop the ACh from constantly sending the 
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signal over and over again to the next cell, the ACh must be removed in order to return 
the site back to its pre-bond form (Calvert, 2002). 
 
Figure 2.  Schematic of synaptic cleft 
 The way the nerve “resets” itself on the postsynaptic side is by using the enzyme 
AChE.  This enzyme contains a serine residue that allows it to bind with the ACh.  It then 
continues to hold onto the acetyl portion of the acetylcholine and allows the choline 
portion to be released back into the synaptic cleft.  This separation of the acetyl group 
and the choline occurs in about 40μs.  The AChE then gets rid of the acetyl through 
hydrolysis and then the AChE is ready to start the process over.  With the rate that the 
AChE can handle ACh, a normal synaptic cleft can handle anywhere up to 1000 impulses 
per second (Calvert, 2002). 
 Once in the body, independent of method, organophosphates do not attack the 
nerve cells, as to popular belief.  The organophosphate will attach itself to the AChE 
enzyme, which will stop AChE from doing its job of separating the acetyl from the 
choline and ceasing further unwanted electrical pulses traveling down the nerve “chain.”  
Nerve agents create a strong bond with the residue of the AChE which prevents 
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hydrolysis from taking place (Zoltani, 2000).  Once the AChE is rendered inactive, a 
buildup of ACh in the synaptic cleft will follow because the receptive state of the 
postsynaptic membrane cannot be reestablished, resulting in cholinergic effects 
throughout the body (Maxwell, 1986; Calvert, 2002).  The only way to reduce the 
symptoms naturally is by either reactivating or creating new AChE, because this is the 
sole way that ACh can be disposed (Costa, 2005).  This statement may only apply to 
Costa’s time horizon and may not apply to the model being studied in this paper. 
Symptoms 
 As mentioned above, as AChE is inhibited, symptoms will begin to develop.  The 
type and severity of the symptoms is dependent on the exposure level of the victim.  Was 
the person exposed to a high concentration for a short amount of time or low 
concentrations for a long duration of time?  Symptoms are also dependent on where the 
nerve agent is concentrated throughout the body.  Is it localized in one area or is it wide 
spread among the body?  An exposure from an organophosphate will affect both the 
muscarinic and nicotinic receptors throughout the body.  The muscarinic receptors 
innervate intraocular muscles, lacrimal and nasal glands, salivary glands, bronchial 
muscles and glands, the heart, muscles of the gut and the bladder.  The symptoms that are 
associated with these receptors after an exposure are miosis, with dim or blurred vision, 
eye pain or headache, tearing, rhinorrhea, salivation, bronchoconstriction and excessive 
respiratory secretions with dyspnea, bradyarrhythmias, hypotension, nausea and 
vomiting, abdominal cramps, diarrhea and bowel incontinence, or urinary incontinence. 
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Nicotinic receptors are found in several places throughout the nervous system.  
They are in the sympathetic and parasympathetic nervous systems, in the neuromuscular 
junction of the somatic muscle, and some are in the central nervous system.  The regular 
functions of these receptors are to allow the simultaneous contraction of a hundred plus 
muscle fibers in order to allow movement.  After a nerve agent exposure and the build up 
of ACh occurs, fasciculations of individual fibers result rather than the coordinated 
contractions of the entire unit.  Without the presence of AChE, these fasciculations will 
progress to fatigue allowing paralysis to quickly follow.  In the parasympathetic system, 
both the muscarinic and nicotinic receptors are found, and they are lined up in series.  
This results in symptoms from both types of receptors.  This amplified effect of the 
parasympathetic output may be the reason that symptoms are predominate in nerve agent 
intoxication and why it is the parasympathetic symptoms that predominate in milder 
exposures (Cannard, 2006). 
 Each type of exposure will cause a variety of symptoms to occur.  When looking 
at a mild inhalation poisoning, the symptoms that will develop within seconds to minutes 
after exposure are, but not limited to, the following: miosis, dim vision, headaches, 
rhinorrhea and excess salivation.  As the poisoning becomes more severe, the symptoms 
will become steadily worse.  A severe vapor exposure will add severe breathing 
difficulties, and generalized muscle twitching.  If an individual is exposed to liquid on 
their skin, the symptoms will vary slightly.  A mild/moderate exposure will produce 
localized twitching and vomiting, and the onset occurs within ten minutes to 18 hours 
after exposure.  A severe case will add convulsions and loss of consciousness.  Onset is 
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also a lot shorter for severe cases in that symptoms will appear minutes to an hour after 
exposure (USAMRICD, 2000).  Table 3 shows a more complete list of what to expect 
when exposed to nerve agents. 
Table 3.  Reactions to Different Exposures 
Type of 
Exposure Symptoms 
Time of Onset after 
exposure 
Vapor   
Mild Miosis, Dim Vision, Head Ache Rhinorrhea, Salivation, Dyspnea Seconds to Minutes 
Severe 
Above plus: 
Severe breathing difficulty 
Generalized muscle twitching, 
        weakness or paralysis 
Convulsion 
Loss of consciousness 
Loss of bladder, bowl control 
Seconds to Minutes 
Liquid on Skin   
Mild 
Muscle twitching at site of exposure 
Sweating at site of exposure 
Nausea, vomiting 
10 minutes to 18 hours 
Severe 
Above plus: 
Severe breathing difficulty 
Generalized muscle twitching, 
        weakness or paralysis 
Convulsion 
Loss of consciousness 
Loss of bladder, bowl control 
Minutes to an hour 
Source: USAMRICD, 2000 
 
 If treatment is not given, the symptoms described above will continue to worsen 
and can become fatal.  The credit for death comes from respiratory failure due to a 
combination of effects from the central and peripheral nervous systems, specifically 
bronchoconstriction, enhanced bronchiolar secretions, paralysis of the respiratory 
muscles, and shut-down of the respiratory control center in the brain (Chambers, 2004, 
Maxwell, 1988).  With the onset of symptoms starting as fast as seconds after exposure, 
action to curb the effects of the nerve agent is paramount. 
 Poisoning by nerve agent can be identified by the characteristics and symptoms 
described above.  If the exposure was cutaneous or ingested through food or water, the 
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pupils may appear to be normal.  If this does occur, then one must rely on the other 
manifestations of nerve poisoning in order to determine exposure.  There are no other 
known chemical agents that produce the type of symptoms that nerve agents produce 
(Federation of American Scientists). 
 Figure 3 shows an example of a list of symptoms that can be experienced when 
given a dose of sarin gas.  The three exposures that were used in this experiment are 
0.00117 milligrams per liter of air (this represents 70 mg-min/m3 at 60 minutes), 0.00058 
milligrams per liter of air (this represents 70 mg-min/m3 at 60 minutes), and 0.00003 
milligrams per liter if air (this represents 2 mg-min/m3 at 60 minutes).   
Effect of different organophosphates 
 Several studies have compared the effects of organophosphate insecticides on 
AChE in both mammalian and non-mammalian species.  Even though the insecticides 
inhibit AChE, they are far less potent then nerve agents (Gray, 1987).  Organophosphates 
can cause many different problems in the body.  Meggs (2003) gives an example at how 
fast and what some of the long term issues are for a dermal/inhalation exposure to the 
organophosphate insecticide chlorpyrifos.  This insecticide is an intermediate 
organophosphate in its ability to inhibit esterase.  The result from the exposure was 






 When examining the affect of the more intoxicating nerve agents, one can see the 
problems that can develop when an exposure occurs.  As the nerve agent begins to infect 
the entire body, the blood flow to certain tissues begins to slow down.  This effect can be 
seen in the kidney, spleen and the skeletal muscle (Maxwell, 1986).  Examining the 
toxicities of soman on the body resulted in an inhibition of up to 80% of the AChE in 
plasma, lung, brain and the heart.  AChE inhibition was not as detrimental in other tissues 
such as the diaphragm, hind limb skeletal muscle, kidney and spleen.  The inhibition in 







Altered Mental Status 
















Dim / Blurred Vision 
Eye Pain/Headache 
Tearing 
















Figure 3.  Symptoms one may experience when exposed to different levels of sarin 
(USAMRICD, 2000, Federation of American Scientists, 2006). 
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with the AChE levels dropping to only 97% of normal (Ibid.).  Maximum inhibitions of 
AChE in all tissues were achieved in 16 minutes (Maxwell, 1988). 
 Other studies looking at sarin describe that low doses will cause an increase in the 
resistance in the airway (Sopori, 2006) making it difficult to breathe.  Hypoxia can then 
occur because of cholinergic stimulation, increased secretion, bronchospasm, and 
weakened respiratory muscles (Meggs, 2003).  Although hypoxia may develop, it doesn’t 
mean that the blood flow throughout the body is decreasing.  This is true in some tissues, 
but the exact opposite in others.  The blood flow to the brain, heart and lungs actually 
increased anywhere from two to four times the normal rates.  Blood flows also decreased 
up to 50% in other tissues such as the kidney, spleen and the skeletal muscle. 
 There are several other areas of the body affected by nerve agents that are not 
mentioned above.  After an exposure, the gastrointestinal tract will have an increase in 
motility and secretions by the gland walls will begin.  Nausea and vomiting are also early 
signs of liquid exposure.  Diarrhea can occur from a large exposure.  The different bodily 
glands will increase their secretions when in contact with a nerve agent, and the skeletal 
muscle will begin to twitch.  After a large amount of agent enters the body, fatigue and 
weakness of muscles are rapidly followed by muscular flaccidity (USAMRICD, 2000). 
Bronchial effects 
 As noted above, the airway is greatly affected when an exposure takes place, 
especially when it is a vapor exposure.  The bronchial passages can help reduce the 
amount of agent that is introduced into the blood stream by the alveolar blood-gas 
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exchange.  The process that takes place inside the bronchial passages is called 
“scrubbing.” 
 Starting with the trachea and extending down to the alveolar spaces are thousands 
of bifurcating airways in which the air travels through the lung to the air-blood exchange.  
These airways vary in size and length.  They get smaller as they progress from one 
generation to the next.  Inside these airways (before reaching the air-blood exchange) is 
where the “scrubbing” takes place.  There are two liquid layers that coat the inside wall 
of the bifurcating airways.  There is a thinner water layer directly adjacent to the wall and 
a thicker glyco-protein layer on top of the water layer.  Ciliated cells line the epithelial 
wall, which extend through the water layer into the glycol-protein layer which can be 




 Scrubbing occurs once particulate matter has been inhaled.  The ciliated cells 
lining the epithelial wall move the glyco-protein layer upward through the bronchial 
passages.  Inhaled particles stick to the glyco-protein layer and with the upward 
movement of the fluids, the particle is transported to the trachea where it is disposed of in 
the gastrointestinal tract (Shelley, 1996).  In the case of gaseous vapors being inhaled, 
Figure 4.  Longitudinal view of bronchial wall segment-







when the molecules are captured and absorbed, they would continue to pass into and out 
of the various fluid or tissue regions depending on the prevailing concentration gradients 
and the diffusivity of the chemical (Shelley, 1996).  An example of this is that if an 
organophosphate has a lot of particulate matter and the gaseous molecules have the 
ability to be absorbed into and out of the tissue regions there is the possibility to have a 
high scrubbing rate.  If the organophosphate has few particulates and the gaseous 
molecules cannot pass through the tissue regions before reaching the blood – gas 
exchange, very little scrubbing will take place. 
 One item to note is that the bronchial tissue is a direct route for the 
organophosphate to enter the bloodstream.  Once the chemical molecules begin to 
infiltrate the tissue of the bronchial walls, the chemical will then be transferred to the 
blood via the tissue blood exchange.  This will increase the concentration within the 
blood (Shelley, 1996) and ultimately the different tissues throughout the body. 
Acetylcholinesterase and acetylcholine levels 
 Acetylcholine (ACh) is vital for body function.  Having too much creates 
symptoms associated with organophosphate exposure.  Keeping this transmitter under 
control is paramount, if it is allowed to build up, death can occur.  ACh is found in the 
peripheral and central nervous systems to assist in the process of cellular communication 
(Aidoo, 2006). 
 There are many different mechanisms that attribute to determining the 
concentration, release, and distribution of ACh into the synaptic cleft.  Some of these 
factors include the number of vesicles releasing ACh, the location of these vesicles, 
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geometry of the cleft, and AChE hydrolysis.  Most of which have not been studied 
qualitatively or in much detail (Aidoo, 2006). 
 In order to obtain results as accurate as possible, a release rate is required.  
According to Aidoo (2006), ACh has been modeled as a continuous release function.  Of 
the thousands of ACh molecules that reach the post-synaptic side of the nerve cell, only 
about 2/3 of the ACh actually activate the receptors, since each receptor requires two 
molecules to open the receptor channel.  Thus, allowing the electric signal to continue 
down the “nerve chain.”  The other ACh molecules that don’t activate the receptors are 
hydrolyzed by AChE.  Of all molecules released into the synaptic cleft, only about 1/5 
actually bind to the post-synaptic side to open receptor channels.  This leads to an initial 
concentration of approximately 300 mM. 
Metabolism (Body Disposing of Agent) 
 There are a couple of ways that the body is able to dispose of an agent that it has 
been exposed to, therefore allowing  the body’s natural processes to return to normal.  
One of the ways that the organophosphates are removed from the body is by the process 
of aging, as described in a latter section.  A chemical change takes place when an 
organophosphate ages to an AChE molecule (Canard, 2006).  At this point the chemical 
can no longer be released into the body to cause additional toxic effects.  A second 
method that can remove organophosphates from the body is that of bronchial scrubbing.  
This is also described in a previous section, but allows the foreign particles to be moved 
from the trachea to the GI tract (Shelley, 1996).  This action helps to prevent the agent 
from moving into the blood stream, or at least slow it down. 
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 A third way that the body can remove the agent is by breathing.  This occurs with 
the blood-gas exchange that takes place in the lungs.  Assuming that the individual has 
been removed from the “danger area” and is no longer taking in any chemical, the agent 
will be transferred back into the trachea and removed by exhaling (Shelley, 1996).  One 
last method that the body can remove organophosphates is by metabolism.  This process 
mostly takes place in the liver, but several other tissue groups have the capability to do so 
(Gearhart, 1994). 
 These processes are imperative in order for the body to “heal” itself.  There may 
be other precautions that are needed in order to help it do so, like administering atropine.  
If the body has no way of disposing of the agent, then it would be difficult to stop the 
symptoms from occurring, which could result in a higher death rate. 
Aging 
 One issue that an individual needs to remember when dealing with a victim 
poisoned with an organophosphate or nerve agent is a concept called aging.  As the nerve 
agent begins its process of inhibiting AChE from doing its job of hydrolyzing ACh, one 
of two things can occur.  The enzyme will return to its free pre-inhibited form and return 
to hydrolyzing ACh or it will “age” and form a permanently inhibited enzyme (Gearhart, 
1994).  If aging occurs, the only way for the body to replace the now useless AChE 
enzyme is by producing more.  This process can take up to several days to accomplish 
(Costa, 2005), and, by then, permanent chronic effects or death can occur.  This occurs 
because once the organophosphate attaches itself to the AChE enzyme, the leaving group 
will break off of the organophosphate, which varies from agent to agent (see Table 1).  If 
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nothing is done to dissociate the organophosphate from the AChE, the bond will mature 
and become permanent.  Aging occurs by the stabilization of the nerve agent-AChE 
complex when dealkylation, the removal of an alkyl group, occurs.  This process can 
develop anywhere from 2 minutes up to 2 days (Cannard, 2006).  Figure 5 shows a 
general schematic of how these reactions happen. 
 
Figure 5.  Schematic representation of biochemical interactions between 
Ops and AChE.  Reaction 1 leads to phosphorylated AChE.  Reaction 2 is 
spontaneous reactivation of AChE.  The rate of this reaction can be 
accelerated by oximes.  Reaction 3 is the aging and leads to a stable, 
negatively charged phosphorylated AChE.  E-OH, active site of the 
enzyme.  Source: Costa, 2005 
Current Treatment Procedures 
There are several ways to treat an individual who comes in contact with 
organophosphates.  Obviously, the best way is to not get exposed by the proper use of 
protective equipment.  However, in a wartime situation, there may not be enough time to 
adequately provide that protection before an exposure occurs.  If the exposure does occur, 
there are three possible methods of treatment.  When treating someone, most of the time, 
more than one method will be used together.  These methods are pretreatment, the use of 
medication, and decontamination. 
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There are other enzymes in the body that organophosphates will target besides 
AChE.  These enzymes are carboxylesterase (CaE) and butyrylcholinesterase (BuChE).  
An important issue about these enzymes is that when they bind with an organophosphate 
there are no toxic effects in the body (Maxwell, 1988).  Prophylaxis with BuChE helps to 
neutralize the organophosphate before it reaches target tissues and inhibits AChE.  In 
order to neutralize the organophosphate, enough BuChE would have to be present in the 
body to be able to reduce the organophosphate by half within ten seconds in order to 
protect the individual from severe toxic onset (Chambers, 2004). 
Even though the levels of BuChE can be easily increased with an injection on the 
battlefield, there are several drawbacks that do not make this procedure very effective.  
The injection would have to be administered at the correct time or it will be unsuccessful.  
If the injection of the BuChE is too early, it might be ineffective, if the individual waits 
too long, they may be incapacitated before they can administer the injection.  Also, the 
individual would have to have some sort of knowledge about how much nerve agent the 
enemy is planning on using to be able to use the correct amount or it will also be rendered 
ineffective.  There are also concerns about repeated doses causing problems with the 
immune system (Chambers, 2004). 
There are three different types of medication that are used in treating individuals 
for organophosphate exposure.  The first is anticholinergics.  Atropine is the typical 
anticholinergic (antimuscarinic) used for organophosphate effects.  Atropine, once 
administered, competitively and reversibly blocks the binding of ACh to the muscarinic 
receptor sites.  It needs to be noted that atropine does not affect the nicotinic receptors 
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(Cannard, 2006).  This is important because symptoms that are associated with the 
nicotinic receptors (i.e. fasciculations) will continue to persist after the treatment is given.  
Therefore, focus should be kept on the symptoms related to the muscarinic receptors 
before deciding to administer additional atropine. 
Oximes are also very common for treating individuals intoxicated with a nerve 
agent.  Oximes act to reactivate any AChE that has been inhibited by an 
organophosphate.  It acts like a crowbar, by prying the chemical off of the enzyme 
allowing the AChE to return to hydrolyzing ACh.  If aging has occurred, then any oxime 
will be rendered useless.  As mentioned previously, aging is permanent and can not be 
reversed.  In order to reduce the likelihood of aging, an oxime should be administered as 
soon as possible after exposure (Ibid).  The third medication is the use of anticonvulsants.  
This is taken to reduce convulsions that are in connection to the exposure.  Diazepam is 
the medicine of choice.  Mortality rates have been reduced in experiments with animals 
treated with diazepam, especially when used in combination with atropine (Ibid). 
The third portion to treating personnel contaminated by a nerve agent is 
decontamination.  This step is imperative, because if not done, many more individuals 
will be exposed to the nerve agent, including the health care provider.  Thoroughly 
flushing with water will dilute the nerve agent’s concentration, depending on the agent, 
making it a relatively nontoxic compound (Cannard, 2006). 
Lack of human subjects 
 Due to the fact that nerve agents pose a risk to the health of humans, it is not 
ethically or humane to do tests on human beings.  This causes a dilemma in trying to 
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discover how organophosphates react with the body as well as the best methods to stop 
any symptoms from occurring.  There are a few cases in which researchers are able to get 
some information where there has been a nerve agent exposure to the human population.  
These are few and far between, but do exist. 
 One example is the attacks in Japan.  The first attack occurred in Matsumoto on 
June 27, 1994.  This was a presumed terrorist attack and approximately 600 personnel 
were poisoned.  Fifty eight of these people were admitted to the hospital and seven died.  
The clinical and laboratory findings were examined on 264 people who sought treatment.  
For those who were severely poisoned, there was a decrease in serum cholinesterase, 
AChE in erythrocytes, serum triglyceride, serum potassium and chloride, and an increase 
in serum creatine kinase, leucocytes, and ketones in urine.  The good news is that there 
were no persistent abnormal physical findings in any of the people examined.  AChE 
levels also returned to normal after 3 months (Morita, 1995). 
 A second sarin attack in Japan happened about a year later on March 20, 1995.  
This attack occurred in the subway system in Tokyo.  It was a much larger attack than the 
one that occurred in Matsumoto.  More than 5,500 people were poisoned and 12 
individuals were killed (Nishiwaki, 2001).  This provided researchers another opportunity 
to learn more about the actual health effects of nerve agent poisoning among humans.  
Nishiwaki (2001) tried to clarify what the chronic effects (if any) of the exposure is, three 
years after the poisoning took place.  One of the tests they performed suggested that there 
were memory problems, but further study was needed. 
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 Another example of an organophosphate poisoning can be found in Meggs (2003) 
paper on the paralysis of an individual due to dermal exposure.  By the simple application 
of a “termite killer” (which was an organophosphate) without using the proper safety 
precautions, such as mask, long pants, shoes that covered the feet, etc., the individual 
found himself in the emergency room with signs of organophosphate poisoning.  This 
particular individual ended up having permanent loss in strength in his hands and in one 
leg and could not urinate without catheterization. 
 Researchers are beginning to look at what happened to the U.S. service members 
who are being diagnosed with Gulf War Syndrome.  It is believed that sarin gas is the 
root cause of this diagnosis.  It is now being reported that over 300,000 American troops 
have been exposed to sub-lethal doses of the gas.  Some of the chronic long term effects 
are that some soldiers have 5% less white brain matter (connective tissue) than soldiers 
who were not exposed.  There was also evidence that those individuals who were 
exposed had lost approximately 20 years with their fine motor skills.  Other long-term 
symptoms experienced where chronic fatigue, muscle weakness and fibromyalgia 
(Kennedy, 2007). 
Acute verses chronic 
 The near term effects of high exposure to chemical warfare agents are well 
documented.  These studies show how potent and fast organophosphates inhibit AChE 
once the nerve agent enters the body and how these exposures can be lethal.  However, 
the effects of low-level exposures have not been studied nearly as much.  There are 
research gaps in understanding the toxicological effects of low-level exposure to 
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chemical warfare agents (Genovese, 2004, Henderson, 2002).  Genovese (2004) defines a 
“low-level” exposure as one that is asymptomatic or produces only mild symptoms 
without producing overt signs of clinical toxicity such as convulsions.  Henderson (2002) 
also states that it is vital that the exposure level used should avoid inducing clinical 
symptoms. 
 One group of individuals repeatedly exposed to an organophosphate insecticide 
similar to sarin is farmers.  Some of the symptoms that have been reported from these 
chronic levels of exposure tend to be along the lines of neuropsychological effects such 
as giddiness, floating sensations, speech difficulties, memory defects, insomnia, 
concentration difficulty, mental confusion, anxiety, and emotional liability.  Studies have 
also shown that individuals exposed in an occupational setting have also had persistent 
neurological damage (Henderson, 2002). 
 This is a good place to start when looking at what the effects of low-level 
exposures cause and what symptoms may be expected.  This presents a problem when 
trying to examine a soldier returning from war who may have been exposed to nerve 
agents.  Soldiers did experience the same type of exposure conditions as those described 
above.  They were probably only exposed to subclinical doses once or at most three or 
four times before their tour was over and they returned home (Henderson, 2002).  
Another example that more closely fits the scenarios that are likely to happen on the 
battlefield is when the terrorists used sarin in Matsuoto and Tokyo, Japan.  A study 
provides evidence that long term muscle, nerve damage, and other central nervous system 
and neurobehavior effects are a result of the exposures (Wilson, 2005). 
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 When comparing two separate studies that look at low-level exposures to sarin, it 
would appear that they contradict each other.  In evaluating the performance effects, 
Genovese (2004) suggests that asymptomatic exposure (i.e. non-conclusive) to chemical 
warfare agents can produce small cognitive and general performance deficits in rats, but 
these deficits were small and the recovery was relatively rapid and complete.  Also, there 
was no evidence of delayed onset.  This suggests that a full recovery is possible following 
the exposure in relation to performance.  Now, when comparing these results with 
Henderson’s (2002) study of the response to rats at low level exposure, they appear to be 
the exact opposite.  It is suggested here that repeated exposures to low-level doses 
resulted in delayed development of brain alterations that could be associated with 
memory loss and cognitive dysfunction. 
Problems with scaling from animals to humans 
 One of the major difficulties in studying organophosphates (especially the 
stronger nerve agents) is not being able to conduct in vivo tests.  Due to ethical problems 
scientists face, toxicity studies are seldom conducted with humans.  Because of this 
dilemma, the test subject ends up being a laboratory animal (Leung, 1995).  By 
performing the tests on laboratory animals, in vivo testing becomes possible.  Researchers 
are able to study and determine how the animal’s body is actually reacting.  This 
however, presents another problem for researchers.  How does the kinetics of the animal 
differ from that of the human and what differences can one expect to see in the human 
with the same type of exposure? 
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 Leung (1995) explains how this relationship is dealt with and some of the 
problems or issues when making comparisons.  Historically, researchers use body size in 
order to extrapolate information from one species to another.  Basically the administered 
dose is scaled by using a ratio of the body weight or the body surface area.  This method 
treats the human as nothing more than a large rodent.  This does cause some issues of 
unreliability of how accurate the extrapolation is because it does not take into account the 
pharmacokinetic differences in the two species.  The human is simply not just a large 
rodent. 
 This is where using PBPK models help to remove or filter some of the 
inaccuracies described above.  The model interspecies extrapolation is based on tissue 
dose rather than administered dose.  The model takes the administered dose and 
transforms it into a target tissue dose.  If there is not enough information on the 
pharmacodynamics of the tissues, then it is assumed that the human tissue is similar to 
that of the rodent (Leung, 1995).  The PBPK model is also advantageous over treating the 
human body as a large rodent because it provides a simple means to explore and examine 
different types of exposure scenarios and how the human body will react to the different 
organophosphates. 
PBPK modeling 
 Physiologically-based pharmacokinetic (PBPK) modeling has been around for 
several decades.  Before the mid 1970s, its primary use was in the pharmaceutical arena.  
It was not until 1974 that these models were extended to analyze environmental 
chemicals.  These models really became popular about 10 years later, when the styrene 
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model was published in 1984.  Over 50 models have been developed to date using 
environmental chemicals (Leung, 1995).  PBPK models are used for several different 
applications, the most common being that of dose extrapolation.  This is done by 
modeling high-to-low doses, going from one type of exposure to another and from 
laboratory animal to human.  A second practice of PBPK models is in route to route 
extrapolation which is based on the total administered dose (Leung, 1995).  PBPK 
models have developed into useful tools which allows for the interpretation of 
pharmacokinetic data (Gearhart, 2005). 
 The models are generally quite simple to construct.  They represent the 
mammalian system in terms of specific tissues or groups of tissues which are all 
connected by the arterial and venous blood flow (Figure 6).  They are set up in such a 
way that a series of differential equations are used to describe the mass balance at the 
different tissues throughout the model (Langenberg, 1997). 
 PBPK models have three vital components that must be present in order for them 
to work properly.  The first is a species specific set of physiological parameters.  This 
includes such things as organ weights and blood flow values for each tissue group to be 
studied.  Most of this information can be gathered from published literature or obtained 
from the closest species of study.  The second component is chemical specific 
parameters.  These parameters are unique for each chemical and deal with tissue 
solubility (partition coefficients), metabolism, and the plasma/tissue binding 
characteristics.  The third component that a PBPK model must have is a specific 





 PBPK models provide a powerful tool for scientists to observe the effects of a 
chemical on the body.  This could not otherwise be done because of the ethical issues 
involved with experimentation on live human subjects.  Since experimentation can be 
conducted on animals, PBPK models can be used as a method for extrapolating between 
different species by using the parameters for that species in question (Sweeny, 2006).  A 
model must be capable of three key outputs.  One, predicting the relationship between the 
organophosphate in question and the toxic effects that the organophosphate delivers to 
the body; two, be amenable to cross-species scaling; and three, accurately predict outside 
the dose range over which its primary validation studies were conducted (Gearhart 1994).  
Sweeny (2006) states that one of the strengths of the PBPK model is in its ability to 



















Figure 6.  General structure of the PBPK model being used for this study. 
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 These models have been used in a variety of different aspects.  According to 
Leung (1995) they can be used to estimate the dose-effect data over a wide range of 
exposure conditions and if validated can be an accurate predictor of outcomes for 
exposure conditions that have not been experimentally tested.  This falls right in with 
what Gearhart (1994) was stating that a model should be able to do.  PBPK modeling 
typically address long term exposure scenarios, where the tissue concentrations 
throughout the body are approaching equilibrium (or saturation) with the outside 
exposure concentrations (Shelley, 1996).  By studying these different scenarios and 
model outputs, scientists can actually make adjustments to regulatory workplace 
exposure standards as well as giving the capability to study a trickle effect on how an 
exposed individual may affect another person who was not in the contaminated zone 
(Shelley, 1996).  PBPK models are also used to simulate multiple exposure routes (such 
as inhalation and dermal), make rational predictions of the disposition of a chemical and 
to visualize, validate, predict, and hypothesize xenobiotic uptake, distribution, 
metabolism, and excretion throughout the body (Gearhart, 2005, Leung, 1995, Shelley, 
1996). 
 When putting all of the information together, the PBPK model becomes the tool 
of choice when conducting a study on chemical uptake in the body.  This is where the 
power of the model lies.  By using these time based simulations, scientists and decision 
makers can better estimate actual chemical doses (Gearhart, 2005) for people who 
actually experience an exposure, whether by accident, applying an insecticide to a yard or 
from being attacked by nerve agents on the battlefield. 
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III.  Methodology 
Development of the model 
Overview 
 The model is set up as a basic physiologically-based pharmacokinetic (PBPK) 
model.  There are several compartments representing different tissues (Figure 6).  The 
tissues are all separated from one another and are connected via the arterial and venous 
blood flows.  This model examines how acetylcholine reacts to the inhibition of 
acetylcholinesterase by organophosphates.  Several processes take place throughout the 
model.  One is the flow of the organophosphate throughout the body.  Once the chemical 
enters the body (by inhalation) it enters the lungs and, via the blood-gas exchange, enters 
the bloodstream which then sends it throughout the body to the different tissues.  A 
second process is the metabolism of the organophosphate.  This reaction is governed by 
Michaelis-Menten kinetics (Gearhart, 1994).  A third process is the inhibition of AChE 
by the organophosphate binding with the enzyme and keeping it from reacting with the 
ACh.  The fourth process inside the model is the hydrolysis of ACh by AChE.  The 
model also examines the effect of butyrylcholinesterase and carboxylesterase, which also 
react with the organophosphate compound.  These enzymes actually help because when 
the organophosphate binds to these enzymes the body does not experience a toxic effect, 
which then reduces the amount of organophosphate that can bind to AChE. 
 Once the organophosphate enters the body (either by dermal or vapor exposure), 
it will enter the blood flow and then be distributed throughout the body.  Each tissue 
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compartment is built in the same manner.  As the concentration accumulates in the tissue, 
a first order inhibition rate occurs with the amount of AChE available in the tissue. 
Dealkalization of the OP 
 To determine the amount of free AChE, one must analyze the concentration of the 
nerve agent and four different rate constants.  The basal level of AChE in each tissue 
results from a balance between normal degradation of AChE and the synthesis of new 
enzymes.  After exposure occurs, the balance between the bimolecular rate of inhibition 
and the rate at which inhibited AChE can regenerate itself governs the amount of free 
(uninhibited) AChE in the tissue.  Once the enzyme is inhibited, it will either return to 
free AChE or it will age and form a permanently inhibited enzyme.  Figure 7 shows these 




The synthesis (or natural creation) rate is defined as a zero order and the rates of 
inhibition, regeneration, and aging are defined as first order rates (Gearhart, 1994). 
Figure 7.  Model for acetylcholinesterase (AChE) inhibition, aging, 
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Link between the AChE and the ACh 
 Once the organophosphate has inhibited the AChE, there is not a way to 
hydrolyze the ACh the body produces; this causes a build up in the synaptic spaces and at 
the muscle or gland junction.  If this buildup becomes too large, symptoms of 
organophosphate exposure will begin to be apparent.  Figure 8 shows the model for the 
buildup of ACh.  The synthesis or natural production of ACh is defined by a zero order 
rate and the hydrolysis of the ACh is defined by a first order rate. 
 
 
Specification of Compartments 
 The PBPK model contains specific tissues (examples: the brain and liver) as well 
as tissue groups (richly and slowly perfused tissues) (Figure 6).  The specific 
compartments describe the tissues that are directly related to the organophosphates, or 
those tissues that need to be examined for any reaction to the agent specifically.  The 
tissue groups also comprise all the other tissues in the body that are not specifically 
mentioned in order to obtain a complete physiology of the mammalian body and to 
maintain mass balance (Gearhart, 1994). 








 The fat compartment is different than the other compartments in the model.  This 
particular tissue group does not have any AChE, BuChE, or CaE reactions and there is no 
ACh built into this portion of the model because the values of these items are so low that 
they are ignored.  This can be seen in the literature in that nobody uses these parameters 
in their models (Gearhart, 1994, Gentry, 2002, Maxwell, 1986). 
 The blood compartments are not target tissues per say, they are an important part 
of the model which performs metabolism and allows us to understand what the 
organophosphate is doing in not so easily sampled parts of the body.  The tissues that 
have the ability to metabolize the organophosphates (brain, liver, kidney, and richly 
perfused tissues) do so according to Michaelis-Menten kinetics (appendix 10).  The 
model is run on STELLA 8.0 software by High Performance Systems, Inc.  Each 
compartment has a set of differential equations that defines the mass balance for the 
amount of organophosphates in the system, the amount of free and inhibited AChE, and 
the amount of ACh the tissues contain.  These equations are in appendix 4. 
 These two compartments were constructed differently than the others due to their 
behavior.  The blood components of the model do not have the capacity to store the 
organophosphates that enters the body.  Several equations were developed that “remove” 
organophosphates by simulating the binding to the different enzymes (AChE, BuChE, 
and CaE).  An issue with setting up the blood compartments in this way is that the actual 
levels of the three enzymes always stay at their initial pre-exposure level.  This will skew 
the actual amounts of the organophosphate metabolized or bound with enzymes 
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circulating throughout the body.  This amount is small enough to press forward with the 
study. 
Parameter Values 
 The PBPK model requires many different parameters in order for it to work 
properly and mimic the physiological nature of the body it represents, in this case, a 
mammalian body.  A majority of the parameters used in this particular PBPK model are 
found from different sources of literature (appendices 5 and 10).  Several of the values 
were not found for specific organophosphates, and, therefore, an analysis was performed.  
This is explained in the sensitivity analysis below.  Some of the parameters include 
synthesis and degradation rates, volume of tissue groups, blood flows, and hydrolysis 
coefficients. 
 Developing the parameter values for ACh is a difficult task to accomplish.  There 
are only a few values that are needed in this model.  These are: the AChE hydrolysis rate 
of ACh, concentration of tissue AChE, tissue volume, concentration of tissue ACh, and 
the tissue ACh release rate.  The concentration of AChE is calculated by dividing the 
amount of AChE in each specific tissue by that tissue’s volume.  The same process is 
used to calculate the ACh concentration.  Finding the hydrolysis rate and the release rate, 
however, are much more difficult.  For this model, the initial amount (steady state) of 
ACh present is 0.100 nmols (Potter, 1970). 
 The hydrolysis rate was not found in the literature.  Therefore, a value was chosen 
by referencing Gearhart’s (1994) value for AChE inhibition.  In this case it is 0.02 nmols-
hr-1.  Once these two values are determined, the release rate can be calculated.  The body 
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releases ACh as needed, not continuously, making it difficult to know when and when not 
to release the transmitter.  According to Potter (1970), this release has been modeled at a 
constant rate, which is how it is used in the model. 
Assumptions 
 Several simplifying assumptions are used in creating this PBPK model.  One of 
those assumptions is that the different tissue concentrations everywhere are in an instant 
equilibrium state with the concentration of blood perfusing the tissue.  A second 
assumption that simplifies the normally employed PBPK model is dealing with inhalation 
exposure.  This creates an instantaneous equilibration of exposure concentration with 
blood flow in the pulmonary blood-gas exchange process (Shelley, 1995). 
Methodology 
Sensitivity Analysis 
 Several different parameter values were not found in the literature for specific 
organophosphates.  These values have a direct impact on how AChE behaves.  The 
parameters in question are; one, the different partition coefficients; two, the Vmax and Km 
values; three, the inhibition rate of AChE; four, the aging rate for the bond that takes 
place between the organophosphate and AChE; and five, the regeneration rate of AChE.  
Therefore, a sensitivity analysis was conducted in order to test a range of values for the 
different parameters. 
 In order to conduct this analysis, realistic values are required.  Gearhart (1994) 
and Gentry (2002) recorded a set of values for each of the parameters needed.  The 
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chemical these parameter values represent is parathion.  Gentry documented the upper, 
lower, and mean limits for each value.  These three values were used as a starting point to 
conduct the sensitivity analysis.  By reducing the lower limits by a given value, additional 
parameter values were created.  This was also done with the upper limit by adding a 
given value to create a total of nine sets of parameter values. 
 A combination of all these values was examined.  This was accomplished by 
testing one value at a time, while holding all other values constant.  Then all the values 
that are not being tested were changed to a new constant and then the tested parameter 
was run again with its different values (see Figure 9 for an example).  This will be done 
with each parameter until completed.  A list of all parameters can be found in appendices 




























Figure 9.  Graph of the different parameter values tested for the regeneration 
rate used in the sensitivity analysis. 
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 The level of ACh in each tissue was tested for sensitivity to the parameter values 
mentioned above.  The testing point is at a time of 60 minutes and the degree of change 
in ACh was examined to determine if the model is sensitive to the parameter in question.  
All values were graphed against each other and sensitivity was determined by the slope of 
the line.  An example can be seen in Figure 10. 


























Figure 10.  Example of a sensitivity report for the regeneration rate.  Notice 
that the first ten trials show sensitivity while the next ten are relatively un-
sensitive. 
Sensitivity Analysis Results 
Inhalation 
 The sensitivity analysis shows there are several areas where the model is sensitive 
to the parameter changes and in other areas where it is not.  The output analyzed is the 
accumulation of ACh.  Each of the five different parameters (or variables) was examined 
independently for inhalation, bronchial scrubbing and dermal effects.  The sensitivity of 




steady increase or decrease in slope, then it is considered sensitive.  If all tissue groups 
have a slope that is approximately zero, then the model is not considered sensitive to the 
parameter. 
 Data points were taken from each model output to compile a behavior of the 
overall levels of ACh in each tissue group.  After every simulation, the point on the graph 
at time 60 minutes was recorded for the level of ACh in each tissue.  These points were 
then plotted against each other on a trial (simulation) vs. percentage graph.  This provides 
a nice visual output of any changes that occur in the different tissues at this point in time. 
 The results for the inhalation portion are as follows (the complete results can be 
seen in appendix 7): 
• Partition Coefficients:  All twenty trials were deemed to be sensitive, but at 
varying degrees. 
• Metabolism:  The model was not sensitive to these parameters across any of the 
trials.  Therefore, a set of values will be chosen for these parameters and they will 
not be changed throughout the testing. 
• Inhibition Coefficient:  All twenty trials were deemed to be sensitive, but at 
varying degrees. 
• Aging Rate:  Only trials one through five were deemed not sensitive.  Six through 
twenty were considered to be sensitive to the changes in values and therefore, the 
parameter combinations for trials six through twenty will be used in the testing 
portion. 
• Regeneration Rate:  Half of the trials for this parameter were considered sensitive 
(trials one through ten).  The model was deemed not sensitive to trials eleven 
through twenty and therefore, these parameter combinations will not be used in 
the testing portion. 
 
 There are eight separate partition coefficients – one for each of the different tissue 
groups (i.e. brain, liver, kidney, richly perfused tissues, slowly perfused tissues, 
diaphragm, bronchial tissue, and the skin).  The partition coefficients are treated as a 
single unit and all of the possible combinations are not used in the sensitivity analysis due 
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to the shear number of simulations that would have to be run and examined.  Therefore, 
when the value of the partition coefficients is changed, all values change in the same 
direction (positive or negative) and by a pre-described amount.  Likewise, the Michaelis-
Menten metabolic parameters for each tissue group are examined in the same manner. 
Bronchial Scrubbing 
 This portion is only to determine if the model is sensitive to the bronchial 
scrubbing coefficient.  This parameter is tested by setting all the other parameters 
(partition coefficients, Michaelis-Menten values, inhibition coefficient, aging rate, and 
regeneration rate) at a fixed value and then changing the scrubbing coefficient (Figure 
11).  If the model is considered sensitive to the bronchial scrubbing coefficient, then it is 
assumed that all combinations of the other parameters are sensitive as well.  This then 
requires additional testing with different combinations of the partition coefficients, the 
Michaelis-Menten values, the inhibition coefficient, the aging rate, and the regeneration 
rate. 
 The bronchial scrubbing coefficient partitions the absorbed agent between 
alveolar blood-gas exchange and bronchial wall absorption.  The results demonstrate that 
the model is not sensitive to bronchial scrubbing, mainly because all of the tissues have 
minimal change in ACh levels.  Additional testing, with different parameter combinations 
and exposures, will be conducted to determine whether or not these results are exclusive 























Figure 11.  The different values of the bronchial scrubbing coefficient that 
were used in the sensitivity analysis. 
Dermal Exposure 
 As was done in the bronchial section, this portion of the sensitivity analysis was 
to determine if the model was sensitive to the transfer coefficient and the skin surface 
area exposed.  Therefore, the partition coefficients, the Michaelis-Menten values, the 
inhibition coefficient, the aging rate, and the regeneration rate are set to a given value and 
the transfer coefficient and skin surface area are changed using different combinations of 
the two.  Again, if any combination of the transfer coefficient and the skin surface area 
are deemed sensitive, then all combinations will be considered sensitive and additional 
testing with more combinations of the other parameters will be completed. 
 After graphing the results of the model, it shows that about two-thirds of the trials 
are sensitive to the parameter changes.  Trials one through forty-four show large changes 
in the levels of ACh.  After trial forty-four, there is really no change in the levels of ACh.  
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The results for the levels of ACh can be seen in Figure 12 and the remaining results can 


























Figure 12.  Results of the sensitivity report for dermal exposure.  Notice 
that the model becomes less and less sensitive after the forty-fourth trial. 
Testing Portion 
 The sensitivity analysis is used to develop the parameter values for testing the 
model under exposure conditions.  The trials tested will be completed in the same manner 
as the sensitivity analysis.  For example, when examining the partition coefficients, the 
inhibition coefficient, the aging rate, and the regeneration rate will be set at value one 
(see appendix 5 for actual values) and the partition coefficient will start at its value one 
and will gradually be increased.  Once all the partition coefficient values are run through 
the model, the inhibition coefficient, aging rate, and regeneration rate will be increased.  
The partition coefficient will be reset to its number one value and increased again until all 
values are completed.  This is repeated until all predetermined combinations are run 
through the model.  After the partition coefficients are tested, the same procedure will 
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follow with the inhibition coefficient, the aging rate, and the regeneration rate for all 
predetermined combinations (see appendix 8 for a list of all combinations). 
 There are three different parts that will be accomplished in testing the model.  The 
inhalation portion, which looks at an inhalation exposure only; a section on bronchial 
scrubbing, which adds an element of scrubbing a particular amount of the 
organophosphate from the air as it is being inhaled; and a dermal section which will 
examine the effects of an organophosphate exposed to the skin.  Each section will be 
tested following the pattern above.  All three sections are set up slightly different than 
each other.  For the inhalation and bronchial scrubbing trials, each set of combinations 
will also be tested against three exposures.  The first being 0.00117 milligrams per liter of 
air, the second 0.00058 milligrams per liter of air, and the third is 0.00003 milligrams per 
liter of air.  The first dermal exposure is 0.37062107 milligrams, the second exposure is 
0.1840554 milligrams, and the third exposure is 0.00954734 milligrams.  These are 
different than the others because of their route of entry.  In order to be able to compare 
the dermal effects with the inhalation effects, the exposures need to be normalized.  This 
is accomplished by determining what the total amount of organophosphate is absorbed in 
the body via inhalation.  Then testing different dermal exposures until one is found that 
absorbs the same amount of organophosphate into the body.  This process is completed 
for the three inhalation exposures. 
 The inhalation portion of the testing will serve as the baseline to be compared to 
the bronchial scrubbing and dermal exposures.  The bronchial scrubbing has an additional 
parameter than the inhalation tests.  This parameter is the called the scrubbing coefficient, 
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which determines the amount of organophosphate that will be “scrubbed” out of the 
airflow.  From the sensitivity analysis, two scrubbing coefficients will be used in the 
testing portion (see appendices 5 and 6 for list of values).  Each combination for the 
partition coefficients, the inhalation coefficient, the aging rate, and the regeneration rate 



























Figure 13.  Set of bronchial exposure trials to be tested for the parameter 
“partition coefficient” in the model. 
 
 The dermal portion of the model has two additional parameters than the inhalation 
portion.  These parameters are the transfer coefficient and the skin surface area.  The 
transfer coefficient determines how much of the organophosphate will actually penetrate 
the skin and the skin surface area defines the amount of skin actually exposed to the 
organophosphate.  The combinations for the partition coefficients, the inhalation 
coefficient, the aging rate, and the regeneration rate will run against different 
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combinations of the transfer coefficient and skin surface area (Figure 14).  Unlike the 
inhalation and bronchial scrubbing portions of the model, the parameter being tested (i.e. 
partition coefficients, inhalation coefficient, aging rate, or regeneration rate) is not 
increased.  Here the mid-point (value 5) is used and it is not increased as it is in the 
inhalation and bronchial sections.  This was to reduce the amount of simulations to run 






























Figure 14.  Set of dermal exposure trials to be tested for the parameter “aging 
rate” in the model. 
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IV.  Analysis and Results 
Analysis and results 
 An organophosphate has chemical specific values for the partition coefficients, 
the inhibition coefficients, the aging rate, and the regeneration rate.  Therefore, each of 
the 100 plus combinations inserted into the model represents a different organophosphate.  
The organophosphates are not specifically named because determining the actual 
partition coefficients, inhibition coefficients, aging rate, and regeneration rate is a 
difficult process.  In order to measure these different parameters, in vivo testing must be 
accomplished.  For this particular model each combination represents a generic 
organophosphate with parameter values determined from a set found in the literature. 
 The parameter values for parathion were used as a starting point.  Nine different 
values were developed for each parameter in each tissue (numbered 1 through 9), all of 
which can be referenced in appendix 5.  Gentry (2002) recorded both the upper and lower 
limits for each of the tissue groups as well as the mean value.  These represented three of 
the values for the model (values 4, 5, and 6).  The other values (1 through 3 and 7 through 
9) were determined by expanding beyond the limits of the upper and lower bounds.  Each 
tissue’s lower bound value was subtracted by a number to obtain a new value (number 
three); the number was then subtracted again to obtain an additional value (number two).  
The process was repeated a third time to obtain the last value (number one).  The same 
process was done with the upper limit; a number was added to each parameter to obtain 
new value seven, then eight, then nine.  The different parameter combinations in the 
model produced a wide range of ACh levels in the different tissues with an exposure of 
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0.00117 milligrams per liter of air.  This suggests that each trial run shows different 
toxicities as well as symptoms that are experienced throughout the body.  The varying 
levels of ACh can be seen with exposures of 0.00058 milligrams per liter of air and 
0.00003 milligrams per liter of air as well.  The three exposures used for both the 
inhalation tests as well as the bronchial scrubbing tests are 0.00117 milligrams per liter of 
air (exposure 1), 0.00058 milligrams per liter of air (exposure 2), and 0.00003 milligrams 
per liter of air (exposure 3). 
 The mass balance for the organophosphate is important to maintain throughout 
the experimentation process.  A correct mass balance helps to create a more realistic 
model and help translate that to what is actually going on inside the body.  This particular 
model’s mass balance was off by approximately seven percent.  A possible reason for this 
is in the construction of the blood compartments.  Due to software limitations they had to 
be constructed differently than the other tissue compartments.  As a result, the 
organophosphate that enters the body does not equal the organophosphate distributed 
throughout the body.  This percentage is small enough not to have any adverse effects on 
the general model output. 
 The inhalation tests are used as the baseline for the rest of the experiments.  This 
provides a basis to compare the bronchial scrubbing and dermal sections of the model.  
Once an inhalation trial is run at exposure 1, the level of ACh buildup for each tissue is 
recorded at time 60 minutes and placed on a graph (trial number vs. percentage).  This is 
repeated for trial two, three, etc.  Once all trials for exposure 1 were completed, they were 
run a second time with exposure 2 and again at exposure 3.  The baseline results are 
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shown in Figure 15.  The trends between the three exposures do not change.  Each tissue 
increases or decreases respectively in each exposure.  The level of ACh attained is the 
only change.  As a result, only exposure 1 will be discussed unless stated otherwise.  The 
full results are displayed in appendix 9. 
Inhalation 
 In examining the results, one parameter is evaluated at a time (i.e. partition 
coefficients, the inhibition coefficient, the aging rate, and the regeneration rate).  This 
helps to compare what the different combinations of parameters are doing under the same 
exposure scenario.  In comparing the different parameters, there was a variation of trends 
noticed throughout the trials.  When the partition coefficient was examined, there were 
definite changes in ACh levels.  As the partition coefficients are increased there is an 
increase in the ACh levels in the brain, liver, kidney, slowly perfused tissue, and the 
diaphragm.  Even though the levels of ACh in the liver and kidney increase, they increase 
at minimal levels when compared to the other tissues.  When examining the structure of 
the model, these results stem from the concentrations of ACh in the different tissues.  
After exposure the concentrations of ACh in the liver and kidney tissue change very little 
when compared to the other tissues.  Since the concentration of ACh does not vary with 
different parameter values, the change in the rate of hydrolyzaiton will be minimized, 
therefore, causing minimal increases in the level of ACh in the liver and kidney as 
parameter values change.  Whereas, the other tissue groups have a higher change in ACh 
concentration with the different parameter values after exposure and therefore, their 
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hydrolysis rate changes more drastically producing higher levels of ACh than in the liver 
or kidney. 
 The richly perfused tissue tends to decrease as the partition coefficients are 
increased (Figure 15a).  This tends to occur because of the amount of BuChE is present in 
the richly perfused tissue.  As the partition coefficient is increased, it decreases the rate in 
which organophosphate leaves the tissue via venous blood.  This in turn gives the 
organophosphate additional time to bind with the BuChE in the tissue.  The richly 
perfused tissues have more of this enzyme than the other tissues.  Therefore, more 
organophosphate is lost due to BuChE than in any of the other tissue.  This binding 
between the organophosphate and the BuChE provides less organophosphate to bind with 
AChE which results in lower levels of ACh in the richly perfused tissues. 
 A second observation is when the inhibition coefficient, aging rate and the 
regeneration rate are increased; the level of ACh is higher in the tissue with the same 
partition coefficients.  This follows the concept that as the inhibition coefficient is 
increased, the less hydrolyzing AChE can perform, which in turn causes ACh to increase.  
With the higher aging rate, AChE is permanently bound with the organophosphate at a 
higher rate, providing a smaller “pool” of inhibited AChE for the body to regenerate back 
into free AChE.  Therefore, the body can not produce and regenerate enough AChE to 
compensate for the amount of AChE that is being inhibited and aged.  This causes the 
levels of ACh to increase in the tissue even though the partition coefficients stay the 
same.  A sample of the different ACh levels in the different tissues at an exposure of 
0.00117 milligrams per liter of air for 60 minutes is shown in Table 4. 
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Partition Coefficients
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a) Exposure 1 
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b) Exposure 2 
Partition Coefficients
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c) Exposure 3 
Figure 15.  This shows the level of ACh (in percentage) in 
different tissues from a variety of organophosphates.  The 
trends are the same for each exposure.  The difference is the 
change in ACh levels.  The levels of ACh are lower when 
exposures 2 and 3 are used.  Note: trial 1 in (a) has the same 
parameter values as trial 2 in (b) and trial 3 in (c).  The only 
difference is the exposure concentration. 
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Table 4.  Examples of ACh Levels in Different Tissues 
Exposure 1
Trials 1 34 7 34 7 25 10 16
Brian 269.5 4617.3 2966.7 4617.3 4250.2 4611.8 4239.2 2743.4
Liver 107.8 164.2 137.0 164.2 140.4 164.1 140.7 130.9
Kidney 106.7 149.0 120.7 149.0 117.0 149.0 117.3 111.4
Richly Perfused 125.7 375.2 209.2 374.2 183.1 375.2 184.8 148.3
Slowly Perfused 110.3 470.7 159.6 468.8 163.3 470.7 164.8 135.8
Diaphragm 106.0 522.4 137.6 521.5 170.6 522.4 171.9 139.2
Tested Parameter
Partition Coeff Inhibition Coeff Aging Rate Regeneration Rate
 
This is a sample of the trials run at exposure 1 (0.00117 mg/l) after 60 minutes has 
transpired.  The numerical values show the increase in ACh, from a baseline of 100%, 
for the different tissues in a given trial.  The tested parameter and trial number 
represents which combination of parameters being run through the model.  For 
example: trial 1 under the partition coefficient parameter shows the brain having 
269.5% of ACh above normal.  Trial 1 represents each of the parameter values 
(partition coefficients, the inhibition coefficient, the aging rate, and the regeneration 
rate) at their lowest values.  Trial 7 represents the inhibition coefficient at its highest 
value, while the partition coefficients, the aging rate, and the regeneration rate are at 
their lowest values.  A complete list of the combinations can be seen in appendix 8. 
 
 The inhibition coefficients had different trends from the partition coefficients.  
The richly perfused tissue, slowly perfused tissue, and the diaphragm each increase 
exponentially, although at different rates (Figure 16a).  The brain (Figure 16b and c) and 
the diaphragm have the same trend types as they did when examining the partition 
coefficients.  A major difference between the partition coefficients and the inhibition 
coefficient is when the partition coefficients, aging rate, and the regeneration rate are 
increased; the levels of ACh in the liver, kidney, richly perfused, and slowly perfused 
tissues remain fairly constant.  This tends to suggest that the inhibition coefficient is not 
dependent on the partition coefficients, aging rate and the regeneration rate.  Upon further 
examination of the model, there is evidence to why this is the case.  In order for aging or 
regeneration of AChE to occur, it must be inhibited first.  Therefore, the amount of AChE 
































































Figure 16.  This shows the levels of ACh in different tissues 
when examining the different inhibition coefficients (a and 
b).  Figure 16c displays the level of ACh present when 
examining different partition coefficients (used to compare 
with Figure 16b). 
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aged into a permanent bond.  The partition coefficients are not directly tied to the 
inhibition coefficient and perform their own computations separately allowing the 
inhibition coefficient to perform on its own. 
 A combination of both the inhibition and partition coefficient trials trends are seen 
in the aging rate combinations.  Each tissue saw an increase in ACh levels as the aging 
rate increased.  This is reasonable because, when the aging rate is increased, the time for 
the bond between AChE and the organophosphate to become permanent is reduced.  
Therefore, AChE is being lost faster, reducing the amount available to hydrolyze ACh, 
causing ACh levels to rise.  There was also an increase in ACh levels when the partition 
coefficients, the inhibition coefficient, and the regeneration rate were increased.  When 
these parameters are at their lower values (i.e. trials 1, 4, and 7 in Figure 17a) the trends 
of the different tissues have a very small slope, but when higher values (i.e. trials 19, 22, 
and 25 in Figure 17a) of the partition coefficients, the inhibition coefficient, and the 
regeneration rate are used it typically looks like the inhibition coefficient trials.  The 
brain increases as well, but as the partition coefficients, inhibition coefficient, and the 
regeneration rate are increased, the increase in ACh is not as prevalent (Figure 17b).  
Upon further examination, the brain never goes above 4600%, regardless of the 
parameter combination.  This may indicate that the brain is approaching its maximum 
value.  Therefore, as the partition coefficients, inhibition coefficient, and the regeneration 
rate are increased, the increase is smaller because it is reaching its new steady-state value. 
 The regeneration rate’s trends were opposite of all the others.  Unlike the previous 
trials, the combinations that were run for this portion showed a decrease in the liver, 
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kidney, slowly perfused tissue, richly perfused tissue, diaphragm, and the brain.  As the 
regeneration rate was increased, it produced less and less of an ACh buildup in the 
tissues.  When the partition coefficients, inhibition coefficient, and the aging rate were 
increased, the drop in ACh levels is greater (Figure 18).  This is reasonable because if 
there is a high regeneration rate, this allows the bound AChE to be freed into unbound 
AChE and allows the ACh to be hydrolyzed, bringing the levels down. 
Aging Rate













































Figure 17.  Displays the level of ACh present in different 
tissues with varying aging rates. 
 57 
Regeneration Rate











































Figure 18.  Displays the level of ACh present in different 
tissues with varying regeneration rates. 
Bronchial Scrubbing 
 Bronchial scrubbing was examined next.  To simplify the comparison process, 
only two of the scrubbing coefficients will be discussed, 1 and 10 (this represents 100% 
and 10% respectfully of the organophosphate being scrubbed from the bronchial or 
conductive zone of the lungs).  For a complete list of data see appendices 5 and 8.  As 
was done in the inhalation section, only exposure 1 will be discussed.  This is because the 
trends for exposures 2 and 3 are the same as exposure 1, the only difference being the 
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actual level the ACh reached during each trial.  Additionally, only the partition 
coefficients will be examined. 
 The output suggests that bronchial scrubbing does not have an effect on how the 
body reacts to organophosphates.  It was thought that there would be a slight delay in 
how fast the levels of ACh in the different tissues would reach those seen in the 
inhalation (baseline) tests.  This was not the case.  There was scarcely a change in the 
amount of ACh buildup in any of the tissues.  This was consistent when using high or low 
scrubbing coefficients.  Both of the bronchial scrubbing coefficients used have a minimal 
change in the level of ACh that is present in each tissue group.  Figure 19 displays the 
lack of change between the inhalation tests with both sets of scrubbing coefficients used.  
This suggests that the amount of organophosphate that is scrubbed from the airways 
enters the bloodstream fast enough to cause no effect on the rate at which the levels of 
ACh will reach at a given time. 
 After looking deeper into the model structure, the exact amount of 
organophosphate is present at any given time when inhalation occurs.  The difference is 
where the organophosphate is located.  Depending on the scrubbing coefficient, the 
organophosphate is either in the arterial blood as it passes through the blood-gas 
exchange or it is in the bronchial tissues being partitioned into the venous blood.  In 
either case the model transfers the organophosphate immediately into the arterial blood 
from the venous blood, minimizing any difference in levels of ACh in any tissue whether 
bronchial scrubbing takes place or not.  These results confirm the sensitivity analysis in 
that the model was found not to be sensitive to changes in the scrubbing coefficient. 
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Partition Coefficients









































































Figure 19.  Displays the rate of change between scrubbing coefficients 1 
(Figure a) and 10 (Figure b).  The trends do not change much between the 
higher (Figure a) and lower (Figure b) scrubbing coefficient.  Figure c 
displays the baseline inhalation ACh levels in the tissues for comparison.  
Note: there is not any change in the levels of ACh in any of the three figures. 
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Dermal 
 Finally, the effects of a dermal exposure were tested.  Unlike the inhalation or 
bronchial scrubbing portions, different exposures are required to make a proper 
comparison.  Instead of an exposure measured in concentration, which is used in the 
inhalation and bronchial scrubbing portions of the test, an exposure measured in mass is 
used for the dermal testing.  This rationale is developed by reviewing the material safety 
data sheet, such as sarin, which states that the LD50 is measured in milligrams (Federation 
of American Scientists, 2006).  The dermal exposures are developed from the three 
inhalation exposures.  The amount of organophosphate absorbed into the body is 
calculated and then varying masses of an organophosphate are entered into the model 
until the amount absorbed equals that of the inhalation exposure.  The three dermal 
exposures used are: 0.37062107 milligrams (exposure 1), 0.1840554 milligrams 
(exposure 2), and 0.00954734 milligrams (exposure 3). 
 The dermal tests have two additional parameters than those in the inhalation 
exposure.  These parameters are the skin transfer coefficient and the skin surface area.  
The skin transfer coefficient determines how much of the organophosphate actually 
enters the body through the skin medium and the skin surface area designates how much 
of the skins surface is exposed to the organophosphate.  When examining the different 
combinations for the partition coefficients, the results showed an increase in ACh levels 
in the liver, kidney, richly perfused tissue, slowly perfused tissue and diaphragm when 
the inhibition coefficient, aging rate, and regeneration rate are increased.  Figure 20 
shows these levels for all three exposures.  This trend remains constant regardless of 
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which transfer coefficient or skin surface area is used.  These trends are also the same 
when examining the outputs for the aging rate and the regeneration rate (full results are 
located in appendix 9). 
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Figure 20.  Trials 4, 13, 22, 31 display the rates of change at 
exposure 1, whereas, trials 5, 14, 23, 32 display the ACh 
levels at exposure 2, and trials 6, 15, 24, 33 display ACh 
levels when exposure 3 is modeled.  All trials are exposures 
to the skin. 
 
 The outputs of the model for the inhibition coefficient provide a different trend 
than that of the partition coefficients, aging rate, and the regeneration rate.  Figure 21a 
and b show that the liver, kidney, and the slowly perfused tissues do not increase nor 
decrease very much.  This reinforces the earlier statement that the inhibition coefficient is 
not dependant on the partition coefficients, aging rate, and the regeneration rate.  The 
diaphragm and the richly perfused tissues are the only two that display any change in 
ACh levels.  When compared to the baseline (inhalation), these are the only tissues that 
have changes in ACh levels. 
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Figure 21.  Displays almost zero slopes for the change in 
ACh levels in each tissue after the transfer coefficient is 
changed (except for the diaphragm and the richly perfused 
tissue).  The difference between Figure a and Figure b is the 
level of ACh in the tissue reaches after exposure. 
 
 Evidence from the results suggests that when a small amount of skin (low surface 
area) is exposed and the organophosphate has a high rate of transfer through the skin, the 
buildup of ACh in the different tissues is lower than that of inhalation.  This is implied by 
the amount of time it takes for the organophosphate to fully enter the blood stream and 
circulate throughout the body will take longer than inhaling the agent (USAMRICD, 
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2000).  This presents the possibility that the levels of ACh in the tissues do not reach the 
same levels as an inhalation exposure.  Exploring a high skin exposure (high surface 
area) and low transfer rate produce higher levels of ACh in the body tissues than the 
baseline did.  Upon further study of the model, these results appear to be the product of 
the exposure normalization process.  The normalization was conducted with a skin 
surface area of 1 cm2.  The new exposure was used for all skin surface areas tested.  It 
appears the exposure should be normalized for each skin surface area used in the model. 
 Examining a small exposure to the skin and a low transfer rate (low transfer 
coefficient and low skin surface area) produce different results than the first two 
scenarios described above.  The levels of ACh in the tissues are lower than those 
demonstrated by the higher transfer coefficient.  This suggests that the time it takes to 
achieve inhalation levels of ACh in the tissues is longer, if reached at all.  At 60 minutes, 
the outputs do not demonstrate whether or not the levels of ACh will actually reach the 
inhalation levels.  When the time of exposure is increased, the levels of ACh do 
eventually reach (and exceed) the levels attained with inhalation (Figure 22). 
 This delay can be contributed to the concentrations of organophosphate in the 
tissue after the exposure takes place.  The volume of the skin is much larger than the 
volume of the bronchial tissue.  The larger volume of the skin produces a lower 
concentration of organophosphate in the tissue, which in turn takes longer for it to 







Figure 22.  Figure a demonstrates the building up of ACh in three 
tissue groups from an inhalation exposure.  The levels of ACh are 
measured at 60 minutes.  Figure b shows the same tissues when the 
body is exposed to a dermal exposure.  As can be seen it takes 88 
minutes of exposure for all of the tissues to at least equal the 
inhalation exposure. 
 
 A piece of the model that required further addressing was the molecular weight of 
each organophosphate.  The model uses the molecular weight to convert milligrams of 
organophosphate to nmols to show how much AChE, CaE, and BuChE is bound.  The 
results of all three testing areas (inhalation, bronchial scrubbing, and dermal) were 
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determined using a single molecular weight.  Fourteen different organophosphates were 
chosen (see Table 5) to be used to test this portion of the model.  Each molecular weight 
was assigned to a different combination of parameter values.  Parathion was used as a 
starting point. 
 
Table 5.  List of organophosphates used in model 
 Organophosphate Molecular 
Weight 
1 Sarin 140.1 
2 Tabun  162.0 
3 Soman 182.2 
4 Ethoprop 242.4 
5 Trichlorfon 275.4 
6 Fenthion 278.3 
7 Propetamphos 281.3 
8 Parathion 291.3 
9 Phosmet 317.3 
10 Malathion 330.4 
11 Tribenuron Methyl 395.4 
12 Dioxathion 456.5 
 
 To match the different molecular weights with a combination of parameter values, 
two chemicals were examined.  These chemicals were diazinon and trichloroethylene.  
The pesticide diazinon has higher partition coefficients than parathion and it also has a 
higher molecular weight (diazinon 304.4 g/mol) than parathion (291.3g/mol) (Poet, 
2004).  Trichloroethylene, which has lower values for its partition coefficients in the 
different tissue groups also has a lower molecular weight than parathion (131.4 g/mol to 
291.3 g/mol) (Covington, 2004).  Using these similarities, if an organophosphate had a 
higher molecular weight than parathion then it was assigned to a set of parameters that 
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were higher than those used for parathion.  This was also done if the molecular weight 
was lower. 
 The results displayed different values in what the build up of ACh was in each of 
the tissue groups.  The ACh levels were both higher and lower than the results provided 
from using only one value.  There was no difference in the trends when comparing the 
results from using multiple molecular weights with the results from using one molecular 
weight (Figure 23).  The difference is seen in the magnitude of ACh in the tissues.  The 
trials that were run with different molecular weights tend to have lower levels than the 
trials that were run where all combinations of parameter values have the same molecular 
weight.
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Figure 23.  Figure a displays the levels of ACh in five different 
tissue groups when a different molecular weight is used for each 
trial that was ran.  Each trial also has a different set of parameter 
combinations (partition coefficients, inhibition coefficient, aging 
rate, and regeneration rate).  Figure b displays the levels of ACh 
when one molecular weight is used for all trials.  It can be seen 
that the trends are the same, only the magnitude is different. 
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V.  Conclusions 
Conclusions 
 With the ease to obtain and produce organophosphates, it appears future attacks 
using these agents as a weapon is only a case of when it will happen.  Being educated on 
what the agents can do as well as how the body reacts to them can have life saving 
results.  Organophosphates with slight differences in the parameter values can have very 
different results in how high the levels of ACh will reach in the various tissues.  For 
example; when the partition coefficients were left unchanged and the inhibition 
coefficient, the aging rate, and the regeneration rate were raised slightly (inhalation tests, 
exposure 1, comparing trial 1 with trial 10), the level of ACh in the brain rose from 270% 
to 1122% respectively. 
 The model also suggested that the relationship between the exposure and the level 
of ACh in the tissue is not linear.  By examining exposures 1 and 2, which is a 50% 
decrease in concentration (0.00117 mg/l to 0.00058 mg/l), the buildup of ACh in the 
tissues decreased less than half.  This is seen in the ACh levels of the brain (26% 
decrease), the liver (12% decrease), and the kidney (6% decrease) after having a 50% 
decrease in exposure level.  This is also seen when comparing exposures 2 and 3 
(0.00058 mg/l and 0.00003 mg/l).  The exposure drops approximately 1,833%, but the 
tissues range from 1,833% (close to linear) to 8% decrease in ACh levels.  These 
different levels suggest that if an individual receives twice the dosage, that person will 
not necessarily receive symptoms twice as bad. 
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 The bronchial scrubbing tests results were compared with the inhalation results, 
and one conclusion was determined.  The bronchial scrubbing action that takes place does 
not have an effect on the ACh levels in different tissues.  When examining the 
organophosphate parathion, the lack of differences in ACh levels can be seen.  For 
example, the brain has an ACh increase of 3,914% after an inhalation exposure of 
0.00117 mg/l (exposure 1).  Using a low scrubbing coefficient, this number is still 
3,914% and with a high scrubbing coefficient it can drop to as low as 3,909%.  This 
suggests that bronchial scrubbing does not have an effect on the intake of 
organophosphates into the body. 
 The dermal exposure tests also produced lower levels of ACh than the inhalation 
exposures under the same conditions.  This tends to support the information found in 
USAMRICD (2000) that symptoms from a dermal exposure can take longer to 
materialize than from an inhalation exposure.  This too can be seen by looking at the 
results for parathion, as stated before the inhalation exposure for the brain produced an 
increase in ACh of 3,868%.  When testing a dermal exposure equivalent to the inhalation 
exposure the ACh level dropped between 3,668% (with a high transfer coefficient) and 
455% (with a low transfer coefficient).  Meggs’ (2003) paper provides an example of an 
individual being exposed to an insecticide for 15 minutes and the next day became 
permanently paralyzed in certain areas of his body.  With the lower levels of ACh, again, 
more time is available to don personal protective equipment or perform decontamination 
procedures with dermal exposure. 
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 It should be noted that the data shown in this study are based on endpoint analysis 
and does not go into examining the dynamic buildup of ACh from the time it enters the 
body. 
Future Work 
 A time of 60 minutes was used throughout this study.  Different time increments 
can be examined to see how much change will occur, if any, in the ACh levels.  Other 
areas of work to investigate are specific organophosphates as information on parameter 
values become available.  This will allow one to identify how much buildup of ACh 
occurs and how that corresponds to the type of symptoms one would experience for 
specific organophosphates.  Future work for a dermal exposure can determine how long it 
would take for an exposure to equal an inhalation exposure for different 
organophosphates (i.e. produce the same amount of ACh buildup in tissue).  Studying 
what dermal exposures will produce the same effects as an inhalation exposure for a fixed 
amount of time.  This is demonstrated by looking at the results of an inhalation exposure 
and recording the ACh levels.  The same dose was administered for a dermal exposure 
(normalized from the inhalation exposure) and using a transfer coefficient of 0.8, it took 
approximately 88 minutes (28 minutes longer) for the dermal levels to reach the same (or 
above) levels as the inhalation.  By experimenting with this with different 
organophosphates, a “lag” time in the ACh levels can be determined to understand the 
type of symptoms to expect when encountering a dermal exposure over an inhalation 
exposure. 
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 Organophosphates are dangerous chemicals, every one of them from insecticides 
to nerve agents.  Being overexposed to any of them can have disastrous results.  This 
study looked at many different agents in a very general perspective.  A main observation 
was that the higher the values for the partition coefficients, the inhibition coefficient, the 
aging rate, and the lower the regeneration rate appeared to produce more toxic effects 
than lower values.  This would suggest that organophosphates with the higher parameter 
values are the worst agents (one that produces the highest levels of ACh in the body) and 
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• Cum_Absorbed_Dose(t) = Cum_Absorbed_Dose(t - dt) + (Dermal_Inflow) * dt 
• INIT Cum_Absorbed_Dose = 0 
• INFLOWS: 
o Dermal_Inflow = Absorption_of_OP__via_Skin 
• Cum__Absorbed_Inh_Dose(t) = Cum__Absorbed_Inh_Dose(t - dt) + 
(Inhalation_Inflow) * dt 
• INIT Cum__Absorbed_Inh_Dose = 0 
• INFLOWS: 
o Inhalation_Inflow = Cardiac_Output  *  Conc_of_OP_Entering_AB  -  
Cardiac_Output  *  Conc_of_OP_Leaving_VB 
Arterial Blood Flow 
• AB_OP__Lost_Enzymes(t) = AB_OP__Lost_Enzymes(t - dt) + (Inhibiting_in_AB) * 
dt 
• INIT AB_OP__Lost_Enzymes = 0 
• INFLOWS: 
o Inhibiting_in_AB = (( 
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_BuChE_in_AB  +  
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_CaE_in_AB  +  
Amount_of_Conc_of__OP__Removed_after_Inhibition_by_AChE_in_AB )  *  
AB__Vol )  /  Delta_T 
• AB_Inhibition_Rate_for_CaE = 0.00108 
• AB_Inhibition_Rate_for__AChE = 0.01416 
• AB_Inhibition_Rate_for__BuChE = 0.4248 
• Amount_of_Conc_of_OP_Removed_after_Inhibition_by_BuChE_in_AB = 
Unit_Converter_nmol_to_mg  *  AB_Inhibition_Rate_for__BuChE  *  
Conc_of_OP_Entering_AB  *  Conc_of__AB_BuChE  *  Delta_T 
• Amount_of_Conc_of_OP_Removed_after_Inhibition_by_CaE_in_AB = 
Unit_Converter_nmol_to_mg  *  AB_Inhibition_Rate_for_CaE  *  Conc_of_AB_CaE  
*  Conc_of_OP_Entering_AB  *  Delta_T 
• Amount_of_Conc_of__OP__Removed_after_Inhibition_by_AChE_in_AB = 
Unit_Converter_nmol_to_mg  *  AB_Inhibition_Rate_for__AChE  *  
Conc_of_OP_Entering_AB *  Conc_of__AB_AChE  *  Delta_T 
• Conc_of_AB_CaE = Initial__Quantity_of__AB_CaE  /  AB__Vol 
• Conc_of_OP_Leaving_AB = Conc_of_OP_Entering_AB  -  
Amount_of_Conc_of__OP__Removed_after_Inhibition_by_AChE_in_AB  -  
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_BuChE_in_AB  -  
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_CaE_in_AB 
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• Conc_of__AB_AChE = Initial_Quantity_of__AB_AChE  /  AB__Vol 
• Conc_of__AB_BuChE = Initial__Quantity_of__AB_BuChE  /  AB__Vol 
• Initial_Quantity_of__AB_AChE = 1.18826 
• Initial__Quantity_of__AB_BuChE = 5.9413 
• Initial__Quantity_of__AB_CaE = 4990.69 
• OP_in_AB = Conc_of_OP_Leaving_AB  *  AB__Vol 
Blood Fraction Coeff 
• Brain_BFC = 0.134 
• Diaphragm_BFC = 0.006 
• Fat_BFC = 0.0360 
• Kidney_BFC = 0.2230 
• Liver_BFC = 0.2700 
• RP_BFC = 0.1583 
• SP_BFC = 0.073 
Brain 
• Brain_CaE(t) = Brain_CaE(t - dt) + (Synthesis_of_Brain_CaE - 
Degradation_of_Brain_CaE - Inhibition_of_Brain_CaE) * dt 
• INIT Brain_CaE = 780 
• INFLOWS: 
o Synthesis_of_Brain_CaE = 15.6 
• OUTFLOWS: 
o Degradation_of_Brain_CaE = .02 *  Brain_CaE 
o Inhibition_of_Brain_CaE = CaE_Inhibition_Rate  *  Conc_of_Brain_CaE  *  
Conc_of_OP_in_Brain  *  Unit_Converter_mg_to_nmol  *  Brain_Vol 
• Brain_OP_Lost_AChE(t) = Brain_OP_Lost_AChE(t - dt) + 
(Brain_OP_Lost_due_to_AChE) * dt 
• INIT Brain_OP_Lost_AChE = 0 
• INFLOWS: 
o Brain_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  
Conc_of_OP_in_Brain  *  Conc_of_Brain_AChE  *  Brain_Vol 
• Brain_OP_Lost_BuChE(t) = Brain_OP_Lost_BuChE(t - dt) + 
(Brain_OP_Lost_due_to_BuChE) * dt 
• INIT Brain_OP_Lost_BuChE = 0 
• INFLOWS: 
o Brain_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_OP_in_Brain  *  Conc_of_Brain_BuChE  *  Brain_Vol   
• Brain_OP_Lost_CaE(t) = Brain_OP_Lost_CaE(t - dt) + 
(Brain_OP_Lost_due_to_CaE) * dt 




o Brain_OP_Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_Brain_CaE  *  
Conc_of_OP_in_Brain  *  Brain_Vol 
• Brain_OP_Lost_Metab(t) = Brain_OP_Lost_Metab(t - dt) + 
(Brain_Metabolism_of_OP) * dt 
• INIT Brain_OP_Lost_Metab = 0 
• INFLOWS: 
o Brain_Metabolism_of_OP = Brain_Vmax_of_OP  *  ( Conc_of_OP_in_Brain  /  
Brain_BPC_of_OP )  /  ( Brain_Km_of_OP  +  ( Conc_of_OP_in_Brain  /  
Brain_BPC_of_OP ))  +  Kf_of_OP  *  ( Conc_of_OP_in_Brain  /  
Brain_BPC_of_OP )  *  Brain_Vol 
• Brain__BuChE(t) = Brain__BuChE(t - dt) + (Synthesis_of_Brain_BuChE - 
Degradation_of_Brain_BuChE - Inhibition_of_Brain_BuChE) * dt 
• INIT Brain__BuChE = 16.9 
• INFLOWS: 
o Synthesis_of_Brain_BuChE = 0.169 
• OUTFLOWS: 
o Degradation_of_Brain_BuChE = Brain__BuChE   *  0.01 
o Inhibition_of_Brain_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Brain_BuChE  *  Conc_of_OP_in_Brain  *  
Unit_Converter_mg_to_nmol  *  Brain_Vol 
• Free_Brain_AChE(t) = Free_Brain_AChE(t - dt) + 
(Natural__Production_of_Brain_AChE + Regeneration_of_Brain_AChE - 
Inhibition_of_Brain_AChE - Natural_Degradation_of_Brain_AChE) * dt 
• INIT Free_Brain_AChE = 49.4 
• INFLOWS: 
o Natural__Production_of_Brain_AChE = Brain_AChE_Synthesis_Rate 
o Regeneration_of_Brain_AChE = AChE_Regeneration_Rate  *  
Inhibited_Brain_AChE 
• OUTFLOWS: 
o Inhibition_of_Brain_AChE = AChE_Inhibition_Rate  *  Conc_of_Brain_AChE  
*  Conc_of_OP_in_Brain  *   Unit_Converter_mg_to_nmol  *  Brain_Vol 
o Natural_Degradation_of_Brain_AChE = Brain_AChE_Degradation_Coeff  *  
Free_Brain_AChE 
• Inhibited_Brain_AChE(t) = Inhibited_Brain_AChE(t - dt) + 
(Inhibition_of_Brain_AChE - Regeneration_of_Brain_AChE - Aged_Brain_AChE) * 
dt 
• INIT Inhibited_Brain_AChE = 0 
• INFLOWS: 
o Inhibition_of_Brain_AChE = AChE_Inhibition_Rate  *  Conc_of_Brain_AChE  
*  Conc_of_OP_in_Brain  *   Unit_Converter_mg_to_nmol  *  Brain_Vol 
• OUTFLOWS: 
o Regeneration_of_Brain_AChE = AChE_Regeneration_Rate  *  
Inhibited_Brain_AChE 
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o Aged_Brain_AChE = AChE_Aging_Rate  *  Inhibited_Brain_AChE 
• OP_in__the_Brain(t) = OP_in__the_Brain(t - dt) + 
(Brain_Arterial_Blood_Flow_of_OP - Brain_Venous_Blood_Flow_of_OP - 
Brain_Metabolism_of_OP - Brain_OP_Lost_due_to_AChE - 
Brain_OP_Lost_due_to_CaE - Brain_OP_Lost_due_to_BuChE) * dt 
• INIT OP_in__the_Brain = 0 
• INFLOWS: 
• Brain_Arterial_Blood_Flow_of_OP = Brain_BFC  *  Conc_of_OP_Leaving_AB  *  
Cardiac_Output 
• OUTFLOWS: 
o Brain_Venous_Blood_Flow_of_OP = ( Brain_BFC  *  Cardiac_Output )  *  ( 
Conc_of_OP_in_Brain  /  Brain_BPC_of_OP )   
o Brain_Metabolism_of_OP = Brain_Vmax_of_OP  *  ( Conc_of_OP_in_Brain  /  
Brain_BPC_of_OP )  /  ( Brain_Km_of_OP  +  ( Conc_of_OP_in_Brain  /  
Brain_BPC_of_OP ))  +  Kf_of_OP  *  ( Conc_of_OP_in_Brain  /  
Brain_BPC_of_OP )  *  Brain_Vol 
o Brain_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  
Conc_of_OP_in_Brain  *  Conc_of_Brain_AChE  *  Brain_Vol 
o Brain_OP_Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_Brain_CaE  *  
Conc_of_OP_in_Brain  *  Brain_Vol 
o Brain_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_OP_in_Brain  *  Conc_of_Brain_BuChE  *  Brain_Vol   
• Brain_AChE_Degradation_Coeff = Brain_AChE_Synthesis_Rate  /  
Brain_AChE_Homeostatic_State 
• Brain_AChE_Homeostatic_State = 49.4 
• Brain_AChE_Percentage = ( Hundred_Percent  /  Brain_AChE_Homeostatic_State )  
*  Free_Brain_AChE 
• Brain_AChE_Synthesis_Rate = 0.0014 
• Conc_of_Brain_AChE = Free_Brain_AChE  /  Brain_Vol 
• Conc_of_Brain_BuChE = Brain__BuChE  /  Brain_Vol 
• Conc_of_Brain_CaE = Brain_CaE  /  Brain_Vol 
• Conc_of_OP_in_Brain = OP_in__the_Brain  /  Brain_Vol 
Brain Con’t 
• Synaptic_Brain_ACh(t) = Synaptic_Brain_ACh(t - dt) + 
(Natural_Production_of_Brain_ACh - Hydrolyzing_Brain_ACh) * dtINIT 
Synaptic_Brain_ACh = 0.100 
• INFLOWS: 
o Natural_Production_of_Brain_ACh = Brain_ACh_Release_Rate 
• OUTFLOWS: 
o Hydrolyzing_Brain_ACh = AChE_Hydrolysis_of_ACh  *  Conc_of_Brain_ACh   
*  Brain_Vol  *  Conc_of_Brain_AChE 
• Brain_ACh_Homeostatic_State = 0.100 
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• Brain_ACh_Percentage = ( Hundred_Percent  /  Brain_ACh_Homeostatic_State )  *  
Synaptic_Brain_ACh 
• Brain_ACh_Release_Rate = 0.0761852 
• Conc_of_Brain_ACh = Synaptic_Brain_ACh  /  Brain_Vol 
Bronchial Scrubbing 
• OP_in_Bronchial_Tissue(t) = OP_in_Bronchial_Tissue(t - dt) + (Bronchial_Intake + 
Bronchial_AB_Flow - Bronchial__VB_Flow) * dt 
• INIT OP_in_Bronchial_Tissue = 0 
• INFLOWS: 
o Bronchial_Intake = Air_Conc  *  Pulmonary_Ventilation_Rate  *  
Scrubbing__Coeff 
o Bronchial_AB_Flow = Bronchial__BFC  *  Cardiac_Output  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o Bronchial__VB_Flow = Cardiac_Output  *  Bronchial__BFC  *  ( 
Conc_of_OP_in_bronchial  /  Bronchial_BPC_of__OP )   
• Bronchial_Vol = .17484 
• Bronchial__BFC = 0.0417 
• Conc_of_OP_in_bronchial = OP_in_Bronchial_Tissue  /  Bronchial_Vol 
Chemical Coeff 
• Kf_of_OP = 0 
• MW = 184.15 
Dermal Exposure 
• OP_in__Skin(t) = OP_in__Skin(t - dt) + (Absorption_of_OP__via_Skin + 
Skin_AB_Flow_of_OP - Skin_VB_Flow_of_OP) * dtINIT OP_in__Skin = 0 
• INFLOWS: 
o Absorption_of_OP__via_Skin = Exposure_to_Skin  *  Skin__Surface_Area  *  
Skin_Transfer_Coeff 
o Skin_AB_Flow_of_OP = Cardiac_Output  *  Conc_of_OP_Leaving_AB  *  
Skin__BFC 
• OUTFLOWS: 
o Skin_VB_Flow_of_OP = Skin__BFC  *  Cardiac_Output  *  ( 
Conc_of__OP_in_Skin  /  Skin_BPC_of_OP )   
• Conc_of__OP_in_Skin = OP_in__Skin  /  Vol_of_Skin 
• Skin__BFC = 0.058 
• Skin__VFC = 0.037 
• Vol_of_Skin = Body_Weight  *  Skin__VFC 
 95 
Diaphragm 
• Diaphragm_CaE(t) = Diaphragm_CaE(t - dt) + (Synthesis_of_Diaphragm__CaE - 
Degradation__of__Diaphragm__CaE - Inhibition_of_Diaphragm__CaE) * dt 
• INIT Diaphragm_CaE = 617.7 
• INFLOWS: 
o Synthesis_of_Diaphragm__CaE = 617.7 
• OUTFLOWS: 
o Degradation__of__Diaphragm__CaE = Diaphragm_CaE 
o Inhibition_of_Diaphragm__CaE = CaE_Inhibition_Rate  *  
Conc_of_Diaphragm__CaE  *  Conc_of_OP_in__Diaphragm  *  
Unit_Converter_mg_to_nmol *  Diaphragm_Vol 
• Diaphragm_OP_Lost_AChE(t) = Diaphragm_OP_Lost_AChE(t - dt) + 
(Diaphragm_OP_Lost_due_to__AChE) * dt 
• INIT Diaphragm_OP_Lost_AChE = 0 
• INFLOWS: 
o Diaphragm_OP_Lost_due_to__AChE = AChE_Inhibition_Rate  *  
Conc_of_Diaphragm_AChE  *  Conc_of_OP_in__Diaphragm  *  Diaphragm_Vol 
• Diaphragm_OP_Lost_BuChE(t) = Diaphragm_OP_Lost_BuChE(t - dt) + 
(Diaphragm_OP_Lost_due_to__BuChE) * dt 
• INIT Diaphragm_OP_Lost_BuChE = 0 
• INFLOWS: 
o Diaphragm_OP_Lost_due_to__BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Diaphragm_BuChE  *  Conc_of_OP_in__Diaphragm  *  
Diaphragm_Vol 
• Diaphragm_OP_Lost_CaE(t) = Diaphragm_OP_Lost_CaE(t - dt) + 
(Diaphragm_OP_Lost_due_to__CaE) * dt 
• INIT Diaphragm_OP_Lost_CaE = 0 
• INFLOWS: 
o Diaphragm_OP_Lost_due_to__CaE = CaE_Inhibition_Rate  *  
Conc_of_Diaphragm__CaE  *  Conc_of_OP_in__Diaphragm  *  Diaphragm_Vol 
• Diaphragm__BuChE(t) = Diaphragm__BuChE(t - dt) + 
(Synthesis_of__Diaphragm__BuChE - Degradation_of_Diaphragm__BuChE - 
Inhibition_of_Diaphragm_BuChE) * dt 
• INIT Diaphragm__BuChE = 2.343 
• INFLOWS: 
o Synthesis_of__Diaphragm__BuChE = 2.343 
• OUTFLOWS: 
o Degradation_of_Diaphragm__BuChE = Diaphragm__BuChE 
o Inhibition_of_Diaphragm_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Diaphragm_BuChE  *  Conc_of_OP_in__Diaphragm  *  




• Free_Diaphragm__AChE(t) = Free_Diaphragm__AChE(t - dt) + 
(Natural_Production_of_Diaphragm_AChE + Regeneration_of__Diaphragm__AChE 
- Inhibition_of_Diaphragm_AChE - Natural_Degradation_of_Diaphragm_AChE) * 
dt 
• INIT Free_Diaphragm__AChE = 1.065 
• INFLOWS: 
o Natural_Production_of_Diaphragm_AChE = Diaphragm_AChE_Synthesis_Rate 
o Regeneration_of__Diaphragm__AChE = AChE_Regeneration_Rate  *  
Inhibited_Diaphragm_AChE 
• OUTFLOWS: 
o Inhibition_of_Diaphragm_AChE = AChE_Inhibition_Rate  *  
Conc_of_Diaphragm_AChE  *  Conc_of_OP_in__Diaphragm  *  
Unit_Converter_mg_to_nmol  *  Diaphragm_Vol 
o Natural_Degradation_of_Diaphragm_AChE = 
Diaphragm_AChE_Degradation_Coeff  *  Free_Diaphragm__AChE 
• Inhibited_Diaphragm_AChE(t) = Inhibited_Diaphragm_AChE(t - dt) + 
(Inhibition_of_Diaphragm_AChE - Regeneration_of__Diaphragm__AChE - 
Aged__Diaphragm_AChE) * dt 
• INIT Inhibited_Diaphragm_AChE = 0 
• INFLOWS: 
o Inhibition_of_Diaphragm_AChE = AChE_Inhibition_Rate  *  
Conc_of_Diaphragm_AChE  *  Conc_of_OP_in__Diaphragm  *  
Unit_Converter_mg_to_nmol  *  Diaphragm_Vol 
• OUTFLOWS: 
o Regeneration_of__Diaphragm__AChE = AChE_Regeneration_Rate  *  
Inhibited_Diaphragm_AChE 
o Aged__Diaphragm_AChE = AChE_Aging_Rate  *  Inhibited_Diaphragm_AChE 
• OP_in_Diaphragm(t) = OP_in_Diaphragm(t - dt) + (Diaphragm_AB_Flow_of_OP - 
Diaphragm_VB_Flow_of_OP - Diaphragm_OP_Lost_due_to__AChE - 
Diaphragm_OP_Lost_due_to__CaE - Diaphragm_OP_Lost_due_to__BuChE) * dt 
• INIT OP_in_Diaphragm = 0 
• INFLOWS: 
o Diaphragm_AB_Flow_of_OP = Cardiac_Output  *  Diaphragm_BFC  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o Diaphragm_VB_Flow_of_OP = Diaphragm_BFC   *   Cardiac_Output   *   ( 
Conc_of_OP_in__Diaphragm   /   Diaphragm_BPC_of_OP )   
o Diaphragm_OP_Lost_due_to__AChE = AChE_Inhibition_Rate  *  
Conc_of_Diaphragm_AChE  *  Conc_of_OP_in__Diaphragm  *  Diaphragm_Vol 
o Diaphragm_OP_Lost_due_to__CaE = CaE_Inhibition_Rate  *  
Conc_of_Diaphragm__CaE  *  Conc_of_OP_in__Diaphragm  *  Diaphragm_Vol 
o Diaphragm_OP_Lost_due_to__BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Diaphragm_BuChE  *  Conc_of_OP_in__Diaphragm  *  
Diaphragm_Vol 
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• Conc_of_Diaphragm_AChE = Free_Diaphragm__AChE  /  Diaphragm_Vol 
• Conc_of_Diaphragm_BuChE = Diaphragm__BuChE  /  Diaphragm_Vol 
• Conc_of_Diaphragm__CaE = Diaphragm_CaE  /  Diaphragm_Vol 
• Conc_of_OP_in__Diaphragm = OP_in_Diaphragm  /   Diaphragm_Vol 
• Diaphragm_AChE_Degradation_Coeff = Diaphragm_AChE_Synthesis_Rate  /  
Diaphragm_AChE_Homeostatic_State 
• Diaphragm_AChE_Homeostatic_State = 1.065 
• Diaphragm_AChE_Percentage = ( Hundred_Percent  /  
Diaphragm_AChE_Homeostatic_State )  *  Free_Diaphragm__AChE 
• Diaphragm_AChE_Synthesis_Rate = 0.053 
Diaphragm Con’t 
• Synaptic_Diaphragm__ACh(t) = Synaptic_Diaphragm__ACh(t - dt) + 
(Natural_Production_of_Diaphragm_ACh - Hydrolyzing_Diaphragm_ACh) * dt 
• INIT Synaptic_Diaphragm__ACh = 0.100 
• INFLOWS: 
o Natural_Production_of_Diaphragm_ACh = Diaphragm_ACh_Release_Rate 
• OUTFLOWS: 
o Hydrolyzing_Diaphragm_ACh = AChE_Hydrolysis_of_ACh  *  
Conc_of__Diaphragm_ACh  *  Conc_of_Diaphragm_AChE *  Diaphragm_Vol 
• Conc_of__Diaphragm_ACh = Synaptic_Diaphragm__ACh  /  Diaphragm_Vol 
• Diaphragm_ACh_Homeostatic_State = 0.100 
• Diaphragm_ACh_Percentage = ( Hundred_Percent  /  
Diaphragm_ACh_Homeostatic_State )  *  Synaptic_Diaphragm__ACh 
• Diaphragm_ACh_Release_Rate = 0.0117162 
Fat 
• OP_in__Fat(t) = OP_in__Fat(t - dt) + (Fat_AB__Flow_of_OP - 
Fat_VB__Flow_of_OP) * dtINIT OP_in__Fat = 0 
• INFLOWS: 
o Fat_AB__Flow_of_OP = Cardiac_Output  *  Fat_BFC  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o Fat_VB__Flow_of_OP = Fat_BFC  *  Cardiac_Output  *  ( 
Conc_of_OP_in_Fat_Tissue  /  Fat_BPC_of_OP )   
• Conc_of_OP_in_Fat_Tissue = OP_in__Fat  /  Fat_Vol 
Flow Constants 
• Cardiac_Output = Cardiac_Flow  *  Body_Weight  ^  0.74 
• GI_Flow_Const = 0 
• Pulmonary_Ventilation_Rate = Pulmonary_Flow  *  Body_Weight  ^  0.74 
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Kidney 
• Free_Kidney_AChE(t) = Free_Kidney_AChE(t - dt) + 
(Natural_Production_of_Kidney_AChE + Regeneration_of_Kidney_AChE - 
Inhibition_of_Kidney_AChE - Natural_Degradation_of_Kidney_AChE) * dt 
• INIT Free_Kidney_AChE = 0.13322 
• INFLOWS: 
o Natural_Production_of_Kidney_AChE = Kidney_AChE_Synthesis_Rate 
o Regeneration_of_Kidney_AChE = AChE_Regeneration_Rate  *  
Inhibited_Kidney_AChE 
• OUTFLOWS: 
o Inhibition_of_Kidney_AChE = AChE_Inhibition_Rate  *  
Conc_of_Kidney_AChE  *  Conc_of_OP_in_Kidney  *  
Unit_Converter_mg_to_nmol  *  Kidney_Vol 
o Natural_Degradation_of_Kidney_AChE = Kidney_AChE_Degradation_Coeff  *  
Free_Kidney_AChE 
• Inhibited_Kidney_AChE(t) = Inhibited_Kidney_AChE(t - dt) + 
(Inhibition_of_Kidney_AChE - Regeneration_of_Kidney_AChE - 
Aged_Kidney_AChE) * dt 
• INIT Inhibited_Kidney_AChE = 0 
• INFLOWS: 
o Inhibition_of_Kidney_AChE = AChE_Inhibition_Rate  *  
Conc_of_Kidney_AChE  *  Conc_of_OP_in_Kidney  *  
Unit_Converter_mg_to_nmol  *  Kidney_Vol 
• OUTFLOWS: 
o Regeneration_of_Kidney_AChE = AChE_Regeneration_Rate  *  
Inhibited_Kidney_AChE 
o Aged_Kidney_AChE = AChE_Aging_Rate  *  Inhibited_Kidney_AChE 
• Kidney_BuChE(t) = Kidney_BuChE(t - dt) + (Synthesis_of__Kidney_BuChE - 
Degradation_of_Kidney_BuChE - Inhibition_of_Kidney_BuChE) * dt 
• INIT Kidney_BuChE = 0.84 
• INFLOWS: 
o Synthesis_of__Kidney_BuChE = 0.84 
• OUTFLOWS: 
o Degradation_of_Kidney_BuChE = Kidney_BuChE 
o Inhibition_of_Kidney_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Kidney_BuChE  *  Conc_of_OP_in_Kidney  *  
Unit_Converter_mg_to_nmol  *  Kidney_Vol 
• Kidney_CaE(t) = Kidney_CaE(t - dt) + (Synthesis_of_Kidney_CaE - 
Inhibition_of_Kidney_CaE - Degradation_of_Kidney_CaE) * dt 
• INIT Kidney_CaE = 4620 
• INFLOWS: 




o Inhibition_of_Kidney_CaE = CaE_Inhibition_Rate  *  Conc_of_Kidney_CaE  *  
Conc_of_OP_in_Kidney  *  Unit_Converter_mg_to_nmol  *  Kidney_Vol 
o Degradation_of_Kidney_CaE = Kidney_CaE 
• Kidney_OP_Lost_AChE(t) = Kidney_OP_Lost_AChE(t - dt) + 
(Kidney_OP_Lost_due_to_AChE) * dt 
• INIT Kidney_OP_Lost_AChE = 0 
• INFLOWS: 
o Kidney_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  
Conc_of_Kidney_AChE  *  Conc_of_OP_in_Kidney  *  Kidney_Vol 
• Kidney_OP_Lost_BuChE(t) = Kidney_OP_Lost_BuChE(t - dt) + 
(Kidney_OP_Lost_due_to_BuChE) * dt 
• INIT Kidney_OP_Lost_BuChE = 0 
• INFLOWS: 
o Kidney_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Kidney_BuChE  *  Conc_of_OP_in_Kidney  *  Kidney_Vol 
• Kidney_OP_Lost_CaE(t) = Kidney_OP_Lost_CaE(t - dt) + 
(Kidney_OP_Lost_due_to_CaE) * dt 
• INIT Kidney_OP_Lost_CaE = 0 
• INFLOWS: 
o Kidney_OP_Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_Kidney_CaE  
*  Conc_of_OP_in_Kidney  *  Kidney_Vol 
• Kidney_OP_Lost_Metab(t) = Kidney_OP_Lost_Metab(t - dt) + 
(Kidney_Metabolism_of_OP) * dt 
• INIT Kidney_OP_Lost_Metab = 0 
• INFLOWS: 
o Kidney_Metabolism_of_OP = Kidney_Vmax_of_OP  *  ( 
Conc_of_OP_in_Kidney  /  Kidney_BPC_of_OP )  /  ( Kidney_Km_of_OP  +  ( 
Conc_of_OP_in_Kidney  /  Kidney_BPC_of_OP ))  +  Kf_of_OP  *  ( 
Conc_of_OP_in_Kidney  /  Kidney_BPC_of_OP )  *  Kidney_Vol 
• OP_in_Kidney(t) = OP_in_Kidney(t - dt) + (Kidney_AB_Flow_of_OP - 
Kidney_VB_Flow_of_OP - Kidney_Metabolism_of_OP - 
Kidney_OP_Lost_due_to_AChE - Kidney_OP_Lost_due_to_BuChE - 
Kidney_OP_Lost_due_to_CaE) * dt 
• INIT OP_in_Kidney = 0 
• INFLOWS: 
o Kidney_AB_Flow_of_OP = Cardiac_Output  *  Kidney_BFC  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o Kidney_VB_Flow_of_OP = ( Kidney_BFC  *  Cardiac_Output )  *  ( 




o Kidney_Metabolism_of_OP = Kidney_Vmax_of_OP  *  ( 
Conc_of_OP_in_Kidney  /  Kidney_BPC_of_OP )  /  ( Kidney_Km_of_OP  +  ( 
Conc_of_OP_in_Kidney  /  Kidney_BPC_of_OP ))  +  Kf_of_OP  *  ( 
Conc_of_OP_in_Kidney  /  Kidney_BPC_of_OP )  *  Kidney_Vol 
o Kidney_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  
Conc_of_Kidney_AChE  *  Conc_of_OP_in_Kidney  *  Kidney_Vol 
o Kidney_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_Kidney_BuChE  *  Conc_of_OP_in_Kidney  *  Kidney_Vol 
o Kidney_OP_Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_Kidney_CaE  
*  Conc_of_OP_in_Kidney  *  Kidney_Vol 
• Conc_of_Kidney_AChE = Free_Kidney_AChE  /  Kidney_Vol 
• Conc_of_Kidney_BuChE = Kidney_BuChE  /  Kidney_Vol 
• Conc_of_Kidney_CaE = Kidney_CaE  /  Kidney_Vol 
• Conc_of_OP_in_Kidney = OP_in_Kidney  /  Kidney_Vol 
• Kidney_AChE_Degradation_Coeff = Kidney_AChE_Synthesis_Rate  /  
Kidney_AChE_Homeostatic_State 
• Kidney_AChE_Homeostatic_State = .13322 
• Kidney_AChE_Percentage = ( Hundred_Percent  /  
Kidney_AChE_Homeostatic_State )  *  Free_Kidney_AChE 
• Kidney_AChE_Synthesis_Rate = 0.053 
Kidney Con’t 
• Synaptic_Kidney_ACh(t) = Synaptic_Kidney_ACh(t - dt) + 
(Natural_Production_of_Kidney_ACh - Hydrolyzing_Kidney_ACh) * dtINIT 
Synaptic_Kidney_ACh = 0.100 
• INFLOWS: 
o Natural_Production_of_Kidney_ACh = Kidney_ACh_Release_Rate 
• OUTFLOWS: 
o Hydrolyzing_Kidney_ACh = AChE_Hydrolysis_of_ACh  *  
Conc_of_Kidney_ACh  *  Conc_of_Kidney_AChE  *  Kidney_Vol 
• Conc_of_Kidney_ACh = Synaptic_Kidney_ACh  /  Kidney_Vol 
• Kidney_ACh_Homeostatic_State = 0.100 
• Kidney_ACh_Percentage = ( Hundred_Percent  /  Kidney_ACh_Homeostatic_State )  
*  Synaptic_Kidney_ACh 
• Kidney_ACh_Release_Rate = 0.001022492 
Liver 
• Free_Liver_AChE(t) = Free_Liver_AChE(t - dt) + 
(Natural__Production_of_Liver_AChE + Regeneration_of_Liver_AChE - 
Inhibition_of_Liver_AChE - Natural_Degradation_of_Liver_AChE) * dt 




o Natural__Production_of_Liver_AChE = Liver_AChE_Synthesis_Rate 
o Regeneration_of_Liver_AChE = AChE_Regeneration_Rate  *  
Inhibited_Liver_AChE 
• OUTFLOWS: 
o Inhibition_of_Liver_AChE = AChE_Inhibition_Rate  *  Conc_of_Liver_AChE  *  
Conc_of_OP_Liver_Tissue  *  Unit_Converter_mg_to_nmol  *  Liver_Vol 
o Natural_Degradation_of_Liver_AChE = Liver_AChE_Degradation_Coeff  *  
Free_Liver_AChE 
• Inhibited_Liver_AChE(t) = Inhibited_Liver_AChE(t - dt) + 
(Inhibition_of_Liver_AChE - Regeneration_of_Liver_AChE - Aged_Liver_AChE) * 
dt 
• INIT Inhibited_Liver_AChE = 0 
• INFLOWS: 
o Inhibition_of_Liver_AChE = AChE_Inhibition_Rate  *  Conc_of_Liver_AChE  *  
Conc_of_OP_Liver_Tissue  *  Unit_Converter_mg_to_nmol  *  Liver_Vol 
• OUTFLOWS: 
o Regeneration_of_Liver_AChE = AChE_Regeneration_Rate  *  
Inhibited_Liver_AChE 
o Aged_Liver_AChE = AChE_Aging_Rate  *  Inhibited_Liver_AChE 
• Liver_BuChE(t) = Liver_BuChE(t - dt) + (Synthesis_of_Liver_BuChE - 
Inhibition_of__Liver_BuChE - Degradation_of__Liver_BuChE) * dt 
• INIT Liver_BuChE = 12 
• INFLOWS: 
o Synthesis_of_Liver_BuChE = .24 
• OUTFLOWS: 
o Inhibition_of__Liver_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_OP_Liver_Tissue  *  Conc_of__Liver_BuChE *  
Unit_Converter_mg_to_nmol  *  Liver_Vol 
o Degradation_of__Liver_BuChE = 0.02  *  Liver_BuChE 
• Liver_CaE(t) = Liver_CaE(t - dt) + (Synthesis_of_Liver_CaE - 
Inhibition_of_Liver_CaE - Degradation_of_Liver_CaE) * dt 
• INIT Liver_CaE = 68250 
• INFLOWS: 
o Synthesis_of_Liver_CaE = 136.5 
• OUTFLOWS: 
o Inhibition_of_Liver_CaE = CaE_Inhibition_Rate  *  Conc_of_Liver_CaE  *  
Conc_of_OP_Liver_Tissue  *  Unit_Converter_mg_to_nmol *  Liver_Vol 
o Degradation_of_Liver_CaE = 0.002  *  Liver_CaE 
• Liver_OP_Lost_AChE(t) = Liver_OP_Lost_AChE(t - dt) + 
(Liver_OP_Lost_due_to_AChE) * dt 





o Liver_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  
Conc_of_Liver_AChE  *  Conc_of_OP_Liver_Tissue  *  Liver_Vol 
• Liver_Op_Lost_BuChE(t) = Liver_Op_Lost_BuChE(t - dt) + 
(Liver_OP_Lost_due_to_BuChE) * dt 
• INIT Liver_Op_Lost_BuChE = 0 
• INFLOWS: 
o Liver_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_OP_Liver_Tissue  *  Conc_of__Liver_BuChE  *  Liver_Vol 
• Liver_OP_Lost_CaE(t) = Liver_OP_Lost_CaE(t - dt) + 
(Liver_OP_Lost_due_to_CaE) * dt 
• INIT Liver_OP_Lost_CaE = 0 
• INFLOWS: 
o Liver_OP_Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_Liver_CaE  *  
Conc_of_OP_Liver_Tissue  *  Liver_Vol 
• Liver_OP_Lost_Metab(t) = Liver_OP_Lost_Metab(t - dt) + 
(Liver_Metabolism_of_OP) * dt 
• INIT Liver_OP_Lost_Metab = 0 
• INFLOWS: 
o Liver_Metabolism_of_OP = Liver_Vmax_of_OP  *  ( Conc_of_OP_Liver_Tissue  
/  Liver_BPC_of_OP )  /  ( Liver_Km_of_OP  +  ( Conc_of_OP_Liver_Tissue  /  
Liver_BPC_of_OP ))  +  Kf_of_OP  *  ( Conc_of_OP_Liver_Tissue  /  
Liver_BPC_of_OP )  *  Liver_Vol 
• OP_in__the_Liver(t) = OP_in__the_Liver(t - dt) + (Liver_AB_Flow_of_OP - 
Liver_VB_Flow_of_OP - Liver_Metabolism_of_OP - Liver_OP_Lost_due_to_AChE 
- Liver_OP_Lost_due_to_BuChE - Liver_OP_Lost_due_to_CaE) * dt 
• INIT OP_in__the_Liver = 0 
• INFLOWS: 
o Liver_AB_Flow_of_OP = Cardiac_Output  *  Liver_BFC  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o Liver_VB_Flow_of_OP = ( Liver_BFC  *  Cardiac_Output )  *  ( 
Conc_of_OP_Liver_Tissue  /  Liver_BPC_of_OP )   
o Liver_Metabolism_of_OP = Liver_Vmax_of_OP  *  ( Conc_of_OP_Liver_Tissue  
/  Liver_BPC_of_OP )  /  ( Liver_Km_of_OP  +  ( Conc_of_OP_Liver_Tissue  /  
Liver_BPC_of_OP ))  +  Kf_of_OP  *  ( Conc_of_OP_Liver_Tissue  /  
Liver_BPC_of_OP )  *  Liver_Vol 
o Liver_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  
Conc_of_Liver_AChE  *  Conc_of_OP_Liver_Tissue  *  Liver_Vol 
o Liver_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  
Conc_of_OP_Liver_Tissue  *  Conc_of__Liver_BuChE  *  Liver_Vol 
o Liver_OP_Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_Liver_CaE  *  
Conc_of_OP_Liver_Tissue  *  Liver_Vol 
• Conc_of_Liver_AChE = Free_Liver_AChE  /  Liver_Vol 
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• Conc_of_Liver_CaE = Liver_CaE  /  Liver_Vol 
• Conc_of_OP_Liver_Tissue = OP_in__the_Liver  /  Liver_Vol 
• Conc_of__Liver_BuChE = Liver_BuChE  /  Liver_Vol 
• Liver_AChE_Degradation_Coeff = Liver_AChE_Synthesis_Rate  /  
Liver_AChE_Homeostatic_State 
• Liver_AChE_Homeostatic_State = 1.5 
• Liver_AChE_Percentage = ( Hundred_Percent  /  Liver_AChE_Homeostatic_State )  
*  Free_Liver_AChE 
• Liver_AChE_Synthesis_Rate = 0.053 
Liver Con’t 
• Synaptic_Liver_ACh(t) = Synaptic_Liver_ACh(t - dt) + 
(Natural_Production_of_Liver_ACh - Hydrolyzing_Liver_ACh) * dt 
• INIT Synaptic_Liver_ACh = 0.100 
• INFLOWS: 
o Natural_Production_of_Liver_ACh = Liver_ACh_Release_Rate 
• OUTFLOWS: 
o Hydrolyzing_Liver_ACh = AChE_Hydrolysis_of_ACh  *  Conc_of__Liver_ACh  
*  Conc_of_Liver_AChE  *  Liver_Vol 
• Conc_of__Liver_ACh = Synaptic_Liver_ACh  /  Liver_Vol 
• Liver_ACh_Homeostatic_State = 0.100 
• Liver_ACh_Percentage = ( Hundred_Percent  /  Liver_ACh_Homeostatic_State )  *  
Synaptic_Liver_ACh  
• Liver_ACh_Release_Rate = 0.001237624 
Lung 
• Exhaled(t) = Exhaled(t - dt) + (Exhale) * dt 
• INIT Exhaled = 0 
• INFLOWS: 
o Exhale = Conc_of_OP_Entering_AB  *   Pulmonary_Ventilation_Rate   /   
Blood_Air_PC 
• Conc_of_OP_Entering_AB = ( Cardiac_Output   *   Conc_of_OP_Leaving_VB   +   
Pulmonary_Ventilation_Rate  *   Post_Scrubbing_Air_Conc )   /   ( Cardiac_Output   
+   Pulmonary_Ventilation_Rate  /   Blood_Air_PC ) 
• Post_Scrubbing_Air_Conc = Air_Conc  *  ( 1  -  Scrubbing__Coeff ) 
Mass Balance of OP in the System 
• TOTAL_MASS(t) = TOTAL_MASS(t - dt) + (Intake) * dt 
• INIT TOTAL_MASS = 0 
• INFLOWS: 
o Intake = Air_Conc   *   Pulmonary_Ventilation_Rate 
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• Distributed = OP_in__the_Brain + OP_in_Diaphragm + OP_in__Fat + 
OP_in_Kidney + OP_in__the_Liver + OP_in__RP + OP_in_SP + Exhaled + 
OP_in_Bronchial_Tissue + OP_in__Skin 
• Distributed_Plus_Motabolism = Distributed + Motabolism 
• Motabolism = Brain_OP_Lost_AChE + Brain_OP_Lost_BuChE + 
Brain_OP_Lost_CaE + Brain_OP_Lost_Metab + Liver_OP_Lost_AChE + 
Liver_Op_Lost_BuChE + Liver_OP_Lost_CaE + Liver_OP_Lost_Metab + 
Kidney_OP_Lost_BuChE + Kidney_OP_Lost_CaE + Kidney_OP_Lost_AChE + 
Kidney_OP_Lost_Metab + RP_OP_Lost_AChE + RP_OP_Lost_BuChE + 
RP_OP_Lost_CaE + RP_OP_Lost_Metab + SP_OP_Lost_AChE + 
SP_OP_Lost_BuChE + SP_OP_Lost__CaE + Diaphragm_OP_Lost_AChE + 
Diaphragm_OP_Lost_CaE + Diaphragm__BuChE + AB_OP__Lost_Enzymes + 
VB_OP_Lost_Enzymes + OP_in_AB + OP_in_VB 
Mich Men Cons 
• Brain_Km_of_OP = 440 
• Brain_Vmax_of_OP = 1605.9 
• Kidney_Km_of_OP = 134 
• Kidney_Vmax_of_OP = 18070.9 
• Liver_Km_of_OP = 50 
• Liver_Vmax_of_OP = 1927.1 
• RP_Km_of_OP = 50 
• RP_Vmax_of_OP = 1933.1 
Other 
• AChE_Hydrolysis_of_ACh = 0.02 
• BuChE_Inhibition_Rate = 0.4602 
• CaE_Inhibition_Rate = 0.00143 
• Delta_T = DT 
• Hundred_Percent = 100 
• Unit_Converter_mg_to_nmol = 1000000  /  MW 
• Unit_Converter_nmol_to_mg = MW  /  1000000 
Partition Coeff 
• Blood_Air_PC = 15.57 
• Brain_BPC_of_OP = 4.6 
• Bronchial_BPC_of__OP = 5.2 
• Diaphragm_BPC_of_OP = .5 
• Fat_BPC_of_OP = 40 
• Kidney_BPC_of_OP = 5.2 
• Liver_BPC_of_OP = 5.2 
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• RP_BPC_of_OP = 5.2 
• Skin_BPC_of_OP = .5 
• SP_BPC_of_OP = .5 
Physical Parameters 
• Body_Weight = 60.6 
• Cardiac_Flow = 14.5 
• Pulmonary_Flow = 17 
Richly Perfused Con’t 
• Synaptic_RP_ACh(t) = Synaptic_RP_ACh(t - dt) + 
(Natural_Production_of_RP_ACh - Hydrolyzing_RP_ACh) * dt 
• INIT Synaptic_RP_ACh = 0.100 
• INFLOWS: 
o Natural_Production_of_RP_ACh = RP_ACh_Release_Rate 
• OUTFLOWS: 
o Hydrolyzing_RP_ACh = AChE_Hydrolysis_of_ACh  *  Conc_of_RP_ACh  *  
Conc_of_RP_AChE  *  RP_Vol 
• Conc_of_RP_ACh = Synaptic_RP_ACh  /  RP_Vol 
• RP_ACh_Homeostatic_State = 0.100 
• RP_ACh_Percentage = ( Hundred_Percent  /  RP_ACh_Homeostatic_State )  *  
Synaptic_RP_ACh 
• RP_ACh_Release_Rate = .008005465 
Richly Perfused Tissues 
• Free_RP_AChE(t) = Free_RP_AChE(t - dt) + (Natural_Production_of_RP_AChE + 
Regeneration_of_RP_AChE - Inhibition_of_RP_AChE - 
Natural_Degradation_of_RP_AChE) * dt 
• INIT Free_RP_AChE = 8.32 
• INFLOWS: 
o Natural_Production_of_RP_AChE = RP_AChE_Synthesis_Rate 
o Regeneration_of_RP_AChE = AChE_Regeneration_Rate  *  Inhibited_RP_AChE 
• OUTFLOWS: 
o Inhibition_of_RP_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_AChE  *  Unit_Converter_mg_to_nmol  *  RP_Vol 
o Natural_Degradation_of_RP_AChE = RP_AChE_Degradation_Coeff  *  
Free_RP_AChE 
• Inhibited_RP_AChE(t) = Inhibited_RP_AChE(t - dt) + (Inhibition_of_RP_AChE - 
Regeneration_of_RP_AChE - Aged_RP_AChE) * dt 




o Inhibition_of_RP_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_AChE  *  Unit_Converter_mg_to_nmol  *  RP_Vol 
• OUTFLOWS: 
o Regeneration_of_RP_AChE = AChE_Regeneration_Rate  *  Inhibited_RP_AChE 
o Aged_RP_AChE = AChE_Aging_Rate  *  Inhibited_RP_AChE 
• OP_in__RP(t) = OP_in__RP(t - dt) + (RP_AB_Flow_of_OP - RP_VB__Flow_of_OP 
- RP_Metabolism_of_OP - RP_OP_Lost_due_to_AChE - 
RP_OP_Lost_due_to_BuChE - RP_OP__Lost__due_to_CaE) * dt 
• INIT OP_in__RP = 0 
• INFLOWS: 
o RP_AB_Flow_of_OP = Cardiac_Output  *  RP_BFC  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o RP_VB__Flow_of_OP = ( RP_BFC *  Cardiac_Output )  *  ( 
Conc_of_OP_in_RP  /  RP_BPC_of_OP ) 
o RP_Metabolism_of_OP = ( RP_Vmax_of_OP  *  ( Conc_of_OP_in_RP  /  
RP_BPC_of_OP ))  /  ( RP_Km_of_OP  +  ( Conc_of_OP_in_RP  /  
RP_BPC_of_OP ))  +  Kf_of_OP  *  ( Conc_of_OP_in_RP  /  RP_BPC_of_OP )  
*  RP_Vol 
o RP_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_AChE  *  RP_Vol 
o RP_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  Conc_of_OP_in_RP  
*  Conc_of_RP_BuChE  *  RP_Vol 
o RP_OP__Lost__due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_CaE  *  RP_Vol 
• RP_BuChE(t) = RP_BuChE(t - dt) + (Synthesis_of_RP_BuChE - 
Inhibition_of_RP_BuChE - Degradation_of_RP_BuChE) * dt 
• INIT RP_BuChE = 205.92 
• INFLOWS: 
o Synthesis_of_RP_BuChE = 205.92 
• OUTFLOWS: 
o Inhibition_of_RP_BuChE = BuChE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_BuChE  *  Unit_Converter_mg_to_nmol  *  RP_Vol 
o Degradation_of_RP_BuChE = RP_BuChE 
• RP_CaE(t) = RP_CaE(t - dt) + (Synthesis_of_RP_CaE - Inhibition_of_RP_CaE - 
Degradation_of_RP_CaE) * dt 
• INIT RP_CaE = 443040 
• INFLOWS: 
o Synthesis_of_RP_CaE = 88.608 
• OUTFLOWS: 
o Inhibition_of_RP_CaE = CaE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_CaE  *  Unit_Converter_mg_to_nmol  *  RP_Vol 
o Degradation_of_RP_CaE = 0.0002  *  RP_CaE 
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• RP_OP_Lost_AChE(t) = RP_OP_Lost_AChE(t - dt) + (RP_OP_Lost_due_to_AChE) 
* dt 
• INIT RP_OP_Lost_AChE = 0 
• INFLOWS: 
o RP_OP_Lost_due_to_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_AChE  *  RP_Vol 
• RP_OP_Lost_BuChE(t) = RP_OP_Lost_BuChE(t - dt) + 
(RP_OP_Lost_due_to_BuChE) * dt 
• INIT RP_OP_Lost_BuChE = 0 
• INFLOWS: 
o RP_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  Conc_of_OP_in_RP  
*  Conc_of_RP_BuChE  *  RP_Vol 
• RP_OP_Lost_CaE(t) = RP_OP_Lost_CaE(t - dt) + (RP_OP__Lost__due_to_CaE) * 
dt 
• INIT RP_OP_Lost_CaE = 0 
• INFLOWS: 
o RP_OP__Lost__due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_OP_in_RP  *  
Conc_of_RP_CaE  *  RP_Vol 
• RP_OP_Lost_Metab(t) = RP_OP_Lost_Metab(t - dt) + (RP_Metabolism_of_OP) * dt 
• INIT RP_OP_Lost_Metab = 0 
• INFLOWS: 
o RP_Metabolism_of_OP = ( RP_Vmax_of_OP  *  ( Conc_of_OP_in_RP  /  
RP_BPC_of_OP ))  /  ( RP_Km_of_OP  +  ( Conc_of_OP_in_RP  /  
RP_BPC_of_OP ))  +  Kf_of_OP  *  ( Conc_of_OP_in_RP  /  RP_BPC_of_OP )  
*  RP_Vol 
• Conc_of_OP_in_RP = OP_in__RP  /  RP_Vol 
• Conc_of_RP_AChE = Free_RP_AChE  /  RP_Vol 
• Conc_of_RP_BuChE = RP_BuChE /  RP_Vol 
• Conc_of_RP_CaE = RP_CaE  /  RP_Vol 
• RP_AChE_Degradation_Coeff = RP_AChE_Synthesis_Rate  /  
RP_AChE_Homeostatic_State 
• RP_AChE_Homeostatic_State = 8.32 
• RP_AChE_Percentage = ( Hundred_Percent  /  RP_AChE_Homeostatic_State )  *  
Free_RP_AChE 
• RP_AChE_Synthesis_Rate = 0.053 
Slowly Perfused Tissues 
• Free_SP_AChE(t) = Free_SP_AChE(t - dt) + (Natural_Production_of_SP_AChE + 
Regeneration__of_SP_AChE - Inhibition_of_SP_AChE - 
Natural_Degradation_of_SP_AChE) * dt 
• INIT Free_SP_AChE = 233.87 
• INFLOWS: 
o Natural_Production_of_SP_AChE = SP_AChE_Synthesis_Rate 
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o Regeneration__of_SP_AChE = AChE_Regeneration_Rate  *  
Inhibited_SP_AChE 
• OUTFLOWS: 
o Inhibition_of_SP_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_SP  *  
Conc_of_SP_AChE  *  Unit_Converter_mg_to_nmol  *  SP_Vol 
o Natural_Degradation_of_SP_AChE = SP_AChE_Degradation__Coeff  *  
Free_SP_AChE 
• Inhibited_SP_AChE(t) = Inhibited_SP_AChE(t - dt) + (Inhibition_of_SP_AChE - 
Regeneration__of_SP_AChE - Aged_SP_AChE) * dt 
• INIT Inhibited_SP_AChE = 0 
• INFLOWS: 
o Inhibition_of_SP_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_SP  *  
Conc_of_SP_AChE  *  Unit_Converter_mg_to_nmol  *  SP_Vol 
• OUTFLOWS: 
o Regeneration__of_SP_AChE = AChE_Regeneration_Rate  *  
Inhibited_SP_AChE 
o Aged_SP_AChE = AChE_Aging_Rate  *  Inhibited_SP_AChE 
• OP_in_SP(t) = OP_in_SP(t - dt) + (SP_Arterial_Blood_Flow_of_OP - 
SP_Venous_Blood_Flow_of_OP - SP_OP_Lost_due__to_AChE - 
SP_OP__Lost_due_to_CaE - SP_OP_Lost_due_to_BuChE) * dt 
• INIT OP_in_SP = 0 
• INFLOWS: 
o SP_Arterial_Blood_Flow_of_OP = Cardiac_Output  *  SP_BFC  *  
Conc_of_OP_Leaving_AB 
• OUTFLOWS: 
o SP_Venous_Blood_Flow_of_OP = ( SP_BFC  *   Cardiac_Output )  *  ( 
Conc_of_OP_in_SP  /  SP_BPC_of_OP ) 
o SP_OP_Lost_due__to_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_SP  *  
Conc_of_SP_AChE  *  SP_Vol 
o SP_OP__Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_OP_in_SP  *  
Conc_of_SP_CaE  *  SP_Vol 
o SP_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  Conc_of_OP_in_SP  
*  Conc_of_SP_BuChE  *  SP_Vol 
• SP_CaE(t) = SP_CaE(t - dt) + (Synthesis_of_SP_CaE - Degradation__of_SP_CaE - 
Inhibition_of_SP_CaE) * dt 
• INIT SP_CaE = 76843 
• INFLOWS: 
o Synthesis_of_SP_CaE = 76843 
• OUTFLOWS: 
o Degradation__of_SP_CaE = SP_CaE 
o Inhibition_of_SP_CaE = CaE_Inhibition_Rate  *  Conc_of_SP_CaE  *  
Conc_of_OP_in_SP  *  Unit_Converter_mg_to_nmol  *  SP_Vol 
• SP_OP_Lost_AChE(t) = SP_OP_Lost_AChE(t - dt) + 
(SP_OP_Lost_due__to_AChE) * dt 
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• INIT SP_OP_Lost_AChE = 0 
• INFLOWS: 
o SP_OP_Lost_due__to_AChE = AChE_Inhibition_Rate  *  Conc_of_OP_in_SP  *  
Conc_of_SP_AChE  *  SP_Vol 
• SP_OP_Lost_BuChE(t) = SP_OP_Lost_BuChE(t - dt) + 
(SP_OP_Lost_due_to_BuChE) * dt 
• INIT SP_OP_Lost_BuChE = 0 
• INFLOWS: 
o SP_OP_Lost_due_to_BuChE = BuChE_Inhibition_Rate  *  Conc_of_OP_in_SP  
*  Conc_of_SP_BuChE  *  SP_Vol 
• SP_OP_Lost__CaE(t) = SP_OP_Lost__CaE(t - dt) + (SP_OP__Lost_due_to_CaE) * 
dt 
• INIT SP_OP_Lost__CaE = 0 
• INFLOWS: 
o SP_OP__Lost_due_to_CaE = CaE_Inhibition_Rate  *  Conc_of_OP_in_SP  *  
Conc_of_SP_CaE  *  SP_Vol 
• SP__BuChE(t) = SP__BuChE(t - dt) + (Synthesis_of__SP_BuChE - 
Degradation_of_SP_BuChE - Inhibition_of_SP_BuChE) * dt 
• INIT SP__BuChE = 200.46 
• INFLOWS: 
o Synthesis_of__SP_BuChE = 200.46 
• OUTFLOWS: 
o Degradation_of_SP_BuChE = SP__BuChE 
o Inhibition_of_SP_BuChE = BuChE_Inhibition_Rate  *  Conc_of_SP_BuChE *  
Conc_of_OP_in_SP  *  Unit_Converter_mg_to_nmol  *  SP_Vol 
• Conc_of_OP_in_SP = OP_in_SP  /  SP_Vol 
• Conc_of_SP_AChE = Free_SP_AChE  /  SP_Vol 
• Conc_of_SP_BuChE = SP__BuChE  /  SP_Vol 
• Conc_of_SP_CaE = SP_CaE  /  SP_Vol 
• SP_AChE_Degradation__Coeff = SP_AChE_Synthesis_Rate  /  
SP_AChE__Homeostatic_State 
• SP_AChE_Percentage = ( Hundred_Percent  /  SP_AChE__Homeostatic_State )  *  
Free_SP_AChE 
• SP_AChE_Synthesis_Rate = 0.053 
• SP_AChE__Homeostatic_State = 233.87 
SP Con’t 
• Synaptic_SP_ACh(t) = Synaptic_SP_ACh(t - dt) + (Natural_Production_of_SP_ACh 
- Hydrolyzing_SP_ACh) * dt 
• INIT Synaptic_SP_ACh = 0.100 
• INFLOWS: 




o Hydrolyzing_SP_ACh = AChE_Hydrolysis_of_ACh  *  Conc_of__SP_ACh  *  
Conc_of_SP_AChE  *  SP_Vol 
• Conc_of__SP_ACh = Synaptic_SP_ACh  /  SP_Vol 
• SP_ACh_Homeostatic_State = 0.100 
• SP_ACh_Percentage = ( Hundred_Percent  /  SP_ACh_Homeostatic_State )  *  
Synaptic_SP_ACh 
• SP_ACh_Release_Rate = 0.013998 
Tissue Volume 
• AB__Vol = AB_VFC   *   Body_Weight 
• Brain_Vol = Brain_VFC  *  Body_Weight 
• Diaphragm_Vol = Body_Weight  *  Diaphragm_VFC 
• Fat_Vol = Fat_VFC  *  Body_Weight 
• Kidney_Vol = Kidney_VFC  *  Body_Weight 
• Liver_Vol = Liver_VFC  *  Body_Weight 
• Lung_Vol = Body_Weight  *   Lung_VFC 
• RP_Vol = Richly_VFC  *  Body_Weight 
• SP_Vol = Slowly_VFC  *  Body_Weight 
• VB__Vol = Body_Weight   *   VB_VFC 
Variable Patameters 
• AChE_Aging_Rate = .05 
• AChE_Inhibition_Rate = .01 
• AChE_Regeneration_Rate = .01 
• Air_Conc = 1 + STEP (-1, 61) 
• Exposure_to_Skin = 0.0 +  Step ( -0.0, 65) 
• Scrubbing__Coeff = .5 
• Skin_Transfer_Coeff = 0 
• Skin__Surface_Area = 0 
Venous Blood Flow 
• VB_OP_Lost_Enzymes(t) = VB_OP_Lost_Enzymes(t - dt) + (Inhibiting_in_VB) * dt 
• INIT VB_OP_Lost_Enzymes = 0 
• INFLOWS: 
o Inhibiting_in_VB = (( 
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_BuChE_in_VB  +  
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_CaE_in_VB  +  
Amount_of_Conc_of_OP__Removed_after_Inhibition_by_AChE_in_VB )  *  
VB__Vol )  /  Delta_T 
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• Amount_of_Conc_of_OP_Removed_after_Inhibition_by_BuChE_in_VB = 
Unit_Converter_nmol_to_mg  *  VB_Inhibition_Rate_for_BuChE  *   
Conc_of__VB_BuChE  *  Conc_of_OP__Entering_VB  *  Delta_T 
• Amount_of_Conc_of_OP_Removed_after_Inhibition_by_CaE_in_VB = 
Unit_Converter_nmol_to_mg  *  VB_Inhibition__Rate_for_CaE  *  
Conc_of_VB_CaE  *  Conc_of_OP__Entering_VB  *  Delta_T 
• Amount_of_Conc_of_OP__Removed_after_Inhibition_by_AChE_in_VB = 
Unit_Converter_nmol_to_mg  *  VB_Inhibition__Rate_for_AChE  *  
Conc_of__VB_AChE  *  Conc_of_OP__Entering_VB  *  Delta_T 
• Conc_of_OP_Leaving_VB = Conc_of_OP__Entering_VB  -  
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_CaE_in_VB  -  
Amount_of_Conc_of_OP__Removed_after_Inhibition_by_AChE_in_VB  -  
Amount_of_Conc_of_OP_Removed_after_Inhibition_by_BuChE_in_VB 
• Conc_of_OP__Entering_VB = ( Brain_Venous_Blood_Flow_of_OP  +  
Diaphragm_VB_Flow_of_OP  +  Fat_VB__Flow_of_OP  +  
Kidney_VB_Flow_of_OP  +  Liver_VB_Flow_of_OP  +  RP_VB__Flow_of_OP  +  
SP_Venous_Blood_Flow_of_OP  +  Bronchial__VB_Flow  +  
Skin_VB_Flow_of_OP )  /  Cardiac_Output 
• Conc_of_VB_CaE = Initial__Quantity_of__VB_CaE  /  VB__Vol 
• Conc_of__VB_AChE = Initial__Quantity_of__VB_AChE  /   VB__Vol 
• Conc_of__VB_BuChE = Initial__Quantity_of__VB_BuChE  /  VB__Vol 
• Initial__Quantity_of__VB_AChE = 3.85416 
• Initial__Quantity_of__VB_BuChE = 19.2708 
• Initial__Quantity_of__VB_CaE = 16187.47 
• OP_in_VB = Conc_of_OP_Leaving_VB  *  VB__Vol 
• VB_Inhibition_Rate_for_BuChE = .4248 
• VB_Inhibition__Rate_for_AChE = 0.01416 
• VB_Inhibition__Rate_for_CaE = 0.00108 
Volume Fraction Coeff 
• AB_VFC = 0.02 
• Brain_VFC = 0.0214 
• Diaphragm_VFC = 0.003 
• Fat_VFC = 0.1700 
• Kidney_VFC = 0.0043 
• Liver_VFC = 0.04 
• Lung_VFC = 0.0086 
• Richly_VFC = 0.0343 
• Slowly_VFC = 0.5514 




Model definition of terms 
Parameters 
Brain BFC A coefficient that determines the blood flow to 
the brain 
 
Liver BFC A coefficient that determines the blood flow to 
the liver 
 
Kidney BFC A coefficient that determines the blood flow to 
the kidney 
 
Fat BFC A coefficient that determines the blood flow to 
the fat 
 
SP BFC A coefficient that determines the blood flow to 
the slowly perfused tissues 
 
RP BFC A coefficient that determines the blood flow to 
the rapidly perfused tissues 
 
Diaphragm BFC A coefficient that determines the blood flow to 
the diaphragm 
 
Body weight Body weight in kilograms 
 
Pulmonary Flow Normalized pulmonary flow 
 
Cardiac Flow Total blood flow throughout the body 
 
Brain Vol The volume of the brain in relation to the body 
 
Liver Vol The volume of the liver in relation to the body 
 
Kidney Vol The volume of the kidney in relation to the 
body 
 
Fat Vol The volume of the fat in relation to the body 
 
SP Vol The volume of the slowly perfused tissues in 
relation to the body 
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RP Vol The volume of the rapidly perfused tissues in 
relation to the body 
 
Diaphragm Vol The volume of the diaphragm in relation to the 
body 
 
Lung Vol The volume of the lung in relation to the body 
 
VB Vol The volume of the venous blood in relation to 
the body 
 
AB Vol The volume of the arterial blood in relation to 
the body 
 
MW Molecular weight of OP to convert ppm by 
volume in air to mg/l air 
Kf of OP 1st order metabolic degradation coefficient 
normalized to body weight (this is 
controversial and I don’t think this is a valid 
parameter; i.e. a 1st order metabolic coefficient 
should be what it is and not scaled to body 
weight) 
 
Brain VFC A coefficient that scales the volume of the 
brain in relation to the body 
 
Liver VFC A coefficient that scales the volume of the 
brain in relation to the body 
 
Kidney VFC A coefficient that scales the volume of the 
brain in relation to the body 
 
Fat VFC A coefficient that scales the volume of the 
brain in relation to the body 
 
Slowly VFC A coefficient that scales the volume of the 
slowly perfused tissues in relation to the body 
 
Richly VFC A coefficient that scales the volume of the 
richly perfused tissues in relation to the body 
 
Diaphragm VFC A coefficient that scales the volume of the 
diaphragm in relation to the body 
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Lung VFC A coefficient that scales the volume of the 
lung in relation to the body 
 
VB VFC A coefficient that scales the volume of the 
venous blood in relation to the body 
 
AB VFC A coefficient that scales the volume of the 
arterial blood in relation to the body 
 
Blood Air PC Blood/air partition coefficient 
 
Brain BPC of OP Brain/blood partition coefficient 
 
Liver BPC of OP Liver/blood partition coefficient 
 
Kidney BPC of OP Kidney/blood partition coefficient 
 
Fat BPC of OP Fat/blood partition coefficient 
 
SP BPC of OP Slowly perfused tissues/blood partition 
coefficient 
 
RP BPC of OP Rapidly perfused tissues/blood partition 
coefficient 
 
Diaphragm BPC of OP Diaphragm/blood partition coefficient 
 
Bronchial BPC of OP Bronchial/blood partition coefficient 
 
Skin BPC of OP Skin/blood partition coefficient 
 
Brain Vmax of OP Maximum metabolic rate in a saturable (or 
Michaelis-Menten) process for the brain 
 
Liver Vmax of OP Maximum metabolic rate in a saturable (or 
Michaelis-Menten) process for the liver 
 
Kidney Vmax of OP Maximum metabolic rate in a saturable (or 
Michaelis-Menten) process for the kidney 
 
RP Vmax of OP Maximum metabolic rate in a saturable (or 
Michaelis-Menten) process for the richly 
perfused tissues 
 
Brain Km of OP Half saturation constant for the brain (mg/l) 
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Liver Km of OP Half saturation constant for the liver (mg/l) 
 
Kidney Km of OP Half saturation constant for the kidney (mg/l) 
 
RP Km of OP Half saturation constant for the richly perfused 
tissues (mg/l) 
 
Cardiac Output Total cardiac output (total systemic blood 
flow) 
 
Pulmonary Ventilation Rate Pulmonary ventilation rate 
 
Air Conc Chemical Concentration of the exterior 
breathing zone Air expressed as mg per liter 
of air 
 
Exposure to Skin Amount of organophosphate (in liquid form) 
that comes in contact with the skin 
 
Scrubbing Coeff Coefficient that determines how much of the 
organophosphate is scrubbed from the 
bronchial zone 
 
Skin Transfer Coeff Coefficient that determines how much of the 
organophosphate is allowed to penetrate the 
skin 
 
Skin Surface Area Amount of skin exposed to an 
organophosphate 
 
AChE Inhibition Rate Number that determines how fast the 
organophosphate inhibits AChE 
 
AChE Aging Rate Number that determines how fast the bonding 
between AChE and the organophosphate 
becomes a permanent bond 
 
AChE Regeneration Rate Number that determines how fast the bound 
between AChE and the organophosphate is 
broken and allows the AChE to become free 
AChE again 
 
Hundred Percent Represents 100% 
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Unit Converter mg to nmol Converts mgs of OP to nmols of OP 
 
Delta T Change in time 
 
AChE Hydrolysis of ACh Coefficient that determines how fast AChE 
will break down the ACh via hydrolysis 
 
Unit Converter nmol to mg Converts nmols of OP to mgs of OP 
Lung 
Conc of OP entering AB Concentration of the OP after it has passed 
through the blood-gas exchange and entered 
the arterial blood flow 
 
Exhale Rate of OP being exhaled at a given time 
 
Exhaled total accumulated amount of OP exhaled from 
the body 
 
Post scrubbing air conc Amount (concentration) of OP entering the 
blood-gas exchange after scrubbing has taken 
place 
 
Arterial Blood Flow 
AB inhibition rate for AChE Coefficient that determines the rate at which 
the OP concentration can be reduced via 
binding with AChE 
 
AB inhibition rate for BuChE Coefficient that determines the rate at which 
the OP concentration can be reduced via 
binding with BuChE 
 
AB inhibition rate for CaE Coefficient that determines the rate at which 
the OP concentration can be reduced via 
binding with CaE 
 
AB OP lost enzymes Accumulation of OP removed from the 
arterial blood due to binding with AChE, 
BuChE and CaE over time 
 
Amount of conc of OP removed Amount the concentration of AChE is reduced 
after inhibition by AChE in AB due to binding with the OP 
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Amount of conc of OP removed Amount the concentration of BuChE is 
after inhibition by BuChE in AB reduced due to binding with the OP 
 
Amount of conc of OP removed Amount the concentration of CaE is reduced 
after inhibition by CaE in AB due to binding with the OP 
 
Inhibiting in AB Rate at which OP is being removed from 
arterial blood due to binding with enzymes 
 
Conc of AB AChE Concentration of AChE in the brain at a given 
time 
 
Conc of AB BuChE Concentration of BuChE in the brain at a 
given time 
 
Conc of AB CaE Concentration of CaE in the brain at a given 
time 
 
Conc of OP leaving AB The concentration of OP being delivered to 
the body after AChE, BuChE and CaE have 
been reduced in concentration through binding 
with the OP 
 
Initial quantity of AB AChE homeostatic amount of AChE in the arterial 
blood 
 
Initial quantity of AB BuChE homeostatic amount of BuChE in the arterial 
blood 
 
Initial quantity of AB CaE homeostatic amount of CaE in the arterial 
blood 
 




Aged Brain AChE Amount of AChE becoming permanently 
bound with the OP 
 
Brain ACh Percentage Amount of ACh in the brain expressed as a 
percentage (100% equals homeostatic state) 
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Brain ACh Release Rate The number used to determine the rate in 
which the ACh is released into the synaptic 
space 
 
Brain AChE Degradation Coeff The coefficient used to determine the rate in 
which the AChE is degraded by natural 
processes 
 
Brain AChE Homeostatic State The natural level of AChE in the brain 
 
Brain AChE Percentage Amount of AChE in the brain expressed as a 
percentage (100% equals homeostatic state) 
 
Brain AChE Synthesis Rate The number used to determine the rate in 
which the AChE is synthesized 
 
Brain Arterial Blood Flow of OP Amount of blood (carrying OP) flowing into 
the brain from the arterial blood system 
 
Brain BuChE Amount of unbound carboxyl esterase 
available in the brain 
 
Brain CaE Amount of unbound butyrylcholinesterese 
available in the brain 
 
Brain ACh Homeostatic State The natural level of ACh in the brain 
 
Brain Metabolism of OP Amount of OP being metabolized 
 
Brain OP lost AChE Accumulated amount of OP removed from 
tissue due to acetylcholinesterase 
 
Brain OP lost due to AChE Amount of OP being bound by 
acetylcholinesterase 
 
Brain OP lost BuChE Accumulated amount of OP removed from 
tissue due to butyrylcholinesterese 
 
Brain OP lost due to BuChE Amount of OP being bound by 
butyrylcholinesterese 
 
Brain OP lost CaE Accumulated amount of OP removed from 
tissue due to carboxyl esterase 
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Brain OP lost due to CaE Amount of OP being bound by carboxyl 
esterase 
 
Brain OP lost Metab Accumulated amount of OP removed from 
tissue due to metabolism 
 
Brain Venous Blood Flow of OP Amount of blood leaving the brain (carrying 
OP) into the venous blood system 
 
Conc of Brain ACh Concentration of ACh in the brain at a given 
time 
 
Conc of Brain AChE Concentration of AChE in the brain at a given 
time 
 
Conc of Brain BuChE Concentration of butyrylcholinesterese in the 
brain at a given time 
 
Conc of Brain CaE Concentration of carboxyl esterase in the brain 
at a given time 
 
Conc of OP in Brain Concentration of OP in the brain at a given 
time 
 
Degradation of Brain BuChE Amount of butyrylcholinesterese being 
degraded by natural processes 
 
Degradation of Brain CaE Amount of carboxyl esterase being degraded 
by natural processes 
 
Free brain AChE Amount of unbound AChE available in the 
brain 
 
Hydrolyzing brain ACh Amount of ACh that binds with AChE 
resulting in the ACh being hydrolyzed 
 
Inhibited Brain AChE Amount of AChE that has been bound by an 
OP 
 
Inhibition of Brain AChE Amount of AChE being bound by OP in the 
brain 
 
Inhibition of Brain BuChE Amount of butyrylcholinesterese that has been 
bound by an OP 
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Inhibition of Brain CaE Amount of carboxyl esterase that has been 
bound by an OP 
 
Natural Production of Brain ACh Amount of ACh released from the pre-
synaptic side of the nerve cell in the brain 
 
Natural Production of Brain AChE Amount of AChE being synthesized into the 
brain 
 
Natural Degradation of Brain AChE Amount of AChE being degraded by natural 
processes 
 
OP in the Brian Amount of OP accumulated in the brain 
 
Regeneration of Brain AChE Amount of bound AChE becoming unbound 
and returning to free AChE 
 
Synthesis of Brain CaE Amount of carboxyl esterase being 
synthesized into the brain 
 
Synthesis of Brain BuChE Amount of butyrylcholinesterese being 
synthesized into the brain 
 
Synaptic Brain ACh Amount of unbound AChE available on the 
post-synaptic side of the nerve cell in the brain 
 
Liver 
Aged Liver AChE Amount of AChE becoming permanently 
bound with the OP 
 
Liver ACh Percentage Amount of ACh in the liver expressed as a 
percentage (100% equals homeostatic state) 
 
Liver ACh Release Rate The number used to determine the rate in 
which the ACh is released into the synaptic 
space 
 
Liver AChE Degradation Coeff The coefficient used to determine the rate in 
which the AChE is degraded by natural 
processes 
 
Liver AChE Homeostatic State The natural level of AChE in the liver 
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Liver AChE Percentage Amount of AChE in the liver expressed as a 
percentage (100% equals homeostatic state) 
 
Liver AChE Synthesis Rate The number used to determine the rate in 
which the AChE is synthesized 
 
Liver AB Flow of OP Amount of blood (carrying OP) flowing into 
the liver from the arterial blood system 
 
Liver BuChE Amount of unbound carboxyl esterase 
available in the liver 
 
Liver CaE Amount of unbound butyrylcholinesterese 
available in the liver 
 
Liver ACh Homeostatic State The natural level of ACh in the liver 
 
Liver Metabolism of OP Amount of OP being metabolized 
 
Liver OP lost AChE Accumulated amount of OP removed from 
tissue due to acetylcholinesterase 
 
Liver OP lost due to AChE Amount of OP being bound by 
acetylcholinesterase 
 
Liver OP lost BuChE Accumulated amount of OP removed from 
tissue due to butyrylcholinesterese 
 
Liver OP lost due to BuChE Amount of OP being bound by 
butyrylcholinesterese 
 
Liver OP lost CaE Accumulated amount of OP removed from 
tissue due to carboxyl esterase 
 
Liver OP lost due to CaE Amount of OP being bound by carboxyl 
esterase 
 
Liver OP lost Metab Accumulated amount of OP removed from 
tissue due to metabolism 
 
Liver VB Flow of OP Amount of blood leaving the liver (carrying 
OP) into the venous blood system 
 




Conc of Liver AChE Concentration of AChE in the liver at a given 
time 
 
Conc of Liver BuChE Concentration of butyrylcholinesterese in the 
liver at a given time 
 
Conc of Liver CaE Concentration of carboxyl esterase in the liver 
at a given time 
 
Conc of OP in Liver Concentration of OP in the liver at a given 
time 
 
Degradation of Liver BuChE Amount of butyrylcholinesterese being 
degraded by natural processes 
 
Degradation of Liver CaE Amount of carboxyl esterase being degraded 
by natural processes 
 
Free liver AChE Amount of unbound AChE available in the 
liver 
 
Hydrolyzing liver ACh Amount of ACh that binds with AChE 
resulting in the ACh being hydrolyzed 
 
Inhibited liver AChE Amount of AChE that has been bound by an 
OP 
 
Inhibition of liver AChE Amount of AChE being bound by OP in the 
liver 
 
Inhibition of liver BuChE Amount of butyrylcholinesterese that has been 
bound by an OP 
 
Inhibition of liver CaE Amount of carboxyl esterase that has been 
bound by an OP 
 
Natural Production of liver ACh Amount of ACh released from the pre-
synaptic side of the nerve cell in the liver 
 
Natural Production of liver AChE Amount of AChE being synthesized into the 
liver 
 




OP in liver Amount of OP accumulated in the liver 
 
Regeneration of liver AChE Amount of bound AChE becoming unbound 
and returning to free AChE 
 
Synthesis of liver CaE Amount of carboxyl esterase being 
synthesized into the liver 
 
Synthesis of liver BuChE Amount of butyrylcholinesterese being 
synthesized into the liver 
 
Synaptic liver ACh Amount of unbound AChE available on the 
post-synaptic side of the nerve cell in the liver 
 
Kidney 
Aged kidney AChE Amount of AChE becoming permanently 
bound with the OP 
 
Kidney ACh Percentage Amount of ACh in the kidney expressed as a 
percentage (100% equals homeostatic state) 
 
Kidney ACh Release Rate The number used to determine the rate in 
which the ACh is released into the synaptic 
space 
 
Kidney AChE Degradation Coeff The coefficient used to determine the rate in 
which the AChE is degraded by natural 
processes 
 
Kidney AChE Homeostatic State The natural level of AChE in the kidney 
 
Kidney AChE Percentage Amount of AChE in the liver expressed as a 
percentage (100% equals homeostatic state) 
 
Kidney AChE Synthesis Rate The number used to determine the rate in 
which the AChE is synthesized 
 
Kidney AB Flow of OP Amount of blood (carrying OP) flowing into 
the kidney from the arterial blood system 
 
Kidney BuChE Amount of unbound carboxyl esterase 
available in the kidney 
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Kidney CaE Amount of unbound butyrylcholinesterese 
available in the kidney 
 
Kidney ACh Homeostatic State The natural level of ACh in the kidney 
 
Kidney Metabolism of OP Amount of OP being metabolized 
 
Kidney OP lost AChE Accumulated amount of OP removed from 
tissue due to acetylcholinesterase 
 
Kidney OP lost due to AChE Amount of OP being bound by 
acetylcholinesterase 
 
Kidney OP lost BuChE Accumulated amount of OP removed from 
tissue due to butyrylcholinesterese 
 
Kidney OP lost due to BuChE Amount of OP being bound by 
butyrylcholinesterese 
 
Kidney OP lost CaE Accumulated amount of OP removed from 
tissue due to carboxyl esterase 
 
Kidney OP lost due to CaE Amount of OP being bound by carboxyl 
esterase 
 
Kidney OP lost Metab Accumulated amount of OP removed from 
tissue due to metabolism 
 
Kidney VB Flow of OP Amount of blood leaving the kidney (carrying 
OP) into the venous blood system 
 
Conc of kidney ACh Concentration of ACh in the kidney at a given 
time 
 
Conc of kidney AChE Concentration of AChE in the kidney at a 
given time 
 
Conc of kidney BuChE Concentration of butyrylcholinesterese in the 
kidney at a given time 
 
Conc of kidney CaE Concentration of carboxyl esterase in the 
kidney at a given time 
 




Degradation of kidney BuChE Amount of butyrylcholinesterese being 
degraded by natural processes 
 
Degradation of kidney CaE Amount of carboxyl esterase being degraded 
by natural processes 
 
Free kidney AChE Amount of unbound AChE available in the 
kidney 
 
Hydrolyzing kidney ACh Amount of ACh that binds with AChE 
resulting in the ACh being hydrolyzed 
 
Inhibited kidney AChE Amount of AChE that has been bound by an 
OP 
 
Inhibition of kidney AChE Amount of AChE being bound by OP in the 
kidney 
 
Inhibition of kidney BuChE Amount of butyrylcholinesterese that has been 
bound by an OP 
 
Inhibition of kidney CaE Amount of carboxyl esterase that has been 
bound by an OP 
 
Natural Production of kidney ACh Amount of ACh released from the pre-
synaptic side of the nerve cell in the kidney 
 
Natural Production of kidney AChE Amount of AChE being synthesized into the 
kidney 
 
Natural Degradation of kidney AChE Amount of AChE being degraded by natural 
processes 
 
OP in kidney Amount of OP accumulated in the kidney 
 
Regeneration of kidney AChE Amount of bound AChE becoming unbound 
and returning to free AChE 
 
Synthesis of kidney CaE Amount of carboxyl esterase being 
synthesized into the kidney 
 
Synthesis of kidney BuChE Amount of butyrylcholinesterese being 
synthesized into the kidney 
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Synaptic kidney ACh Amount of unbound AChE available on the 
post-synaptic side of the nerve cell in the 
kidney 
 
Richly Perfused Tissues 
Aged RP AChE Amount of AChE becoming permanently 
bound with the OP 
 
RP ACh Percentage Amount of ACh in the RP expressed as a 
percentage (100% equals homeostatic state) 
 
RP ACh Release Rate The number used to determine the rate in 
which the ACh is released into the synaptic 
space 
 
RP AChE Degradation Coeff The coefficient used to determine the rate in 
which the AChE is degraded by natural 
processes 
 
RP AChE Homeostatic State The natural level of AChE in the RP 
 
RP AChE Percentage Amount of AChE in the liver expressed as a 
percentage (100% equals homeostatic state) 
 
RP AChE Synthesis Rate The number used to determine the rate in 
which the AChE is synthesized 
 
RP AB Flow of OP Amount of blood (carrying OP) flowing into 
the RP from the arterial blood system 
 
RP BuChE Amount of unbound carboxyl esterase 
available in the RP 
 
RP CaE Amount of unbound butyrylcholinesterese 
available in the RP 
 
RP ACh Homeostatic State The natural level of ACh in the RP 
 
RP Metabolism of OP Amount of OP being metabolized 
 
RP OP lost AChE Accumulated amount of OP removed from 
tissue due to acetylcholinesterase 
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RP OP lost due to AChE Amount of OP being bound by 
acetylcholinesterase 
 
RP OP lost BuChE Accumulated amount of OP removed from 
tissue due to butyrylcholinesterese 
 
RP OP lost due to BuChE Amount of OP being bound by 
butyrylcholinesterese 
 
RP OP lost CaE Accumulated amount of OP removed from 
tissue due to carboxyl esterase 
 
RP OP lost due to CaE Amount of OP being bound by carboxyl 
esterase 
 
RP OP lost Metab Accumulated amount of OP removed from 
tissue due to metabolism 
 
RP VB Flow of OP Amount of blood leaving the RP (carrying 
OP) into the venous blood system 
 
Conc of RP ACh Concentration of ACh in the RP at a given 
time 
 
Conc of RP AChE Concentration of AChE in the RP at a given 
time 
 
Conc of RP BuChE Concentration of butyrylcholinesterese in the 
RP at a given time 
 
Conc of RP CaE Concentration of carboxyl esterase in the RP 
at a given time 
 
Conc of OP in RP Concentration of OP in the RP at a given time 
 
Degradation of RP BuChE Amount of butyrylcholinesterese being 
degraded by natural processes 
 
Degradation of RP CaE Amount of carboxyl esterase being degraded 
by natural processes 
 
Free RP AChE Amount of unbound AChE available in the RP 
 
Hydrolyzing RP ACh Amount of ACh that binds with AChE 
resulting in the ACh being hydrolyzed 
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Inhibited RP AChE Amount of AChE that has been bound by an 
OP 
 
Inhibition of RP AChE Amount of AChE being bound by OP in the 
RP 
 
Inhibition of RP BuChE Amount of butyrylcholinesterese that has been 
bound by an OP 
 
Inhibition of RP CaE Amount of carboxyl esterase that has been 
bound by an OP 
 
Natural Production of RP ACh Amount of ACh released from the pre-
synaptic side of the nerve cell in the RP 
 
Natural Production of RP AChE Amount of AChE being synthesized into the 
RP 
 
Natural Degradation of RP AChE Amount of AChE being degraded by natural 
processes 
 
OP in RP Amount of OP accumulated in the RP 
 
Regeneration of RP AChE Amount of bound AChE becoming unbound 
and returning to free AChE 
 
Synthesis of RP CaE Amount of carboxyl esterase being 
synthesized into the RP 
 
Synthesis of RP BuChE Amount of butyrylcholinesterese being 
synthesized into the RP 
 
Synaptic RP ACh Amount of unbound AChE available on the 
post-synaptic side of the nerve cell in the RP 
 
Fat 
OP in Fat Amount of OP accumulated in the fat 
 
Fat AB flow of OP Amount of blood (carrying OP) flowing into 
fat from the arterial blood system 
 
Fat VB flow of OP Amount of blood leaving fat (carrying OP) 
into the venous blood system 
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Conc of OP in fat tissue Concentration of OP in fat at a given time 
 
Slowly Perfused Tissues 
Aged SP AChE Amount of AChE becoming permanently 
bound with the OP 
 
SP ACh Percentage Amount of ACh in the SP expressed as a 
percentage (100% equals homeostatic state) 
 
SP ACh Release Rate The number used to determine the rate in 
which the ACh is released into the synaptic 
space 
 
SP AChE Degradation Coeff The coefficient used to determine the rate in 
which the AChE is degraded by natural 
processes 
 
SP AChE Homeostatic State The natural level of AChE in the SP 
 
SP AChE Percentage Amount of AChE in the liver expressed as a 
percentage (100% equals homeostatic state) 
 
SP AChE Synthesis Rate The number used to determine the rate in 
which the AChE is synthesized 
 
SP Arterial Blood Flow of OP Amount of blood (carrying OP) flowing into 
the SP from the arterial blood system 
 
SP BuChE Amount of unbound carboxyl esterase 
available in the SP 
 
SP CaE Amount of unbound butyrylcholinesterese 
available in the SP 
 
SP ACh Homeostatic State The natural level of ACh in the SP 
 
SP OP lost AChE Accumulated amount of OP removed from 
tissue due to acetylcholinesterase 
 




SP OP lost BuChE Accumulated amount of OP removed from 
tissue due to butyrylcholinesterese 
 
SP OP lost due to BuChE Amount of OP being bound by 
butyrylcholinesterese 
 
SP OP lost CaE Accumulated amount of OP removed from 
tissue due to carboxyl esterase 
 
SP OP lost due to CaE Amount of OP being bound by carboxyl 
esterase 
 
SP Venous Blood Flow of OP Amount of blood leaving the SP (carrying OP) 
into the venous blood system 
 
Conc of SP ACh Concentration of ACh in the SP at a given 
time 
 
Conc of SP AChE Concentration of AChE in the SP at a given 
time 
 
Conc of SP BuChE Concentration of butyrylcholinesterese in the 
SP at a given time 
 
Conc of SP CaE Concentration of carboxyl esterase in the SP at 
a given time 
 
Conc of OP in SP Concentration of OP in the SP at a given time 
 
Degradation of SP BuChE Amount of butyrylcholinesterese being 
degraded by natural processes 
 
Degradation of SP CaE Amount of carboxyl esterase being degraded 
by natural processes 
 
Free SP AChE Amount of unbound AChE available in the SP 
 
Hydrolyzing SP ACh Amount of ACh that binds with AChE 
resulting in the ACh being hydrolyzed 
 
Inhibited SP AChE Amount of AChE that has been bound by an 
OP 
 




Inhibition of SP BuChE Amount of butyrylcholinesterese that has been 
bound by an OP 
 
Inhibition of SP CaE Amount of carboxyl esterase that has been 
bound by an OP 
 
Natural Production of SP ACh Amount of ACh released from the pre-
synaptic side of the nerve cell in the SP 
 
Natural Production of SP AChE Amount of AChE being synthesized into the 
SP 
 
Natural Degradation of SP AChE Amount of AChE being degraded by natural 
processes 
 
OP in SP Amount of OP accumulated in the SP 
 
Regeneration of SP AChE Amount of bound AChE becoming unbound 
and returning to free AChE 
 
Synthesis of SP CaE Amount of carboxyl esterase being 
synthesized into the SP 
 
Synthesis of SP BuChE Amount of butyrylcholinesterese being 
synthesized into the SP 
 
Synaptic SP ACh Amount of unbound AChE available on the 
post-synaptic side of the nerve cell in the SP 
 
Diaphragm 
Aged Diaphragm AChE Amount of AChE becoming permanently 
bound with the OP 
 
Diaphragm ACh Percentage Amount of ACh in the diaphragm expressed 
as a percentage (100% equals homeostatic 
state) 
 
Diaphragm ACh Release Rate The number used to determine the rate in 




Diaphragm AChE Degradation Coeff The coefficient used to determine the rate in 
which the AChE is degraded by natural 
processes 
 
Diaphragm AChE Homeostatic State The natural level of AChE in the diaphragm 
 
Diaphragm AChE Percentage Amount of AChE in the diaphragm expressed 
as a percentage (100% equals homeostatic 
state) 
 
Diaphragm AChE Synthesis Rate The number used to determine the rate in 
which the AChE is synthesized 
 
Diaphragm AB Flow of OP Amount of blood (carrying OP) flowing into 
the diaphragm from the arterial blood system 
 
Diaphragm BuChE Amount of unbound carboxyl esterase 
available in the diaphragm 
 
Diaphragm CaE Amount of unbound butyrylcholinesterese 
available in the diaphragm 
 
Diaphragm ACh Homeostatic State The natural level of ACh in the diaphragm 
 
Diaphragm OP lost AChE Accumulated amount of OP removed from 
tissue due to acetylcholinesterase 
 
Diaphragm OP lost due to AChE Amount of OP being bound by 
acetylcholinesterase 
 
Diaphragm OP lost BuChE Accumulated amount of OP removed from 
tissue due to butyrylcholinesterese 
 
Diaphragm OP lost due to BuChE Amount of OP being bound by 
butyrylcholinesterese 
 
Diaphragm OP lost CaE Accumulated amount of OP removed from 
tissue due to carboxyl esterase 
 
Diaphragm OP lost due to CaE Amount of OP being bound by carboxyl 
esterase 
 
Diaphragm VB Flow of OP Amount of blood leaving the diaphragm 
(carrying OP) into the venous blood system 
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Conc of Diaphragm ACh Concentration of ACh in the diaphragm at a 
given time 
 
Conc of Diaphragm AChE Concentration of AChE in the diaphragm at a 
given time 
 
Conc of Diaphragm BuChE Concentration of butyrylcholinesterese in the 
diaphragm at a given time 
 
Conc of Diaphragm CaE Concentration of carboxyl esterase in the 
diaphragm at a given time 
 
Conc of OP in Diaphragm Concentration of OP in the diaphragm at a 
given time 
 
Degradation of Diaphragm BuChE Amount of butyrylcholinesterese being 
degraded by natural processes 
 
Degradation of Diaphragm CaE Amount of carboxyl esterase being degraded 
by natural processes 
 
Free Diaphragm AChE Amount of unbound AChE available in the 
diaphragm 
 
Hydrolyzing Diaphragm ACh Amount of ACh that binds with AChE 
resulting in the ACh being hydrolyzed 
 
Inhibited Diaphragm AChE Amount of AChE that has been bound by an 
OP 
 
Inhibition of Diaphragm AChE Amount of AChE being bound by OP in the 
diaphragm 
 
Inhibition of Diaphragm BuChE Amount of butyrylcholinesterese that has been 
bound by an OP 
 
Inhibition of Diaphragm CaE Amount of carboxyl esterase that has been 
bound by an OP 
 
Natural Production of Diaphragm ACh Amount of ACh released from the pre-
synaptic side of the nerve cell in the 
diaphragm 
 




Natural Degradation of Diaphragm AChE Amount of AChE being degraded by natural 
processes 
 
OP in Diaphragm Amount of OP accumulated in the diaphragm 
 
Regeneration of Diaphragm AChE Amount of bound AChE becoming unbound 
and returning to free AChE 
 
Synthesis of Diaphragm CaE Amount of carboxyl esterase being 
synthesized into the diaphragm 
 
Synthesis of Diaphragm BuChE Amount of butyrylcholinesterese being 
synthesized into the diaphragm 
 
Synaptic Diaphragm ACh Amount of unbound AChE available on the 
post-synaptic side of the nerve cell in the 
diaphragm 
 
Venous Blood Flow 
Amount of Conc of OP removed Amount the concentration of AChE is reduced 
after inhibition by AChE in VB due to binding with the OP 
 
Amount of Conc of OP removed Amount the concentration of BuChE is 
after inhibition by BuChE in VB reduced due to binding with the OP 
 
Amount of Conc of OP removed Amount the concentration of CaE is reduced 
after inhibition by CaE in VB due to binding with the OP 
 
Conc of OP entering VB summation of OP concentrations leaving 
 
Conc of OP leaving VB The concentration of OP being returned from 
the body after AChE, BuChE and CaE have 
been reduced in concentration through binding 
with the OP 
 
Conc of VB AChE Concentration of AChE in the brain at a given 
time 
 
Conc of VB BuChE Concentration of BuChE in the brain at a 
given time 
 




Inhibiting in VB Rate at which OP is being removed from 
venous blood due to binding with enzymes 
 
Initial quantity of VB AChE homeostatic amount of AChE in the venous 
blood 
 
Initial quantity of VB BuChE homeostatic amount of BuChE in the venous 
blood 
 
Initial quantity of VB CaE homeostatic amount of CaE in the venous 
blood 
 
OP in VB Amount of OP accumulated in the venous 
blood 
 
VB inhibition rate for AChE Coefficient that determines the rate at which 
the OP concentration can be reduced via 
binding with AChE 
 
VB inhibition rate for BuChE Coefficient that determines the rate at which 
the OP concentration can be reduced via 
binding with BuChE 
 
VB inhibition rate for CaE Coefficient that determines the rate at which 
the OP concentration can be reduced via 
binding with CaE 
 
VB OP lost enzymes Accumulation of OP removed from the 
venous blood due to binding with AChE, 
BuChE and CaE over time 
 
Bronchial 
OP in bronchial tissue Amount of OP accumulated in the bronchial 
tissue 
 
Bronchial AB flow Amount of blood (carrying OP) flowing into 
the bronchial tissue from the arterial blood 
system 
 
Bronchial VB flow Amount of blood leaving the bronchial tissue 
(carrying OP) into the venous blood system 
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Bronchial intake Amount of OP being delivered to the 
bronchial tissues via the air way/breathing 
zone by inhaling 
 
Bronchial BFC A coefficient that determines the blood flow to 
the bronchial tissue 
 
Bronchial Vol The volume of the bronchial tissue in relation 
to the body 
 
Conc of OP in Bronchial Concentration of OP in the bronchial tissue at 
a given time 
 
Dermal 
OP in the skin Amount of OP accumulated in the skin 
 
Absorption of OP via skin Rate at which an OP is entering the body via 
the skin 
 
Skin VB flow of OP Amount of blood leaving the skin (carrying 
OP) into the venous blood system 
 
Skin AB flow of OP Amount of blood (carrying OP) flowing into 
the skin from the arterial blood system 
 
Skin BFC A coefficient that determines the blood flow to 
the skin 
 
Vol of skin The volume of the skin in relation to the body 
 
Conc of OP in skin Concentration of OP in the skin at a given 
time 
 
Skin VFC A coefficient that scales the volume of the 





Model differential equations 

















































( ) BuChESPSPBuChECaESPSPCaEAChESPSPAChEVSPASPSPSPSP CCKCCKCCKCCQ
dt
dCV ××−××−××−−×=×  
 
( ) BuChEDpDpBuChECaEDpDpCaEAChEDpDpAChEVDpADpDpDpDp CCKCCKCCKCCQ
dt
dCV ××−××−××−−×=×  
 
( ) CConcVRVBSABSBSBSBS SAirPCCQ
dt




dCV SATCVSkASkSkSkSk +++−×=×  
Legend: 
VBr = Volume of brain (liters) 
VLr = Volume of liver (liters) 
VKd = Volume of kidney (liters) 
VRP = Volume of richly perfused tissues (liters) 
VSP = Volume of slowly perfused tissues (liters) 
VDp = Volume of diaphragm (liters) 
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VBS = Volume of bronchial tissue (liters) 
VSk = Volume of skin (liters) 
QBr = Cardiac Output to the brain (liters per hour) 
QLr = Cardiac Output to the liver (liters per hour) 
QKd = Cardiac Output to the kidney (liters per hour) 
QRP = Cardiac Output to the richly perfused tissues (liters per hour) 
QSP = Cardiac Output to the slowly perfused tissues (liters per hour) 
QDp = Cardiac Output to the diaphragm (liters per hour) 
QBS = Cardiac Output to the bronchial tissue (liters per hour) 
QSk = Cardiac Output to the skin (liters per hour) 
CABr = Concentration of OP in the arterial brain (mg per liter) 
CALr = Concentration of OP in the arterial liver (mg per liter) 
CAKd = Concentration of OP in the arterial kidney (mg per liter) 
CARP = Concentration of OP in the arterial richly perfused tissues (mg per liter) 
CASP = Concentration of OP in the arterial slowly perfused tissues (mg per liter) 
CADp = Concentration of OP in the arterial diaphragm (mg per liter) 
CABS = Concentration of OP in the arterial bronchial tissue (mg per liter) 
CASk = Concentration of OP in the arterial skin (mg per liter) 
CVBr = Concentration of OP in the venous brain (mg per liter) 
CVLr = Concentration of OP in the venous liver (mg per liter) 
CVKd = Concentration of OP in the venous kidney (mg per liter) 
CVRP = Concentration of OP in the venous richly perfused tissues (mg per liter) 
CVSP = Concentration of OP in the venous slowly perfused tissues (mg per liter) 
 139 
CVDp = Concentration of OP in the venous diaphragm (mg per liter) 
CVBS = Concentration of OP in the venous bronchial tissue (mg per liter) 
CVSk = Concentration of OP in the venous skin (mg per liter) 
VmaxBr = Maximum rate of OP hydrolysis in brain (mg per hour) 
VmaxLr = Maximum rate of OP hydrolysis in liver (mg per hour) 
VmaxKd = Maximum rate of OP hydrolysis in kidney (mg per hour) 
VmaxRP = Maximum rate of OP hydrolysis in richly perfused tissues (mg per hour) 
KmBr = Michaelis-Menten constant for OP in brain (mg per liter) 
KmLr = Michaelis-Menten constant for OP hydrolysis in liver (mg per hour) 
KmKd = Michaelis-Menten constant for OP hydrolysis in kidney (mg per hour) 
KmRP = Michaelis-Menten constant for OP hydrolysis in richly perfused tissues (mg per 
hour) 
KAChE = Bimolecular rate constant for OP reaction with AChE (nM-hr)-1 
KCaE = Bimolecular rate constant for OP reaction with CaE (nM-hr)-1 
KBuChE = Bimolecular rate constant for OP reaction with BuChE (nM-hr)-1 
CBr = Concentration of OP in the brain compartment (mg per liter) 
CLr = Concentration of OP in the liver compartment (mg per liter) 
CKd = Concentration of OP in the kidney compartment (mg per liter) 
CRP = Concentration of OP in the richly perfused compartment (mg per liter) 
CSP = Concentration of OP in the slowly perfused compartment (mg per liter) 
CDp = Concentration of OP in the diaphragm compartment (mg per liter) 
CAChEBr = AChE concentration in the brain (nmol per liter) 
CAChELr = AChE concentration in the liver (nmol per liter) 
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CAChEKd = AChE concentration in the kidney (nmol per liter) 
CAChERP = AChE concentration in the richly perfused tissues (nmol per liter) 
CAChESP = AChE concentration in the slowly perfused tissues (nmol per liter) 
CAChEDp = AChE concentration in the diaphragm (nmol per liter) 
CCaEBr = CaE concentration in the brain (nmol per liter) 
CCaELr = CaE concentration in the liver (nmol per liter) 
CCaEKd = CaE concentration in the kidney (nmol per liter) 
CCaERP = CaE concentration in the richly perfused tissues (nmol per liter) 
CCaESP = CaE concentration in the slowly perfused tissues (nmol per liter) 
CCaEDp = CaE concentration in the diaphragm (nmol per liter) 
CBuChEBr = BuChE concentration in the brain (nmol per liter) 
CBuChELr = BuChE concentration in the liver (nmol per liter) 
CBuChEKd = BuChE concentration in the kidney (nmol per liter) 
CBuChERP = BuChE concentration in the richly perfused tissues (nmol per liter) 
CBuChESP = BuChE concentration in the slowly perfused tissues (nmol per liter) 
CBuChEDp = BuChE concentration in the diaphragm (nmol per liter) 
PVR = Pulmonary ventilation rate (liters per hour) 
AirConc = Chemical concentration of the external breathing area of the exterior breathing 
zone (mg per liter of air) 
SC = Bronchial scrubbing coefficient (unitless) 
STC = Skin transfer coefficient (cm2-hr)-1 
SSA = Skin surface area (cm2) 
OP = Exposure to the skin (mg) 
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KAChE = Bimolecular rate constant for OP reaction with AChE (nM-hr)-1 
CAChEBr = Concentration of free AChE in the brain (nM) 
CAChELr = Concentration of free AChE in the liver (nM) 
CAChEKd = Concentration of free AChE in the kidney (nM) 
CAChERP = Concentration of free AChE in the richly perfused tissues (nM) 
CAChESP = Concentration of free AChE in the slowly perfused tissues (nM) 
CAChEDp = Concentration of free AChE in the diaphragm (nM) 
Conversion = Changes units from mg per liter to nmol per liter 
KRAChE = Rate of regeneration of inhibited AChE (hr-1) 
KAAChE = Rate of aging of inhibited AChE (hr-1) 
AChEBr = Inhibited AChE in the brain (nM) 
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AChELr = Inhibited AChE in the liver (nM) 
AChEKd = Inhibited AChE in the kidney (nM) 
AChERP = Inhibited AChE in the richly perfused tissues (nM) 
AChESP = Inhibited AChE in the slowly perfused tissues (nM) 
AChEDp = Inhibited AChE in the diaphragm (nM) 



































dCV ×××−=×  
 
Legend: 
AChRR = ACh release rate from presynaptic side (nM per hour) 
AChHyd = AChE hydrolysis of ACh coefficient (nM-hr)-1 
CAChBr = Concentration of ACh in the brain (nM) 
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CAChLr = Concentration of ACh in the liver (nM) 
CAChKd = Concentration of ACh in the kidney (nM) 
CAChRP = Concentration of ACh in the richly perfused tissues (nM) 
CAChSP = Concentration of ACh in the slowly perfused tissues (nM) 









Simulations run for sensitivity analysis 
Inhalation
There will only be five different trials for this section in order to reduce the amount of simulations run.
The values for each trial will correspond to trials 1, 3, 5, 7. and 9.
During this section of the analysis there will be 100 simulations conducted. 
Note: The numbers shown in the matrix are equal to the values for that trial
when only one parameter was being changed at the time.  For example, for trial 1
the partition coeff = 0.68 for air, -3.26 for brain, etc and the aging rate = 0.05.
Partition Coefficients
Trial Part Coeff Metabolism Inhibition Aging Rate
Regneneration 
Rate
1 1 3 3 3 3
2 3 3 3 3 3
3 5 3 3 3 3
4 7 3 3 3 3
5 9 3 3 3 3
6 1 5 5 5 5
7 3 5 5 5 5
8 5 5 5 5 5
9 7 5 5 5 5
10 9 5 5 5 5
11 1 7 7 7 7
12 3 7 7 7 7
13 5 7 7 7 7
14 7 7 7 7 7
15 9 7 7 7 7
16 1 9 9 9 9
17 3 9 9 9 9
18 5 9 9 9 9
19 7 9 9 9 9
20 9 9 9 9 9  
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Metabolism
Trial Part Coeff Metabolism Inhibition Aging Rate
Regneneration 
Rate
1 3 1 3 3 3
2 3 3 3 3 3
3 3 5 3 3 3
4 3 7 3 3 3
5 3 9 3 3 3
6 5 1 5 5 5
7 5 3 5 5 5
8 5 5 5 5 5
9 5 7 5 5 5
10 5 9 5 5 5
11 7 1 7 7 7
12 7 3 7 7 7
13 7 5 7 7 7
14 7 7 7 7 7
15 7 9 7 7 7
16 9 1 9 9 9
17 9 3 9 9 9
18 9 5 9 9 9
19 9 7 9 9 9
20 9 9 9 9 9
Inhibition Coeff
Trial Part Coeff Metabolism Inhibition Aging Rate
Regneneration 
Rate
1 3 3 1 3 3
2 3 3 3 3 3
3 3 3 5 3 3
4 3 3 7 3 3
5 3 3 9 3 3
6 5 5 1 5 5
7 5 5 3 5 5
8 5 5 5 5 5
9 5 5 7 5 5
10 5 5 9 5 5
11 7 7 1 7 7
12 7 7 3 7 7
13 7 7 5 7 7
14 7 7 7 7 7
15 7 7 9 7 7
16 9 9 1 9 9
17 9 9 3 9 9
18 9 9 5 9 9
19 9 9 7 9 9
20 9 9 9 9 9  
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Aging Rate
Trial Part Coeff Metabolism Inhibition Aging Rate
Regneneration 
Rate
1 3 3 3 1 3
2 3 3 3 3 3
3 3 3 3 5 3
4 3 3 3 7 3
5 3 3 3 9 3
6 5 5 5 1 5
7 5 5 5 3 5
8 5 5 5 5 5
9 5 5 5 7 5
10 5 5 5 9 5
11 7 7 7 1 7
12 7 7 7 3 7
13 7 7 7 5 7
14 7 7 7 7 7
15 7 7 7 9 7
16 9 9 9 1 9
17 9 9 9 3 9
18 9 9 9 5 9
19 9 9 9 7 9
20 9 9 9 9 9
Regeneration Rate
Trial Part Coeff Metabolism Inhibition Aging Rate
Regneneration 
Rate
1 3 3 3 3 1
2 3 3 3 3 3
3 3 3 3 3 5
4 3 3 3 3 7
5 3 3 3 3 9
6 5 5 5 5 1
7 5 5 5 5 3
8 5 5 5 5 5
9 5 5 5 5 7
10 5 5 5 5 9
11 7 7 7 7 1
12 7 7 7 7 3
13 7 7 7 7 5
14 7 7 7 7 7
15 7 7 7 7 9
16 9 9 9 9 1
17 9 9 9 9 3
18 9 9 9 9 5
19 9 9 9 9 7





Results of sensitivity analysis 
Inhalation
Partition Coefficients
Trial Brain Liver Kidney RP SP Diaphragm
1 2287.349 132.472 127.113 265.145 188.081 139.552
2 3712.917 151.725 131.093 299.801 259.452 178.314
3 4267.946 159.702 126.957 260.496 287.979 245.295
4 4507.311 164.156 130.560 246.515 310.205 353.874
5 4548.697 165.152 132.625 246.438 319.287 396.053
6 3927.770 155.915 144.600 436.506 432.266 227.655
7 4417.043 166.811 147.999 466.422 599.407 334.518
8 4554.706 169.018 144.618 432.929 631.960 452.009
9 4610.730 170.170 151.091 421.847 662.511 580.484
10 4620.191 170.385 153.870 420.918 669.993 614.371
11 4537.722 168.583 155.343 535.414 783.422 431.334
12 4616.254 172.083 156.883 546.677 843.247 569.233
13 4636.469 172.591 155.340 533.600 851.171 655.606
14 4644.238 172.878 158.802 530.009 860.449 724.318
15 4645.477 172.916 159.530 529.157 861.479 737.958
16 4594.648 170.610 157.449 551.679 846.633 520.569
17 4518.758 172.825 158.485 558.982 879.131 639.658
18 4645.210 173.131 157.662 550.806 883.776 704.627
19 4649.014 173.298 159.807 548.309 888.551 751.404




Trial Brain Liver Kidney RP SP Diaphragm
1 3716.968 149.843 130.758 297.982 254.821 176.238
2 3709.891 151.873 131.116 301.287 258.808 178.248
3 3823.208 156.337 132.647 317.913 277.532 187.172
4 3902.557 158.777 133.939 334.120 294.763 195.511
5 3916.416 159.136 134.176 337.212 298.054 197.120
6 4542.303 167.954 143.607 426.536 610.717 433.514
7 4540.837 168.367 143.810 428.013 614.085 435.168
8 4551.075 169.202 144.652 435.145 630.086 451.400
9 4558.108 169.618 145.335 441.017 642.263 460.751
10 4559.963 169.706 146.182 443.197 646.802 466.828
11 4635.525 172.640 155.237 520.891 855.798 708.896
12 4635.459 172.689 155.822 521.495 856.329 710.528
13 4635.950 172.808 157.697 524.737 859.636 717.492
14 4636.315 172.878 158.700 527.712 862.566 723.371
15 4636.382 172.889 158.853 528.300 863.137 724.482
16 4641.445 173.220 158.553 541.028 888.251 751.097
17 4603.638 173.239 158.813 541.400 888.379 751.978
18 4641.572 173.287 159.636 543.297 889.686 755.667
19 4641.677 173.315 160.074 544.991 890.798 758.718
20 4641.696 173.319 160.141 545.321 891.014 759.288
Inhibition Coeff
Trial Brain Liver Kidney RP SP Diaphragm
1 2192.580 132.473 115.416 171.434 144.641 125.915
2 3703.333 152.021 131.116 300.872 260.299 178.380
3 4368.106 165.548 147.597 463.919 596.803 326.016
4 4564.875 171.224 156.381 540.399 831.008 545.592
5 4596.143 172.268 158.129 554.485 871.067 619.964
6 3545.837 148.452 112.325 152.828 151.363 149.998
7 4286.988 161.436 126.700 257.499 283.394 243.861
8 4540.287 169.246 144.270 430.676 625.316 446.459
9 4612.781 172.454 154.905 528.056 840.644 644.531
10 4624.973 173.045 157.142 546.608 877.043 695.838
11 4402.793 158.196 125.014 153.509 165.345 213.217
12 4564.382 165.428 141.474 260.116 333.879 378.100
13 4622.933 170.399 153.537 434.850 687.813 595.198
14 4644.238 172.630 158.599 530.009 858.332 724.870
15 4648.699 173.060 159.521 547.998 885.729 751.607
16 4485.499 159.603 131.281 153.071 167.682 239.909
17 4586.293 165.880 146.486 259.259 342.431 421.412
18 4628.474 170.501 155.838 434.219 696.501 628.098
19 4645.755 172.651 159.406 529.551 860.314 738.951




Trial Brain Liver Kidney RP SP Diaphragm
1 3686.607 151.735 131.050 300.464 259.512 177.970
2 3715.944 151.779 131.093 301.080 260.096 178.612
3 4025.268 152.304 131.614 308.564 267.429 181.910
4 4154.787 152.682 132.003 313.951 273.201 184.491
5 4167.170 152.762 132.087 315.008 274.439 185.004
6 4401.006 168.764 143.257 407.335 562.885 418.187
7 4415.681 168.789 143.361 409.464 568.227 420.794
8 4558.338 169.085 144.618 434.836 633.834 451.625
9 4609.644 169.303 145.558 450.645 677.530 472.041
10 4614.321 169.355 145.765 453.292 684.769 475.928
11 4565.572 172.683 157.187 472.420 715.525 667.732
12 4569.573 172.691 157.246 475.551 723.709 670.717
13 4607.703 172.786 157.950 510.674 815.872 704.357
14 4621.079 172.878 158.466 530.009 862.566 724.870
15 4622.317 172.908 158.578 533.039 868.644 728.680
16 4589.899 173.115 158.867 479.421 727.073 704.152
17 4592.475 173.120 158.909 482.944 735.981 706.923
18 4616.959 173.194 159.418 522.286 835.178 737.910
19 4625.553 173.276 159.791 543.667 883.927 756.603
20 4626.360 173.306 159.873 547.019 890.228 760.066
Regeneration Rate
Trial Brain Liver Kidney RP SP Diaphragm
1 4015.318 152.419 131.856 311.338 270.841 183.375
2 3715.944 151.670 131.093 301.080 260.096 178.380
3 2903.063 149.199 128.637 271.116 230.190 164.154
4 1699.058 143.222 123.075 217.620 182.240 140.266
5 1180.202 138.479 119.063 188.336 158.927 128.210
6 4612.413 169.298 146.000 455.089 688.706 480.562
7 4600.294 169.220 145.686 450.403 675.691 474.027
8 4558.338 168.950 144.618 434.836 633.834 452.616
9 4442.308 168.195 141.804 396.525 539.335 401.882
10 4331.683 167.461 139.302 365.458 470.864 362.796
11 4646.569 172.988 159.019 537.564 872.243 733.412
12 4646.408 172.980 158.997 537.038 871.277 732.711
13 4645.846 172.953 158.919 535.201 867.906 730.267
14 4644.238 172.878 158.700 530.009 858.332 723.371
15 4642.631 172.802 158.483 524.900 848.841 716.602
16 4650.420 173.403 160.291 552.732 894.948 765.039
17 4650.386 173.399 160.285 552.524 894.615 764.803
18 4650.270 173.387 160.264 551.798 893.447 763.977
19 4649.938 173.353 160.202 549.730 890.115 761.627




Trial Brain Liver Kidney RP SP Diaphragm
1 4666.299 174.162 161.173 579.177 935.867 799.175
2 4666.856 174.171 161.181 579.235 935.968 799.259
3 4667.292 174.179 161.186 579.289 936.065 799.335
4 4667.635 174.185 161.190 579.339 936.158 799.403
5 4667.913 174.191 161.194 579.386 936.247 799.463
6 4668.142 174.195 161.196 579.430 936.332 799.518
7 4668.334 174.200 161.198 579.470 936.141 799.567
8 4668.497 174.203 161.199 579.508 936.493 799.612
9 4668.637 174.206 161.201 579.544 936.568 799.652
10 4668.759 174.209 161.202 579.577 936.640 799.688
11 4668.865 174.211 161.202 579.608 936.709 799.721  
 
Dermal Exposure
Trial Brain Liver Kidney RP SP Diaphragm
1 4353.463 158.866 129.087 278.308 287.636 258.972
2 4315.633 156.818 127.262 261.970 261.795 242.351
3 4268.066 154.312 125.285 244.911 237.098 225.706
4 4206.614 151.261 123.145 227.232 213.828 209.142
5 4124.295 147.563 120.817 209.038 192.172 192.736
6 4008.570 143.080 118.262 190.459 172.252 176.414
7 3835.068 137.625 115.432 171.677 154.144 160.209
8 3549.571 130.940 112.267 152.928 137.886 144.198
9 3007.950 122.686 108.698 134.502 123.475 128.558
10 1739.934 112.471 104.639 116.731 110.867 113.621
11 100.000 100.000 100.000 100.000 100.000 100.000
12 4585.638 171.015 149.250 489.095 741.764 531.462
13 4577.821 170.645 148.131 475.378 717.116 511.085
14 4567.970 170.175 146.801 459.450 686.152 487.903
15 4555.128 169.556 145.183 441.044 646.523 461.087
16 4537.675 168.704 143.163 419.696 595.036 429.646
17 4512.599 167.459 140.566 393.405 527.829 392.235
18 4473.671 165.481 137.097 354.906 441.831 346.882
19 4405.896 161.907 132.235 309.099 339.383 290.896
20 4264.508 154.312 125.244 245.396 236.166 225.563
21 3831.646 137.625 115.409 171.905 153.830 160.163
22 100.000 100.000 100.000 100.000 100.000 100.000
23 4630.029 173.334 157.826 564.710 892.862 721.547
24 4628.110 173.256 157.488 562.848 888.067 713.435
25 4625.722 173.158 157.068 560.428 881.952 703.420  
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26 4622.663 173.030 156.528 557.158 873.901 690.741
27 4618.586 172.857 155.810 552.514 862.847 674.168
28 4612.859 172.610 154.808 545.454 846.797 651.561
29 4604.193 172.230 153.314 533.596 821.576 618.800
30 4589.518 171.564 150.844 510.290 777.084 566.704
31 4560.092 170.175 146.571 459.450 684.922 487.455
32 4465.841 165.481 136.916 357.906 440.931 346.639
33 100.000 100.000 100.000 100.000 100.000 100.000
34 4624.579 173.859 160.067 572.790 925.629 778.152
35 4623.965 173.839 159.981 572.426 924.621 776.016
36 4623.221 173.814 159.873 571.968 923.836 773.343
37 4622.295 173.782 159.935 571.343 921.585 769.906
38 4621.103 173.740 159.552 570.540 919.289 765.327
39 4619.495 173.682 159.296 569.421 916.039 758.934
40 4617.174 173.595 158.913 567.639 911.077 749.399
41 4613.451 173.451 158.278 564.503 902.563 733.717
42 4606.242 173.158 157.014 557.555 884.611 703.269
43 4584.737 172.230 153.264 530.732 824.196 618.677
44 100.000 100.000 100.000 100.000 100.000 100.000
45 4656.533 173.997 161.047 578.032 929.111 794.212
46 4656.325 173.992 161.022 577.927 928.797 793.631
47 4656.080 173.985 160.991 577.295 928.411 792.903
48 4655.784 173.975 160.951 577.627 927.921 791.145
49 4655.330 173.961 160.898 577.405 927.276 790.699
50 4654.675 173.942 160.824 577.098 926.379 788.142
51 4653.763 173.915 160.713 576.641 925.043 789.236
52 4652.364 173.871 160.529 575.880 922.823 781.734
53 4649.841 173.787 160.164 574.337 918.362 772.687
54 4643.194 173.542 159.090 569.385 904.524 745.748
55 100.000 100.000 100.000 100.000 100.000 100.000
56 4630.539 174.032 161.059 578.607 930.162 796.639
57 4630.397 174.029 161.058 578.558 930.000 796.377
58 4630.230 174.025 161.056 578.499 929.806 796.083
59 4630.030 174.020 161.054 578.424 929.569 795.706
60 4629.786 174.014 161.051 578.328 929.259 795.202
61 4629.475 174.007 161.038 578.198 928.847 794.496
62 4629.061 173.996 160.992 578.009 928.256 793.431
63 4628.460 173.978 160.916 577.685 927.306 791.640
64 4627.157 173.306 160.764 577.052 925.461 788.142
65 4623.748 193.832 160.312 577.052 919.992 776.999




Simulations run for testing portion 
Inhalation
Partition Coefficients
Trial Exposure (mg/l) Partition Coeff Metabolism Inhibition Coeff Aging Rate
Regeneration 
Rate
1 1 1 5 3 3 3
2 2 1 5 3 3 3
3 3 1 5 3 3 3
4 1 5 5 3 3 3
5 2 5 5 3 3 3
6 3 5 5 3 3 3
7 1 9 5 3 3 3
8 2 9 5 3 3 3
9 3 9 5 3 3 3
10 1 1 5 5 5 5
11 2 1 5 5 5 5
12 3 1 5 5 5 5
13 1 5 5 5 5 5
14 2 5 5 5 5 5
15 3 5 5 5 5 5
16 1 9 5 5 5 5
17 2 9 5 5 5 5
18 3 9 5 5 5 5
19 1 1 5 7 7 7
20 2 1 5 7 7 7
21 3 1 5 7 7 7
22 1 5 5 7 7 7
23 2 5 5 7 7 7
24 3 5 5 7 7 7
25 1 9 5 7 7 7
26 2 9 5 7 7 7
27 3 9 5 7 7 7
28 1 1 5 9 9 9
29 2 1 5 9 9 9
30 3 1 5 9 9 9
31 1 5 5 9 9 9
32 2 5 5 9 9 9
33 3 5 5 9 9 9
34 1 9 5 9 9 9
35 2 9 5 9 9 9





Trial Exposure (mg) Partition Coeff Metabolism Inhibition Coeff Aging Rate
Regeneration 
Rate
1 1 3 5 1 3 3
2 2 3 5 1 3 3
3 3 3 5 1 3 3
4 1 3 5 5 3 3
5 2 3 5 5 3 3
6 3 3 5 5 3 3
7 1 3 5 9 3 3
8 2 3 5 9 3 3
9 3 3 5 9 3 3
10 1 5 5 1 5 5
11 2 5 5 1 5 5
12 3 5 5 1 5 5
13 1 5 5 5 5 5
14 2 5 5 5 5 5
15 3 5 5 5 5 5
16 1 5 5 9 5 5
17 2 5 5 9 5 5
18 3 5 5 9 5 5
19 1 7 5 1 7 7
20 2 7 5 1 7 7
21 3 7 5 1 7 7
22 1 7 5 5 7 7
23 2 7 5 5 7 7
24 3 7 5 5 7 7
25 1 7 5 9 7 7
26 2 7 5 9 7 7
27 3 7 5 9 7 7
28 1 9 5 1 9 9
29 2 9 5 1 9 9
30 3 9 5 1 9 9
31 1 9 5 5 9 9
32 2 9 5 5 9 9
33 3 9 5 5 9 9
34 1 9 5 9 9 9
35 2 9 5 9 9 9




Trial Exposure (mg) Partition Coeff Metabolism Inhibition Coeff Aging Rate
Regeneration 
Rate
1 1 5 5 5 1 5
2 2 5 5 5 1 5
3 3 5 5 5 1 5
4 1 5 5 5 5 5
5 2 5 5 5 5 5
6 3 5 5 5 5 5
7 1 5 5 5 9 5
8 2 5 5 5 9 5
9 3 5 5 5 9 5
10 1 7 5 7 1 7
11 2 7 5 7 1 7
12 3 7 5 7 1 7
13 1 7 5 7 5 7
14 2 7 5 7 5 7
15 3 7 5 7 5 7
16 1 7 5 7 9 7
17 2 7 5 7 9 7
18 3 7 5 7 9 7
19 1 9 5 9 1 9
20 2 9 5 9 1 9
21 3 9 5 9 1 9
22 1 9 5 9 5 9
23 2 9 5 9 5 9
24 3 9 5 9 5 9
25 1 9 5 9 9 9
26 2 9 5 9 9 9
27 3 9 5 9 9 9
Regeneration Rate
Trial Exposure (mg) Partition Coeff Metabolism Inhibition Coeff Aging Rate
Regeneration 
Rate
1 1 3 5 3 3 1
2 2 3 5 3 3 1
3 3 3 5 3 3 1
4 1 3 5 3 3 5
5 2 3 5 3 3 5
6 3 3 5 3 3 5
7 1 3 5 3 3 9
8 2 3 5 3 3 9
9 3 3 5 3 3 9
10 1 5 5 5 5 1
11 2 5 5 5 5 1
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12 3 5 5 5 5 1
13 1 5 5 5 5 5
14 2 5 5 5 5 5
15 3 5 5 5 5 5
16 1 5 5 5 5 9
17 2 5 5 5 5 9








Coeff Partition Coeff Inhibition Coeff Aging Rate
Regeneration 
Rate
1 1 1 1 3 3 3
2 2 1 1 3 3 3
3 3 1 1 3 3 3
4 1 10 1 3 3 3
5 2 10 1 3 3 3
6 3 10 1 3 3 3
7 1 1 5 3 3 3
8 2 1 5 3 3 3
9 3 1 5 3 3 3
10 1 10 5 3 3 3
11 2 10 5 3 3 3
12 3 10 5 3 3 3
13 1 1 9 3 3 3
14 2 1 9 3 3 3
15 3 1 9 3 3 3
16 1 10 9 3 3 3
17 2 10 9 3 3 3
18 3 10 9 3 3 3
19 1 1 1 5 5 5
20 2 1 1 5 5 5
21 3 1 1 5 5 5
22 1 10 1 5 5 5
23 2 10 1 5 5 5
24 3 10 1 5 5 5
25 1 1 5 5 5 5
26 2 1 5 5 5 5
27 3 1 5 5 5 5
28 1 10 5 5 5 5
29 2 10 5 5 5 5
30 3 10 5 5 5 5
31 1 1 9 5 5 5
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32 2 1 9 5 5 5
33 3 1 9 5 5 5
34 1 10 9 5 5 5
35 2 10 9 5 5 5
36 3 10 9 5 5 5
37 1 1 1 7 7 7
38 2 1 1 7 7 7
39 3 1 1 7 7 7
40 1 10 1 7 7 7
41 2 10 1 7 7 7
42 3 10 1 7 7 7
43 1 1 5 7 7 7
44 2 1 5 7 7 7
45 3 1 5 7 7 7
46 1 10 5 7 7 7
47 2 10 5 7 7 7
48 3 10 5 7 7 7
49 1 1 9 7 7 7
50 2 1 9 7 7 7
51 3 1 9 7 7 7
52 1 10 9 7 7 7
53 2 10 9 7 7 7
54 3 10 9 7 7 7
55 1 1 1 9 9 9
56 2 1 1 9 9 9
57 3 1 1 9 9 9
58 1 10 1 9 9 9
59 2 10 1 9 9 9
60 3 10 1 9 9 9
61 1 1 5 9 9 9
62 2 1 5 9 9 9
63 3 1 5 9 9 9
64 1 10 5 9 9 9
65 2 10 5 9 9 9
66 3 10 5 9 9 9
67 1 1 9 9 9 9
68 2 1 9 9 9 9
69 3 1 9 9 9 9
70 1 10 9 9 9 9
71 2 10 9 9 9 9










Coeff Partition Coeff Inhibition Coeff Aging Rate
Regeneration 
Rate
1 1 1 3 1 3 3
2 2 1 3 1 3 3
3 3 1 3 1 3 3
4 1 10 3 1 3 3
5 2 10 3 1 3 3
6 3 10 3 1 3 3
7 1 1 3 5 3 3
8 2 1 3 5 3 3
9 3 1 3 5 3 3
10 1 10 3 5 3 3
11 2 10 3 5 3 3
12 3 10 3 5 3 3
13 1 1 3 9 3 3
14 2 1 3 9 3 3
15 3 1 3 9 3 3
16 1 10 3 9 3 3
17 2 10 3 9 3 3
18 3 10 3 9 3 3
19 1 1 5 1 5 5
20 2 1 5 1 5 5
21 3 1 5 1 5 5
22 1 10 5 1 5 5
23 2 10 5 1 5 5
24 3 10 5 1 5 5
25 1 1 5 5 5 5
26 2 1 5 5 5 5
27 3 1 5 5 5 5
28 1 10 5 5 5 5
29 2 10 5 5 5 5
30 3 10 5 5 5 5
31 1 1 5 9 5 5
32 2 1 5 9 5 5
33 3 1 5 9 5 5
34 1 10 5 9 5 5
35 2 10 5 9 5 5
36 3 10 5 9 5 5
37 1 1 7 1 7 7
38 2 1 7 1 7 7
39 3 1 7 1 7 7
40 1 10 7 1 7 7
41 2 10 7 1 7 7
42 3 10 7 1 7 7
43 1 1 7 5 7 7
44 2 1 7 5 7 7
45 3 1 7 5 7 7
 
 161 
46 1 10 7 5 7 7
47 2 10 7 5 7 7
48 3 10 7 5 7 7
49 1 1 7 9 7 7
50 2 1 7 9 7 7
51 3 1 7 9 7 7
52 1 10 7 9 7 7
53 2 10 7 9 7 7
54 3 10 7 9 7 7
55 1 1 9 1 9 9
56 2 1 9 1 9 9
57 3 1 9 1 9 9
58 1 10 9 1 9 9
59 2 10 9 1 9 9
60 3 10 9 1 9 9
61 1 1 9 5 9 9
62 2 1 9 5 9 9
63 3 1 9 5 9 9
64 1 10 9 5 9 9
65 2 10 9 5 9 9
66 3 10 9 5 9 9
67 1 1 9 9 9 9
68 2 1 9 9 9 9
69 3 1 9 9 9 9
70 1 10 9 9 9 9
71 2 10 9 9 9 9




Coeff Partition Coeff Metabolism Inhibition Coeff Aging Rate
1 1 1 5 5 5 1
2 2 1 5 5 5 1
3 3 1 5 5 5 1
4 1 10 5 5 5 1
5 2 10 5 5 5 1
6 3 10 5 5 5 1
7 1 1 5 5 5 5
8 2 1 5 5 5 5
9 3 1 5 5 5 5
10 1 10 5 5 5 5
11 2 10 5 5 5 5
12 3 10 5 5 5 5
13 1 1 5 5 5 9
14 2 1 5 5 5 9
15 3 1 5 5 5 9
16 1 10 5 5 5 9
17 2 10 5 5 5 9
 
 162 
18 3 10 5 5 5 9
19 1 1 7 5 7 1
20 2 1 7 5 7 1
21 3 1 7 5 7 1
22 1 10 7 5 7 1
23 2 10 7 5 7 1
24 3 10 7 5 7 1
25 1 1 7 5 7 5
26 2 1 7 5 7 5
27 3 1 7 5 7 5
28 1 10 7 5 7 5
29 2 10 7 5 7 5
30 3 10 7 5 7 5
31 1 1 7 5 7 9
32 2 1 7 5 7 9
33 3 1 7 5 7 9
34 1 10 7 5 7 9
35 2 10 7 5 7 9
36 3 10 7 5 7 9
37 1 1 9 5 9 1
38 2 1 9 5 9 1
39 3 1 9 5 9 1
40 1 10 9 5 9 1
41 2 10 9 5 9 1
42 3 10 9 5 9 1
43 1 1 9 5 9 5
44 2 1 9 5 9 5
45 3 1 9 5 9 5
46 1 10 9 5 9 5
47 2 10 9 5 9 5
48 3 10 9 5 9 5
49 1 1 9 5 9 9
50 2 1 9 5 9 9
51 3 1 9 5 9 9
52 1 10 9 5 9 9
53 2 10 9 5 9 9




Coeff Partition Coeff Metabolism Inhibition Coeff Aging Rate
1 1 1 3 5 3 3
2 2 1 3 5 3 3
3 3 1 3 5 3 3
4 1 10 3 5 3 3
5 2 10 3 5 3 3
6 3 10 3 5 3 3
7 1 1 3 5 3 3
 
 163 
8 2 1 3 5 3 3
9 3 1 3 5 3 3
10 1 10 3 5 3 3
11 2 10 3 5 3 3
12 3 10 3 5 3 3
13 1 1 3 5 3 3
14 2 1 3 5 3 3
15 3 1 3 5 3 3
16 1 10 3 5 3 3
17 2 10 3 5 3 3
18 3 10 3 5 3 3
19 1 1 5 5 5 5
20 2 1 5 5 5 5
21 3 1 5 5 5 5
22 1 10 5 5 5 5
23 2 10 5 5 5 5
24 3 10 5 5 5 5
25 1 1 5 5 5 5
26 2 1 5 5 5 5
27 3 1 5 5 5 5
28 1 10 5 5 5 5
29 2 10 5 5 5 5
30 3 10 5 5 5 5
31 1 1 5 5 5 5
32 2 1 5 5 5 5
33 3 1 5 5 5 5
34 1 10 5 5 5 5
35 2 10 5 5 5 5

















1 1 2 1 5 3 3 3
2 2 2 1 5 3 3 3
3 3 2 1 5 3 3 3
4 1 2 1 5 5 5 5
5 2 2 1 5 5 5 5
6 3 2 1 5 5 5 5
7 1 2 1 5 7 7 7
8 2 2 1 5 7 7 7
9 3 2 1 5 7 7 7
10 1 2 1 5 9 9 9
11 2 2 1 5 9 9 9
 
 164 
12 3 2 1 5 9 9 9
13 1 10 1 5 3 3 3
14 2 10 1 5 3 3 3
15 3 10 1 5 3 3 3
16 1 10 1 5 5 5 5
17 2 10 1 5 5 5 5
18 3 10 1 5 5 5 5
19 1 10 1 5 7 7 7
20 2 10 1 5 7 7 7
21 3 10 1 5 7 7 7
22 1 10 1 5 9 9 9
23 2 10 1 5 9 9 9
24 3 10 1 5 9 9 9
25 1 2 3 5 3 3 3
26 2 2 3 5 3 3 3
27 3 2 3 5 3 3 3
28 1 2 3 5 5 5 5
29 2 2 3 5 5 5 5
30 3 2 3 5 5 5 5
31 1 2 3 5 7 7 7
32 2 2 3 5 7 7 7
33 3 2 3 5 7 7 7
34 1 2 3 5 9 9 9
35 2 2 3 5 9 9 9
36 3 2 3 5 9 9 9
37 1 10 3 5 3 3 3
38 2 10 3 5 3 3 3
39 3 10 3 5 3 3 3
40 1 10 3 5 5 5 5
41 2 10 3 5 5 5 5
42 3 10 3 5 5 5 5
43 1 10 3 5 7 7 7
44 2 10 3 5 7 7 7
45 3 10 3 5 7 7 7
46 1 10 3 5 9 9 9
47 2 10 3 5 9 9 9
48 3 10 3 5 9 9 9
49 1 7 5 5 3 3 3
50 2 7 5 5 3 3 3
51 3 7 5 5 3 3 3
52 1 7 5 5 5 5 5
53 2 7 5 5 5 5 5
54 3 7 5 5 5 5 5
55 1 7 5 5 7 7 7
56 2 7 5 5 7 7 7
57 3 7 5 5 7 7 7
58 1 7 5 5 9 9 9
59 2 7 5 5 9 9 9
60 3 7 5 5 9 9 9
 
 165 
61 1 10 5 5 3 3 3
62 2 10 5 5 3 3 3
63 3 10 5 5 3 3 3
64 1 10 5 5 5 5 5
65 2 10 5 5 5 5 5
66 3 10 5 5 5 5 5
67 1 10 5 5 7 7 7
68 2 10 5 5 7 7 7
69 3 10 5 5 7 7 7
70 1 10 5 5 9 9 9
71 2 10 5 5 9 9 9
72 3 10 5 5 9 9 9
73 1 8 7 5 3 3 3
74 2 8 7 5 3 3 3
75 3 8 7 5 3 3 3
76 1 8 7 5 5 5 5
77 2 8 7 5 5 5 5
78 3 8 7 5 5 5 5
79 1 8 7 5 7 7 7
80 2 8 7 5 7 7 7
81 3 8 7 5 7 7 7
82 1 8 7 5 9 9 9
83 2 8 7 5 9 9 9
84 3 8 7 5 9 9 9
85 1 10 7 5 3 3 3
86 2 10 7 5 3 3 3
87 3 10 7 5 3 3 3
88 1 10 7 5 5 5 5
89 2 10 7 5 5 5 5
90 3 10 7 5 5 5 5
91 1 10 7 5 7 7 7
92 2 10 7 5 7 7 7
93 3 10 7 5 7 7 7
94 1 10 7 5 9 9 9
95 2 10 7 5 9 9 9















1 1 2 1 3 5 3 3
2 2 2 1 3 5 3 3
3 3 2 1 3 5 3 3
4 1 2 1 5 5 5 5
5 2 2 1 5 5 5 5
6 3 2 1 5 5 5 5
7 1 2 1 7 5 7 7
8 2 2 1 7 5 7 7
9 3 2 1 7 5 7 7
 
 166 
10 1 2 1 9 5 9 9
11 2 2 1 9 5 9 9
12 3 2 1 9 5 9 9
13 1 10 1 3 5 3 3
14 2 10 1 3 5 3 3
15 3 10 1 3 5 3 3
16 1 10 1 5 5 5 5
17 2 10 1 5 5 5 5
18 3 10 1 5 5 5 5
19 1 10 1 7 5 7 7
20 2 10 1 7 5 7 7
21 3 10 1 7 5 7 7
22 1 10 1 9 5 9 9
23 2 10 1 9 5 9 9
24 3 10 1 9 5 9 9
25 1 2 3 3 5 3 3
26 2 2 3 3 5 3 3
27 3 2 3 3 5 3 3
28 1 2 3 5 5 5 5
29 2 2 3 5 5 5 5
30 3 2 3 5 5 5 5
31 1 2 3 7 5 7 7
32 2 2 3 7 5 7 7
33 3 2 3 7 5 7 7
34 1 2 3 9 5 9 9
35 2 2 3 9 5 9 9
36 3 2 3 9 5 9 9
37 1 10 3 3 5 3 3
38 2 10 3 3 5 3 3
39 3 10 3 3 5 3 3
40 1 10 3 5 5 5 5
41 2 10 3 5 5 5 5
42 3 10 3 5 5 5 5
43 1 10 3 7 5 7 7
44 2 10 3 7 5 7 7
45 3 10 3 7 5 7 7
46 1 10 3 9 5 9 9
47 2 10 3 9 5 9 9
48 3 10 3 9 5 9 9
49 1 7 5 3 5 3 3
50 2 7 5 3 5 3 3
51 3 7 5 3 5 3 3
52 1 7 5 5 5 5 5
53 2 7 5 5 5 5 5
54 3 7 5 5 5 5 5
55 1 7 5 7 5 7 7
56 2 7 5 7 5 7 7
57 3 7 5 7 5 7 7
58 1 7 5 9 5 9 9
 
 167 
59 2 7 5 9 5 9 9
60 3 7 5 9 5 9 9
61 1 10 5 3 5 3 3
62 2 10 5 3 5 3 3
63 3 10 5 3 5 3 3
64 1 10 5 5 5 5 5
65 2 10 5 5 5 5 5
66 3 10 5 5 5 5 5
67 1 10 5 7 5 7 7
68 2 10 5 7 5 7 7
69 3 10 5 7 5 7 7
70 1 10 5 9 5 9 9
71 2 10 5 9 5 9 9
72 3 10 5 9 5 9 9
73 1 8 7 3 5 3 3
74 2 8 7 3 5 3 3
75 3 8 7 3 5 3 3
76 1 8 7 5 5 5 5
77 2 8 7 5 5 5 5
78 3 8 7 5 5 5 5
79 1 8 7 7 5 7 7
80 2 8 7 7 5 7 7
81 3 8 7 7 5 7 7
82 1 8 7 9 5 9 9
83 2 8 7 9 5 9 9
84 3 8 7 9 5 9 9
85 1 10 7 3 5 3 3
86 2 10 7 3 5 3 3
87 3 10 7 3 5 3 3
88 1 10 7 5 5 5 5
89 2 10 7 5 5 5 5
90 3 10 7 5 5 5 5
91 1 10 7 7 5 7 7
92 2 10 7 7 5 7 7
93 3 10 7 7 5 7 7
94 1 10 7 9 5 9 9
95 2 10 7 9 5 9 9















1 1 2 1 5 5 5 5
2 2 2 1 5 5 5 5
3 3 2 1 5 5 5 5
4 1 2 1 7 7 5 7
5 2 2 1 7 7 5 7
6 3 2 1 7 7 5 7
7 1 2 1 9 9 5 9
 
 168 
8 2 2 1 9 9 5 9
9 3 2 1 9 9 5 9
10 1 10 1 5 5 5 5
11 2 10 1 5 5 5 5
12 3 10 1 5 5 5 5
13 1 10 1 7 7 5 7
14 2 10 1 7 7 5 7
15 3 10 1 7 7 5 7
16 1 10 1 9 9 5 9
17 2 10 1 9 9 5 9
18 3 10 1 9 9 5 9
19 1 2 3 5 5 5 5
20 2 2 3 5 5 5 5
21 3 2 3 5 5 5 5
22 1 2 3 7 7 5 7
23 2 2 3 7 7 5 7
24 3 2 3 7 7 5 7
25 1 2 3 9 9 5 9
26 2 2 3 9 9 5 9
27 3 2 3 9 9 5 9
28 1 10 3 5 5 5 5
29 2 10 3 5 5 5 5
30 3 10 3 5 5 5 5
31 1 10 3 7 7 5 7
32 2 10 3 7 7 5 7
33 3 10 3 7 7 5 7
34 1 10 3 9 9 5 9
35 2 10 3 9 9 5 9
36 3 10 3 9 9 5 9
37 1 7 5 5 5 5 5
38 2 7 5 5 5 5 5
39 3 7 5 5 5 5 5
40 1 7 5 7 7 5 7
41 2 7 5 7 7 5 7
42 3 7 5 7 7 5 7
43 1 7 5 9 9 5 9
44 2 7 5 9 9 5 9
45 3 7 5 9 9 5 9
46 1 10 5 5 5 5 5
47 2 10 5 5 5 5 5
48 3 10 5 5 5 5 5
49 1 10 5 7 7 5 7
50 2 10 5 7 7 5 7
51 3 10 5 7 7 5 7
52 1 10 5 9 9 5 9
53 2 10 5 9 9 5 9
54 3 10 5 9 9 5 9
55 1 8 7 5 5 5 5
56 2 8 7 5 5 5 5
 
 169 
57 3 8 7 5 5 5 5
58 1 8 7 7 7 5 7
59 2 8 7 7 7 5 7
60 3 8 7 7 7 5 7
61 1 8 7 9 9 5 9
62 2 8 7 9 9 5 9
63 3 8 7 9 9 5 9
64 1 10 7 5 5 5 5
65 2 10 7 5 5 5 5
66 3 10 7 5 5 5 5
67 1 10 7 7 7 5 7
68 2 10 7 7 7 5 7
69 3 10 7 7 7 5 7
70 1 10 7 9 9 5 9
71 2 10 7 9 9 5 9















1 1 2 1 3 3 3 5
2 2 2 1 3 3 3 5
3 3 2 1 3 3 3 5
4 1 2 1 5 5 5 5
5 2 2 1 5 5 5 5
6 3 2 1 5 5 5 5
7 1 10 1 3 3 3 5
8 2 10 1 3 3 3 5
9 3 10 1 3 3 3 5
10 1 10 1 5 5 5 5
11 2 10 1 5 5 5 5
12 3 10 1 5 5 5 5
13 1 2 3 3 3 3 5
14 2 2 3 3 3 3 5
15 3 2 3 3 3 3 5
16 1 2 3 5 5 5 5
17 2 2 3 5 5 5 5
18 3 2 3 5 5 5 5
19 1 10 3 3 3 3 5
20 2 10 3 3 3 3 5
21 3 10 3 3 3 3 5
22 1 10 3 5 5 5 5
23 2 10 3 5 5 5 5
24 3 10 3 5 5 5 5
25 1 7 5 3 3 3 5
26 2 7 5 3 3 3 5
27 3 7 5 3 3 3 5
28 1 7 5 5 5 5 5
29 2 7 5 5 5 5 5
 
 170 
30 3 7 5 5 5 5 5
31 1 10 5 3 3 3 5
32 2 10 5 3 3 3 5
33 3 10 5 3 3 3 5
34 1 10 5 5 5 5 5
35 2 10 5 5 5 5 5
36 3 10 5 5 5 5 5
37 1 8 7 3 3 3 5
38 2 8 7 3 3 3 5
39 3 8 7 3 3 3 5
40 1 8 7 5 5 5 5
41 2 8 7 5 5 5 5
42 3 8 7 5 5 5 5
43 1 10 7 3 3 3 5
44 2 10 7 3 3 3 5
45 3 10 7 3 3 3 5
46 1 10 7 5 5 5 5
47 2 10 7 5 5 5 5





Results of testing portion 
Inhalation
Partition Coefficients
Trial Brain Liver Kidney RP SP Diaphragm
1 269.525 107.777 106.739 125.692 110.283 105.998
2 165.845 103.953 103.504 112.413 104.838 102.923
3 102.615 100.210 100.190 100.622 100.238 100.148
4 2360.831 118.305 106.048 122.579 116.260 119.858
5 1075.959 109.013 103.106 110.842 107.288 109.259
6 116.139 100.449 100.165 100.538 100.338 100.428
7 4006.352 120.167 111.916 119.829 117.211 145.804
8 3360.696 109.614 106.365 109.567 107.618 120.508
9 159.708 100.457 100.337 100.463 100.338 100.762
10 1122.306 120.621 117.295 184.862 134.831 119.061
11 430.894 111.455 109.922 140.889 115.905 109.274
12 108.485 100.664 100.599 101.981 100.755 100.468
13 3868.485 138.563 115.862 174.693 156.566 162.611
14 3052.568 123.233 108.906 135.628 124.183 129.428
15 157.565 101.410 100.520 101.709 101.065 101.351
16 4447.962 140.982 126.719 165.688 160.088 237.404
17 4222.809 124.518 116.491 131.263 125.208 164.453
18 369.086 101.438 101.057 101.463 101.060 102.398
19 3513.990 142.194 134.490 341.047 232.342 162.710
20 2210.845 128.403 123.734 235.628 156.490 130.648
21 129.516 102.106 101.904 106.451 102.419 101.531
22 4504.056 158.081 132.687 320.700 138.250 287.447
23 4314.970 145.145 121.904 219.413 188.387 195.204
24 376.410 104.376 101.652 105.539 103.380 104.399
25 4598.509 159.527 143.908 301.346 331.880 435.539
26 4541.989 146.487 133.593 205.645 192.078 291.794
27 1711.400 104.474 103.311 104.770 103.378 107.832
28 4037.903 150.457 141.148 411.775 325.824 198.871
29 3208.218 137.201 130.701 302.673 195.413 148.735
30 149.809 103.296 102.967 110.267 103.797 102.425
31 4555.929 162.945 139.392 393.530 452.274 365.978
32 4465.703 152.974 128.747 281.941 250.283 245.716
33 678.615 106.720 102.574 108.802 105.278 106.967
34 4617.254 164.189 149.043 375.247 470.715 522.441
35 4579.857 154.086 140.337 263.575 256.778 370.945




Trial Brain Liver Kidney RP SP Diaphragm
1 248.781 106.120 102.881 109.942 105.063 103.623
2 457.740 102.890 101.435 104.817 102.353 101.729
3 102.301 100.140 100.074 100.241 100.112 100.085
4 2966.653 136.971 120.720 209.156 159.594 137.593
5 1730.785 122.682 112.167 152.572 125.765 117.900
6 125.709 101.420 100.753 102.484 101.148 100.872
7 4318.359 162.567 144.818 439.414 469.104 280.026
8 3950.517 152.726 134.884 340.804 266.700 193.078
9 298.765 107.060 105.773 113.343 105.969 104.585
10 570.050 106.638 101.999 106.782 104.850 106.078
11 251.897 102.989 100.992 103.297 102.216 102.839
12 104.699 100.139 100.051 100.166 100.105 100.132
13 3851.938 138.565 115.863 174.700 156.571 162.614
14 3022.617 123.236 108.907 135.634 124.187 129.431
15 156.275 101.411 100.520 101.710 101.065 101.352
16 4507.178 163.376 139.904 391.512 451.668 366.580
17 4338.167 153.314 129.177 283.474 253.996 246.407
18 651.545 106.962 102.647 109.130 105.475 107.102
19 2417.108 107.134 103.185 105.916 104.940 111.482
20 928.261 103.086 101.585 102.877 102.230 105.176
21 111.515 100.139 100.080 100.143 100.103 100.208
22 4448.898 140.111 122.238 165.504 157.999 215.525
23 4199.146 123.882 113.213 131.078 124.385 153.737
24 270.494 101.402 100.805 101.466 101.039 102.120
25 4608.367 164.084 146.114 377.924 467.649 488.495
26 4559.060 154.017 136.468 266.795 256.719 339.696
27 2021.083 106.949 104.036 107.873 105.352 111.168
28 3287.449 107.237 104.137 105.758 104.943 113.823
29 1741.460 103.096 102.060 102.799 102.225 106.158
30 115.826 100.137 100.102 100.138 100.101 100.230
31 4510.396 140.403 126.302 163.833 158.129 236.786
32 4348.804 123.957 116.236 130.236 124.334 163.818
33 365.171 101.384 101.285 101.416 101.024 102.355
34 4617.254 164.189 149.043 374.195 468.776 521.453
35 4579.857 154.086 140.337 263.575 256.778 370.945




Trial Brain Liver Kidney RP SP Diaphragm
1 3047.263 136.461 114.515 166.319 150.010 153.413
2 2072.959 121.577 108.038 131.953 121.682 125.237
3 149.589 101.293 100.462 101.555 100.967 101.192
4 3863.337 138.506 115.846 174.693 156.566 162.611
5 3047.871 123.199 108.897 135.628 124.183 129.428
6 157.477 101.408 100.519 101.709 101.065 101.351
7 4250.210 140.360 117.042 183.058 163.277 170.577
8 3668.261 124.789 109.681 139.227 126.630 133.080
9 165.314 101.531 100.573 101.870 101.165 101.509
10 4092.805 152.541 132.970 220.097 216.802 281.370
11 3572.751 136.951 121.883 162.603 150.777 188.479
12 380.921 102.973 101.537 103.092 102.137 103.638
13 4458.495 156.441 137.052 263.956 271.523 348.009
14 4252.757 142.159 126.022 185.183 170.741 229.743
15 693.791 103.728 102.092 104.010 102.778 105.441
16 4591.032 159.747 140.752 312.908 343.692 409.781
17 4529.585 147.052 130.014 213.007 196.953 273.158
18 1330.044 104.663 102.704 105.128 103.552 107.376
19 4278.263 155.749 140.130 230.630 230.915 334.510
20 3903.283 140.619 128.909 170.241 158.482 216.808
21 475.965 103.528 102.253 103.546 102.458 104.280
22 4525.571 160.285 144.804 296.978 235.144 431.591
23 4389.340 147.535 134.691 208.791 195.734 288.479
24 1158.434 104.924 103.499 105.226 103.631 107.851
25 4611.770 164.106 148.986 375.247 470.715 522.441
26 4574.373 154.016 140.292 263.575 256.778 370.945
27 2594.270 106.872 105.086 107.592 105.272 112.401
Regeneration Rate
Trial Brain Liver Kidney RP SP Diaphragm
1 1098.366 116.901 108.398 132.944 116.783 111.792
2 396.372304 108.610176 104.387 115.664 107.620 105.608
3 107.518512 100.444 100.237 100.769 100.358 100.275
4 627.237 114.545 106.962 126.811 113.713 109.179
5 290.697 107.304 103.586 112.859 106.270 104.372
6 106.101 100.373 100.192 100.638 100.296 100.215
7 255.151 108.623 103.619 113.611 107.002 103.927
8 169.276 104.122 101.790 106.608 103.238 101.855
9 103.047 100.202 100.092 100.333 100.155 100.091
10 4239.238 140.750 117.296 184.841 164.805 171.928
11 3654.258 125.150 109.850 140.257 127.354 133.781
12 167.014 101.563 100.585 101.910 101.190 101.542
13 3863.337 138.506 115.846 174.693 156.566 162.611  
 
 174 
14 3047.871 123.199 108.874 135.628 124.183 129.428
15 159.477 101.408 100.519 101.709 101.065 101.351
16 2743.358 130.928 111.438 148.343 135.794 139.224
17 1700.133 117.199 106.147 123.324 115.781 118.403




Trial Brain Liver Kidney RP SP Diaphragm
1 272.200 107.900 106.800 126.000 110.400 106.000
2 166.700 104.000 103.500 112.600 104.900 102.900
3 102.600 100.200 100.200 100.600 100.200 100.100
4 272.200 107.900 106.800 126.000 110.400 106.000
5 166.700 104.000 103.500 112.600 104.900 102.900
6 102.600 100.200 100.200 100.600 100.200 100.100
7 2443.900 119.100 106.300 123.700 117.100 120.700
8 1141.900 109.400 103.200 111.300 107.600 109.600
9 116.800 100.500 100.200 100.600 100.400 100.400
10 2447.100 119.200 106.300 123.700 117.200 120.700
11 1143.900 109.400 103.200 111.400 107.700 109.600
12 116.900 100.500 100.200 100.600 100.400 100.400
13 4028.300 121.200 112.400 120.800 118.200 148.300
14 3412.600 110.100 106.600 110.000 108.000 121.700
15 163.400 100.500 100.400 100.500 100.400 100.800
16 4053.600 121.400 112.500 120.900 118.300 148.400
17 3435.500 110.200 106.800 110.000 108.000 121.700
18 163.900 100.500 100.400 100.500 100.400 100.800
19 1140.300 120.800 117.400 186.100 135.400 119.100
20 436.400 111.600 110.000 141.500 116.100 109.300
21 108.600 100.700 100.600 102.000 100.800 100.500
22 1141.600 120.900 117.400 186.100 135.300 119.100
23 436.800 111.600 110.000 141.400 116.100 109.300
24 108.600 100.700 100.600 102.000 100.800 100.500
25 3909.400 139.700 116.400 178.300 159.800 165.200
26 3122.600 124.100 109.200 137.300 125.400 130.600
27 160.600 101.500 100.500 101.800 101.100 101.400
28 3914.100 139.700 116.400 178.400 159.900 165.200
29 3126.900 124.100 107.200 137.300 125.500 130.600
30 160.700 101.500 100.500 101.800 101.100 101.400
31 4436.300 142.000 127.400 168.800 163.700 244.000
32 4221.700 125.300 117.100 132.700 126.500 168.000
33 389.200 101.500 101.100 101.500 101.100 102.500
34 4462.400 142.300 127.500 169.300 164.200 244.300
35 4248.900 125.500 117.200 133.000 126.800 168.100
36 392.500 101.500 101.100 101.500 101.100 102.500  
 
 175 
37 3557.200 142.600 134.700 344.600 235.600 163.200
38 2256.200 128.700 123.900 238.000 157.600 130.900
39 129.900 102.100 101.900 106.600 102.500 101.500
40 3557.700 142.600 134.700 344.700 235.600 163.200
41 2256.700 128.700 123.900 238.000 157.600 130.900
42 129.900 102.100 101.900 106.600 102.500 101.500
43 4514.800 158.800 133.400 328.900 332.200 294.500
44 4338.500 146.100 122.500 225.100 193.800 199.200
45 397.900 104.600 101.700 105.800 103.500 104.600
46 4519.700 158.900 133.400 329.300 332.600 294.600
47 4343.500 146.100 122.500 225.300 193.900 199.200
48 398.500 104.600 101.700 105.800 103.500 104.600
49 4581.200 159.900 144.400 308.700 346.100 445.700
50 4524.400 147.200 134.200 210.700 198.000 300.700
51 1813.100 104.200 103.500 105.000 103.500 108.200
52 4604.600 160.400 144.600 310.300 348.700 447.100
53 4550.400 147.600 134.400 211.600 198.900 301.200
54 1836.000 104.700 103.500 105.000 103.600 108.200
55 4066.100 150.800 141.300 415.200 330.300 198.800
56 3246.100 137.500 130.900 305.500 197.100 149.000
57 150.200 103.300 103.000 110.400 103.800 102.400
58 4066.700 150.800 141.300 415.200 330.300 198.800
59 3246.600 137.500 130.900 305.500 197.100 149.000
60 150.200 103.300 103.000 110.400 103.800 102.400
61 4575.900 163.700 140.100 400.900 470.600 374.100
62 4477.300 153.700 129.400 289.100 259.300 251.100
63 725.700 107.000 102.700 109.200 105.500 107.200
64 4580.700 163.800 140.100 401.300 471.200 374.200
65 4482.200 153.800 129.400 289.400 259.500 251.200
66 727.200 107.000 102.700 109.200 105.500 107.200
67 44600.400 164.400 149.300 381.600 487.800 531.100
68 4560.800 154.600 140.800 270.000 266.000 380.700
69 2680.000 107.100 105.300 107.900 105.500 113.000
70 4622.500 164.800 149.600 383.700 491.800 533.000
71 4586.000 154.900 141.000 271.300 267.700 381.700
72 2707.800 107.200 105.300 108.000 105.500 113.000
71 4586.000 154.900 141.000 271.300 267.700 381.700
72 2707.800 107.200 105.300 108.000 105.500 113.000
Inhibition Coefficieint
Trial Brain Liver Kidney RP SP Diaphragm
1 255.800 106.400 103.000 110.300 105.300 103.700
2 159.900 103.000 101.500 105.000 102.400 101.800
3 103.400 100.100 100.100 100.200 100.100 100.100
4 255.800 106.400 103.000 110.300 105.300 103.700
5 160.000 103.000 101.500 105.000 102.400 101.800  
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6 102.400 100.100 100.100 100.200 100.100 100.100
7 3028.900 137.800 121.100 213.300 162.300 138.500
8 1796.500 123.300 112.400 154.500 126.800 118.300
9 126.600 101.500 100.800 102.600 101.200 100.900
10 3030.000 137.800 121.100 213.300 162.300 138.500
11 1797.300 123.300 112.400 154.600 126.800 118.300
12 126.600 101.500 100.800 102.600 101.200 100.900
13 4339.700 163.100 145.200 445.000 163.100 145.200
14 3985.400 153.400 135.300 347.200 274.300 195.000
15 308.200 107.200 103.900 113.800 106.200 104.700
16 4341.000 163.100 145.300 445.100 484.100 283.800
17 3986.700 153.400 135.400 347.300 274.400 195.000
18 308.300 107.200 103.900 113.800 106.200 104.700
19 623.600 107.000 102.100 107.100 105.100 106.300
20 266.500 103.100 101.000 103.400 102.300 103.000
21 105.000 100.100 100.100 100.200 100.100 100.100
22 624.600 107.000 102.100 107.100 105.400 106.300
23 266.700 103.100 101.000 103.500 102.300 103.000
24 105.000 100.100 100.000 100.200 100.100 100.100
25 3909.400 139.700 116.400 178.300 159.800 165.200
26 3122.600 124.100 109.200 137.300 125.400 130.600
27 160.600 101.500 100.500 101.800 101.100 101.400
28 3914.100 139.700 116.400 178.400 159.900 165.200
29 3126.900 124.100 107.200 137.300 125.500 130.600
30 160.700 101.500 100.500 101.800 101.100 101.400
31 4520.700 163.900 140.500 398.600 468.900 374.600
32 4362.900 154.100 129.800 290.400 262.900 251.700
33 711.800 107.200 102.700 109.500 105.700 107.400
34 4525.500 164.000 140.600 399.000 469.600 374.800
35 4367.700 154.200 129.800 290.700 263.200 251.600
36 713.100 107.300 102.700 109.500 105.700 107.400
37 2518.000 107.600 103.300 106.200 105.200 112.100
38 999.100 103.200 101.700 103.000 102.300 105.500
39 112.100 100.100 100.100 100.100 100.100 100.100
40 2533.600 107.600 103.300 106.200 105.200 112.100
41 1006.500 103.300 101.700 103.000 102.400 105.500
42 112.100 100.100 100.100 100.200 100.100 100.200
43 4449.600 141.300 122.900 168.800 161.700 221.200
44 4213.900 124.800 113.700 132.600 125.800 156.600
45 282.900 101.500 100.800 101.500 101.100 102.200
46 4466.200 141.400 123.000 169.200 162.000 221.400
47 4230.900 124.900 113.700 132.800 125.900 156.700
48 284.100 101.500 100.800 101.500 101.100 102.200
49 4602.900 164.500 146.600 385.000 485.900 498.000
50 4554.300 154.700 137.100 273.700 266.400 348.900
51 2126.100 107.200 104.200 108.200 105.600 111.700
52 4617.700 164.700 146.700 386.300 488.300 499.100
53 4570.500 154.900 137.200 274.500 267.400 349.400  
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54 2141.100 107.300 104.200 108.300 105.600 111.700
55 3342.900 107.700 104.300 106.000 105.200 114.600
56 1843.500 103.200 102.100 102.900 102.300 106.500
57 116.600 100.100 100.100 100.100 100.100 100.200
58 3371.100 107.700 104.300 106.100 105.300 114.600
59 1865.900 103.300 102.200 103.000 102.400 106.500
60 116.700 100.100 100.100 100.100 100.100 100.200
61 4496.000 141.400 127.000 166.900 161.700 243.400
62 4341.800 124.800 116.800 131.700 125.600 167.300
63 385.600 101.400 101.100 101.500 101.100 102.500
64 4522.500 141.800 127.100 167.500 162.200 243.800
65 4369.600 125.000 116.900 131.900 125.900 167.500
66 388.200 101.500 101.100 101.500 101.100 102.500
67 44600.400 164.400 149.300 381.600 487.800 531.100
68 4560.800 154.600 140.800 270.000 266.000 380.700
69 2680.000 107.100 105.300 107.900 105.500 113.000
70 4622.500 164.800 149.600 383.700 491.800 533.000
71 4586.000 154.900 141.000 271.300 267.700 381.700
72 2707.800 107.200 105.300 108.000 105.500 113.000
Aging Rate
Trial Brain Liver Kidney RP SP Diaphragm
1 3103.200 137.600 115.000 169.400 152.800 155.500
2 2133.200 122.400 108.300 133.400 122.800 126.200
3 152.100 101.400 100.500 101.600 101.000 101.200
4 3106.000 137.700 115.000 169.500 152.900 155.500
5 2135.000 122.400 108.300 133.500 122.800 126.200
6 152.200 101.400 100.500 101.600 101.000 101.200
7 3909.400 139.700 116.400 178.300 159.800 165.200
8 3122.600 124.100 109.200 137.300 125.400 130.600
9 160.600 101.500 100.500 101.800 101.100 101.400
10 3914.100 139.700 116.400 178.400 159.900 165.200
11 3126.900 124.100 107.200 137.300 125.500 130.600
12 160.700 101.500 100.500 101.800 101.100 101.400
13 4285.100 141.500 117.600 187.200 167.100 173.600
14 3737.800 125.700 110.000 141.300 128.200 134.500
15 169.100 101.600 100.600 102.000 101.200 101.600
16 4290.000 141.600 117.600 187.300 167.200 173.600
17 3742.700 125.700 110.000 141.400 128.200 134.500
18 169.100 101.600 100.600 102.000 101.200 101.600
19 4115.100 153.500 133.700 225.000 223.500 289.300
20 3614.000 137.900 122.600 165.500 153.600 192.900
21 397.600 103.100 101.600 103.200 102.200 103.800
22 4128.000 133.700 133.800 225.300 223.900 289.300
23 3625.300 138.000 122.600 135.700 153.700 192.900
24 398.300 103.100 101.600 103.200 102.200 103.800  
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25 4464.800 157.300 137.700 270.400 282.000 357.300
26 4267.800 143.100 126.700 189.200 174.900 235.900
27 738.900 103.900 102.200 104.200 102.900 105.700
28 4480.000 157.500 137.900 271.200 283.000 357.700
29 4283.700 143.300 126.800 189.600 175.300 236.100
30 743.300 103.900 102.200 104.200 102.900 105.700
31 4590.700 160.400 141.400 320.600 358.600 419.600
32 4531.100 148.000 130.700 218.400 203.000 280.900
33 1398.300 104.900 102.800 105.400 103.700 107.700
34 4606.200 160.700 141.500 321.600 360.300 426.300
35 4547.600 148.200 130.800 219.000 203.600 281.200
36 1409.500 104.900 102.800 105.400 103.700 107.700
37 4287.000 156.500 140.800 235.600 238.000 344.300
38 3927.000 141.500 129.600 173.400 161.700 223.200
39 498.000 103.700 102.400 103.700 102.600 104.500
40 4306.700 156.900 140.900 236.100 238.600 344.400
41 3946.600 141.800 129.700 173.600 161.900 223.000
42 499.500 103.700 102.400 103.700 102.600 104.500
43 4521.700 160.800 145.300 303.200 337.000 441.400
44 4388.900 148.300 135.400 213.400 201.100 296.900
45 1219.900 105.100 103.700 105.500 103.800 108.200
46 4543.700 161.200 145.500 304.600 339.100 442.600
47 4413.500 148.600 135.500 214.200 201.900 297.300
48 1232.200 105.200 103.700 105.500 103.800 108.200
49 44600.400 164.400 149.300 381.600 487.800 531.100
50 4560.800 154.600 140.800 270.000 266.000 380.700
51 2680.000 107.100 105.300 107.900 105.500 113.000
52 4622.500 164.800 149.600 383.700 491.800 533.000
53 4586.000 154.900 141.000 271.300 267.700 381.700
54 2707.800 107.200 105.300 108.000 105.500 113.000
Regeneration Rate
Trial Brain Liver Kidney RP SP Diaphragm
1 1255.000 117.800 108.800 135.000 117.900 112.400
2 431.000 109.100 104.600 116.600 108.100 105.900
3 107.900 100.500 100.200 100.800 100.400 100.300
4 1255.900 117.800 108.800 135.000 117.900 112.400
5 431.200 109.100 104.600 116.600 108.100 105.900
6 108.000 100.500 100.200 100.800 100.400 100.300
7 649.800 115.100 107.100 127.800 114.200 109.400
8 298.600 107.600 103.700 113.300 106.500 104.500
9 106.300 100.400 100.200 100.700 100.300 100.200
10 650.000 115.100 107.100 127.800 114.200 109.400
11 298.600 107.600 103.700 113.300 106.500 104.500
12 106.300 100.400 100.200 100.700 100.300 100.200
13 259.000 108.900 103.700 114.000 107.200 103.900  
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14 170.900 104.200 101.800 106.800 103.300 101.900
15 103.100 100.200 100.100 100.300 100.200 100.100
16 259.100 108.900 103.700 114.000 107.200 103.900
17 171.000 104.200 101.800 106.800 103.300 101.900
18 103.100 100.200 100.100 100.300 100.200 100.100
19 4272.100 141.900 117.900 189.000 168.700 174.980
20 3722.500 126.100 110.200 142.200 128.800 135.200
21 170.900 101.600 100.600 102.000 101.200 101.600
22 4277.000 142.000 117.900 189.200 168.900 175.000
23 3727.400 126.100 110.200 142.300 128.800 135.200
24 171.000 101.600 100.600 102.000 101.200 101.600
25 3909.400 139.700 116.400 178.300 159.800 165.200
26 3122.600 124.100 109.200 137.300 125.400 130.600
27 160.600 101.500 100.500 101.800 101.100 101.400
28 3914.100 139.700 116.400 178.400 159.900 165.200
29 3126.900 124.100 107.200 137.300 125.500 130.600
30 160.700 101.500 100.500 101.800 101.100 101.400
31 2808.900 132.000 111.800 150.600 137.700 140.800
32 1765.200 117.900 106.400 124.400 116.600 119.100
33 136.700 101.000 100.400 101.200 100.700 100.900
34 2812.700 132.100 111.800 150.700 137.800 140.800
35 1768.000 117.900 106.400 124.400 116.600 119.100




Trial Brain Liver Kidney RP SP Diaphragm
1 1947.194 114.710 104.933 117.978 112.616 115.658
2 788.988 107.248 102.521 108.679 105.753 107.341
3 112.713 100.362 100.133 100.435 100.273 100.345
4 3667.559 133.410 113.371 159.511 143.135 149.592
5 2700.925 119.460 107.363 128.447 118.944 123.348
6 144.001 101.137 100.420 101.380 100.859 101.089
7 4462.555 154.452 129.258 286.370 265.231 253.601
8 4218.055 140.685 118.920 196.392 167.729 176.259
9 292.320 103.548 101.339 104.462 102.720 103.541
10 4548.097 160.450 136.281 360.132 375.992 324.290
11 4412.282 149.100 125.433 250.651 214.450 218.332
12 484.473 105.472 102.090 107.077 104.239 105.601
13 170.629 101.597 100.575 101.899 101.202 101.528
14 130.178 100.786 100.286 100.936 100.588 100.747
15 100.972 100.638 100.014 100.046 100.029 100.037
16 454.778 104.884 101.790 106.072 103.822 104.837
17 220.197 102.443 100.897 102.984 101.864 102.361
18 103.034 100.120 100.045 100.147 100.092 100.116  
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19 2243.587 114.053 105.472 120.121 112.486 115.903
20 849.624 107.434 102.824 109.748 105.971 107.724
21 109.285 100.384 100.146 100.475 100.289 100.376
22 3180.530 120.303 108.249 132.421 119.844 125.286
23 1634.389 111.214 104.359 115.581 109.388 112.263
24 114.071 100.603 100.230 100.748 100.446 100.592
25 3718.867 149.858 117.331 182.791 176.700 176.353
26 3134.724 129.087 109.312 137.446 129.047 133.444
27 164.156 101.479 100.534 101.760 101.113 101.414
28 4434.144 163.393 134.072 327.697 376.976 311.775
29 4182.896 150.066 122.298 221.154 205.276 203.083
30 413.352 104.537 101.662 105.624 103.536 104.475
31 4616.141 170.292 149.243 483.428 730.736 531.301
32 4567.528 164.553 139.939 396.032 479.793 376.247
33 2070.432 113.159 105.104 118.603 111.498 114.708
34 4634.613 171.627 153.091 517.715 814.063 607.194
35 4606.704 167.766 145.846 456.154 633.503 464.488
36 3043.844 119.126 107.720 129.948 118.283 123.384
37 677.939 106.478 102.263 107.758 105.112 106.522
38 283.206 103.194 101.136 103.801 102.438 103.112
39 105.090 100.158 100.059 100.191 100.120 100.152
40 2502.003 117.207 106.664 125.326 116.729 120.731
41 1189.849 109.422 103.474 112.255 102.832 109.873
42 116.423 100.498 100.186 100.606 100.377 100.479
43 4156.808 138.357 117.476 186.030 159.166 167.931
44 3517.499 124.431 110.052 141.310 126.283 132.554
45 156.532 101.572 100.595 101.949 101.186 101.549
46 4377.999 146.989 123.771 235.779 199.515 205.986
47 4011.118 132.869 114.555 166.822 142.803 151.655
48 194.612 102.449 100.933 103.075 101.838 102.440
49 4262.471 160.705 126.128 252.727 274.520 239.598
50 3811.519 146.555 115.614 171.744 163.959 165.934
51 239.175 102.646 100.946 103.147 102.006 102.561
52 4544.075 168.757 143.074 418.693 593.928 428.506
53 4408.499 161.749 131.964 306.424 335.198 288.125
54 915.707 107.904 102.907 110.120 106.433 108.124
55 4636.282 172.261 154.230 525.494 838.608 632.828
56 4609.966 169.607 147.821 470.214 693.492 504.001
57 3243.355 121.219 108.566 133.953 121.382 126.775
58 4646.646 122.920 156.633 545.240 877.347 686.667
59 4631.003 171.174 152.040 509.295 792.278 584.639
60 3847.717 129.187 112.565 154.929 134.573 142.539
61 2969.884 126.125 108.415 133.182 125.225 129.517
62 1706.454 112.971 104.384 115.779 110.911 113.666
63 4020.368 153.019 119.290 196.469 193.463 188.983
64 4121.567 147.377 120.646 208.344 190.719 191.708
65 3538.464 130.649 112.097 152.172 137.044 143.368
66 192.932 102.631 100.746 102.471 101.542 101.953  
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67 4555.695 163.207 138.267 378.954 437.010 353.520
68 4432.588 152.199 127.309 267.499 240.514 236.345
69 632.638 106.224 102.356 108.047 104.921 106.379
70 4606.029 166.833 144.443 443.025 592.268 440.669
71 4531.486 158.712 134.368 339.948 337.314 301.974
72 1235.129 109.458 103.653 112.836 107.718 110.120
73 4539.602 169.836 143.788 474.003 639.184 446.155
74 4400.030 165.202 132.597 326.423 389.398 299.526
75 970.761 108.386 102.900 110.074 106.737 108.519
76 4624.377 172.551 154.432 540.582 839.245 638.689
77 4584.236 170.702 148.608 473.671 715.816 509.244
78 2872.422 121.173 108.057 131.639 121.247 126.029
79 4654.120 173.610 1858.997 567.220 909.724 744.467
80 4644.866 172.961 156.479 545.999 876.486 683.253
81 4267.291 142.798 120.295 206.787 176.753 184.692
82 4658.059 173.803 159.824 571.830 919.736 764.746
83 4651.990 173.377 158.160 558.439 899.669 723.008
84 4439.745 150.964 126.981 265.094 230.162 230.647
85 4262.471 160.705 126.128 252.727 274.520 239.598
86 3811.519 146.555 115.614 171.744 163.959 165.934
87 239.175 102.646 100.916 103.147 102.009 102.532
88 4544.075 168.757 143.074 418.693 593.928 428.506
89 4408.499 161.749 131.964 306.424 335.198 288.125
90 915.707 107.904 102.907 110.120 106.433 108.124
91 4636.282 172.261 154.230 525.494 838.608 632.828
92 4609.966 169.607 147.821 470.214 693.492 504.001
93 3243.355 121.219 108.566 133.953 121.382 126.775
94 4646.646 122.920 156.633 545.240 877.347 686.667
95 4631.003 171.174 152.040 509.295 792.278 584.639
96 3847.717 129.187 112.565 154.929 134.573 142.539
Inhibition Coefficient
Trial Brain Liver Kidney RP SP Diaphragm
1 2621.650 132.253 117.756 187.629 145.687 129.837
2 1342.950 119.100 110.169 141.965 120.245 114.298
3 120.193 101.147 100.610 102.006 100.927 100.704
4 3667.559 133.410 113.371 159.511 143.135 149.592
5 2700.925 117.460 107.363 128.447 118.944 123.348
6 144.001 101.137 100.420 101.380 100.859 101.089
7 4383.933 134.530 119.101 151.937 143.844 191.789
8 4059.472 119.871 111.033 124.714 118.969 142.041
9 221.350 101.176 100.649 101.185 100.839 101.704
10 4457.910 134.663 122.859 150.483 143.781 209.050
11 4247.429 119.860 113.657 123.977 118.861 149.689
12 280.963 101.109 100.828 101.138 100.824 101.888
13 221.575 104.885 102.570 108.861 104.117 103.081  
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14 149.561 102.477 101.307 104.376 102.026 101.529
15 101.793 100.123 100.067 100.216 100.100 100.076
16 454.778 104.884 101.790 106.072 103.822 104.837
17 220.477 102.447 100.898 102.984 101.864 102.361
18 103.034 100.120 100.045 100.148 100.092 100.116
19 1623.394 104.884 102.769 105.232 103.757 107.879
20 543.667 102.433 101.389 102.565 101.825 103.750
21 105.420 100.118 100.070 100.126 100.089 100.180
22 2360.160 104.830 106.823 105.040 103.701 108.892
23 850.785 102.400 101.773 102.466 101.794 104.182
24 106.583 100.117 100.090 100.122 100.088 100.199
25 4142.274 160.382 139.414 383.298 374.374 231.118
26 3573.963 147.437 127.959 270.984 209.702 162.245
27 209.569 104.541 102.389 108.204 103.809 102.854
28 4441.353 163.507 134.125 327.697 376.976 311.775
29 4182.896 150.066 122.298 221.154 205.532 203.150
30 413.352 104.537 101.662 105.624 103.536 104.475
31 4585.596 165.416 141.940 312.150 401.401 439.549
32 4521.542 152.336 129.613 206.879 109.385 283.529
33 1457.983 104.534 102.573 104.844 103.474 107.265
34 4594.659 165.660 145.777 309.014 405.950 478.000
35 4549.209 152.770 133.887 204.021 209.611 313.042
36 2175.855 104.482 103.275 104.665 103.421 108.186
37 1160.949 117.416 109.247 137.329 117.895 112.740
38 442.955 109.363 104.928 117.956 108.414 106.196
39 108.156 100.504 100.270 100.881 100.407 100.310
40 2502.003 117.707 106.664 125.326 116.729 120.731
41 1189.849 109.422 103.474 112.255 107.832 109.873
42 116.423 100.498 100.186 100.606 100.377 100.479
43 3977.744 118.046 110.036 121.987 116.717 137.037
44 3124.004 109.496 105.338 110.595 107.747 116.739
45 138.167 100.492 100.287 100.521 100.368 100.744
46 4194.129 118.021 112.472 121.321 116.609 143.649
47 3620.323 109.430 106.745 110.234 107.658 119.268
48 151.562 100.485 100.366 100.501 100.362 100.822
49 4386.891 166.679 147.298 460.469 581.808 322.920
50 4066.288 158.484 137.441 363.613 335.142 215.290
51 354.645 107.871 104.140 114.808 106.917 105.121
52 4544.075 168.757 143.074 418.693 593.928 428.506
53 4408.499 161.749 131.964 306.424 335.198 288.125
54 915.707 107.904 102.907 110.120 106.433 108.124
55 4613.240 169.771 149.643 408.508 633.843 559.946
56 4577.345 163.909 139.904 290.245 354.357 410.615
57 2766.489 107.947 104.479 108.740 106.350 113.602
58 4615.919 169.830 152.519 406.319 641.089 593.666
59 4588.572 164.213 143.913 287.023 357.829 449.004
60 3363.574 107.881 105.374 108.435 106.270 115.561
61 3448.636 145.009 126.171 254.730 194.714 155.224  
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62 2404.241 129.632 116.178 176.972 139.317 126.147
63 139.267 102.043 101.080 103.595 101.663 101.258
64 4121.567 147.377 120.646 208.344 190.719 191.708
65 3532.378 130.594 112.082 152.172 137.044 143.368
66 192.932 102.031 100.746 102.471 101.542 101.953
67 4506.079 149.433 127.777 195.290 193.680 265.086
68 4344.408 131.554 117.443 145.490 137.541 180.192
69 415.757 102.017 101.154 102.123 101.508 103.087
70 4538.677 149.800 132.033 192.717 193.830 292.739
71 4427.770 131.189 120.739 143.286 136.555 193.336
72 622.643 101.989 101.473 102.040 101.482 103.436
73 4584.309 171.892 156.462 550.924 830.983 553.696
74 4486.176 169.281 151.476 505.692 703.369 402.467
75 1521.565 120.739 111.075 146.704 122.685 115.890
76 4624.377 172.551 154.432 540.582 839.245 638.689
77 4584.236 170.702 148.008 473.671 715.816 509.244
78 2872.422 121.173 108.057 131.639 121.247 126.029
79 4639.865 172.767 157.700 536.308 857.276 715.864
80 4625.643 171.330 153.404 465.414 751.566 627.192
81 4125.079 121.659 112.010 127.504 121.316 147.182
82 4638.674 172.713 158.844 535.109 858.906 732.229
83 4626.120 171.325 155.599 436.783 757.081 654.977
84 4290.076 121.663 114.807 126.694 121.209 155.889
85 4386.891 166.679 147.298 460.469 581.808 322.920
86 4066.288 158.484 137.441 363.613 335.142 215.290
87 354.645 107.871 104.140 114.808 106.917 105.121
88 4544.075 168.757 143.074 418.693 593.928 428.506
89 4408.499 161.749 131.964 306.424 335.198 288.125
90 915.707 107.904 102.907 110.120 106.433 108.124
91 4613.240 169.771 149.643 408.508 633.843 559.946
92 4577.345 163.909 139.904 290.245 354.357 410.615
93 2766.489 107.947 104.479 108.740 106.350 113.602
94 4615.919 169.830 152.519 406.319 641.089 593.666
95 4588.572 164.213 143.913 287.023 357.829 449.004
96 3363.574 107.881 105.374 108.435 106.270 115.561
Aging Coefficient
Trial Brain Liver Kidney RP SP Diaphragm
1 3667.559 133.410 113.371 159.511 143.135 149.592
2 2700.925 119.460 107.363 128.447 118.944 123.348
3 144.001 101.137 100.420 101.380 100.859 101.089
4 4407.579 152.239 133.647 235.490 229.931 306.320
5 4149.424 137.473 122.737 168.363 154.349 203.545
6 510.430 103.042 101.693 103.222 102.230 104.364
7 4486.162 156.562 141.846 266.240 273.182 384.305
8 4311.776 142.966 131.212 188.084 173.313 252.359  
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9 861.057 103.981 102.844 104.189 102.906 106.286
10 454.778 104.844 101.790 106.072 103.822 104.837
11 220.477 102.447 100.850 102.984 101.864 102.361
12 103.034 100.120 100.045 100.148 100.092 100.116
13 2607.884 112.177 106.885 114.437 110.187 120.225
14 1433.995 106.366 103.572 107.029 104.895 109.639
15 112.721 100.323 100.185 100.343 100.236 100.458
16 3132.127 115.506 111.013 118.855 113.410 129.595
17 2053.117 108.307 105.901 109.132 106.406 113.972
18 117.334 100.433 100.314 100.446 100.308 100.657
19 4441.353 163.507 134.125 327.692 376.976 311.775
20 4182.896 150.066 122.298 221.154 205.532 203.150
21 413.352 104.537 101.662 105.624 103.536 104.475
22 4594.851 170.492 152.305 437.418 651.931 601.282
23 4530.362 164.038 143.838 337.711 400.718 446.945
24 2487.102 111.384 106.428 113.356 109.406 118.657
25 4612.304 171.448 156.031 459.959 699.200 662.514
26 4568.145 166.466 150.072 364.576 467.470 530.444
27 3030.131 114.545 110.328 117.440 112.372 127.265
28 2502.003 117.707 106.664 125.326 116.729 120.731
29 1189.849 109.422 103.474 112.255 107.832 109.873
30 116.423 100.498 100.186 100.606 100.377 100.479
31 4088.701 135.106 121.124 160.984 147.603 191.948
32 3523.634 121.613 112.482 129.424 121.293 142.665
33 203.160 101.328 100.752 101.408 100.972 101.895
34 4269.781 140.638 129.441 178.896 164.125 235.915
35 3859.981 126.451 118.905 138.458 128.436 163.232
36 271.189 101.763 101.269 101.826 101.262 102.711
37 4544.075 168.757 143.074 418.693 593.928 428.506
38 4408.499 161.749 131.964 306.424 335.198 288.125
39 915.207 107.904 102.907 110.120 106.433 108.124
40 4622.453 172.383 156.350 495.943 788.740 683.604
41 4586.382 169.804 151.098 420.853 610.720 577.825
42 3311.199 118.643 110.687 124.234 117.426 134.771
43 4631.819 172.830 158.567 509.838 812.658 723.293
44 4606.430 170.937 155.239 445.558 664.127 644.218
45 3697.922 123.102 116.472 131.681 123.099 151.364
46 4121.567 147.377 120.646 208.344 190.719 191.208
47 3532.378 130.594 112.082 152.172 137.044 143.368
48 192.932 102.031 100.746 102.471 101.452 101.953
49 4515.795 162.414 142.298 315.800 365.162 422.639
50 4374.301 149.727 131.675 220.789 210.880 284.332
51 1194.038 105.318 102.983 105.807 104.035 107.932
52 4558.358 165.144 148.916 348.442 430.459 507.433
53 4463.968 154.352 140.080 249.947 248.718 358.114
54 1737.615 106.969 104.955 107.565 105.275 111.479
55 4626.377 172.551 154.432 540.583 839.245 638.689
56 4584.236 170.702 148.008 473.671 715.816 509.244  
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57 2872.422 121.173 108.057 131.639 121.247 126.029
58 4647.187 173.585 159.890 561.372 893.069 764.651
59 4634.181 173.016 158.075 526.399 842.375 721.285
60 4199.265 139.653 124.253 175.812 161.429 215.218
61 4649.943 173.700 160.583 564.587 898.966 778.412
62 4640.396 173.288 159.584 535.479 856.755 749.487
63 4345.937 145.071 132.824 197.240 182.931 268.597
64 4544.075 168.757 143.074 418.693 593.928 428.506
65 4408.499 161.749 131.964 306.424 335.198 288.125
66 915.207 107.904 102.907 110.120 106.433 108.124
67 4622.453 172.383 156.350 495.943 788.740 683.604
68 4622.453 172.383 156.350 495.943 610.720 577.825
69 3369.092 119.358 111.107 125.427 118.327 136.519
70 4631.819 172.830 158.567 509.838 812.658 723.293
71 4606.430 170.937 155.239 445.558 664.127 644.218
72 3697.922 123.102 116.472 131.681 123.099 151.364
Regeneration Rate
Trial Brain Liver Kidney RP SP Diaphragm
1 485.217 111.803 105.692 121.351 110.726 107.278
2 241.900 105.909 102.916 110.314 104.982 103.494
3 104.878 100.301 100.155 100.516 100.239 100.173
4 3667.559 133.410 133.371 159.511 143.135 149.592
5 2700.925 119.460 107.363 128.447 118.944 123.348
6 144.001 101.137 100.420 101.380 100.859 101.089
7 123.325 101.320 100.668 102.251 101.053 100.757
8 110.945 100.652 100.332 101.112 100.518 100.373
9 100.459 100.032 100.017 100.056 100.026 100.019
10 454.778 104.884 101.790 106.072 103.822 104.837
11 220.477 102.447 100.898 102.984 101.864 102.361
12 103.034 100.120 100.045 100.148 100.092 100.116
13 485.217 111.803 105.692 121.351 110.726 107.278
14 241.900 105.909 102.916 100.314 104.982 103.494
15 104.459 100.032 100.017 100.056 100.239 100.173
16 4441.353 163.507 134.125 327.697 376.976 311.775
17 4182.896 150.066 122.298 221.154 205.532 203.150
18 413.332 104.537 101.662 105.624 103.536 104.475
19 123.325 101.320 100.668 102.251 101.053 100.757
20 110.945 100.652 100.332 101.112 400.518 100.373
21 100.459 100.032 100.017 100.056 100.026 100.019
22 2502.003 117.707 106.664 125.325 116.729 120.731
23 1189.849 109.422 103.474 112.255 107.832 109.873
24 116.423 100.498 100.186 100.606 100.377 100.479
25 2938.138 152.402 128.274 267.451 225.443 163.428
26 1900.293 136.386 117.392 183.015 149.729 129.284
27 140.970 102.180 101.097 103.732 101.756 101.256  
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28 4544.075 168.757 143.074 418.693 593.928 428.506
29 4408.499 161.749 131.964 306.424 355.198 288.125
30 915.707 107.904 102.907 110.120 106.433 108.174
31 963.057 120.476 109.666 139.405 120.943 113.534
32 420.914 110.446 105.061 118.734 109.328 106.378
33 108.976 100.540 100.276 100.921 100.429 100.310
34 4121.567 147.377 120.646 208.344 190.719 191.708
35 3532.378 130.594 112.082 152.172 137.044 143.368
36 192.932 102.031 100.746 102.471 101.542 101.953
37 4053.276 166.543 145.901 479.870 523.745 298.390
38 3431.556 158.942 134.999 349.757 307.075 196.712
39 262.992 106.535 103.216 111.448 105.553 103.881
40 4624.377 172.551 154.432 540.582 839.245 638.689
41 4584.236 170.702 148.008 473.671 715.816 509.244
42 2872.422 121.173 108.057 131.639 212.247 126.029
43 2938.138 152.402 128.274 267.451 225.443 163.428
44 1900.293 136.386 117.392 183.015 149.729 129.284
45 140.970 102.108 101.097 103.732 101.756 101.256
46 4544.075 168.757 143.074 418.693 593.928 428.506
47 4408.499 161.749 131.964 306.424 355.198 288.125






NAME VALUE  UNITS SOURCE 
Parameters 
Blood Faction Coeff 
Brain BFC 0.134  Unitless a 
Liver BFC 0.2700  Unitless a 
Kidney BFC 0.2230  Unitless a 
Fat BFC 0.0360  Unitless a 
SP BFC 0.073  Unitless a 
RP BFC 0.1583  Unitless a 
Diaphragm BFC 0.006  Unitless a 
Physical Parameters 
Body weight 60.6  kg  a 
Pulmonary Flow 17    a 
Cardiac Flow 14.5    a 
Chemical Coeff 
MW 184.15  g/mol 
Volume Fraction Coeff 
Brain VFC 0.0214  Unitless a 
Liver VFC 0.04  Unitless a 
Kidney VFC 0.0043  Unitless a 
Fat VFC 0.17  Unitless a 
 188 
Slowly VFC 0.5514  Unitless a 
Richly VFC 0.0343  Unitless a 
Diaphragm VFC 0.003  Unitless a 
Lung VFC 0.0086  Unitless a 
VB VFC 0.057  Unitless a 
AB VFC 0.02  Unitless a 
Partition Coeff 
Blood Air PC Varies  Unitless b 
Brain BPC of OP Varies  Unitless b 
Liver BPC of OP Varies  Unitless b 
Kidney BPC of OP Varies  Unitless b 
Fat BPC of OP Varies  Unitless b 
SP BPC of OP Varies  Unitless b 
RP BPC of OP Varies  Unitless b 
Diaphragm BPC of OP Varies  Unitless b 
Bronchial BPC of OP Varies  Unitless b 
Skin BPC of OP Varies  Unitless b 
Mich Men Cons 
Brain Vmax of OP Varies  mg/hr  b 
Liver Vmax of OP Varies  mg/hr  b 
Kidney Vmax of OP Varies  mg/hr  b 
RP Vmax of OP Varies  mg/hr  b 
Brain Km of OP Varies  mg/l  b 
 189 
Liver Km of OP Varies  mg/l  b 
Kidney Km of OP Varies  mg/l  b 
RP Km of OP Varies  mg/l  b 
Variable Parameters 
Air Conc Varies  mg/l 
Exposure to Skin Varies  mg 
Scrubbing Coeff Varies  Unitless 
Skin Transfer Coeff Varies  (cm2 - hr)-1 
Skin Surface Area Varies  cm2 
AChE Inhibition Rate Varies  1/hr  b 
AChE Aging Rate Varies  1/hr  b 
AChE Regeneration Rate Varies  1/hr  b 
Other 
Hundred Percent 100  Unitless 
AChE Hydrolysis of ACh 0.02  (nM - hr)-1 
Lung 
Exhaled 0   mg 
Arterial Blood Flow 
AB inhibition rate for AChE 0.01416  (nM - hr)-1 a 
AB inhibition rate for BuChE 0.4248  (nM - hr)-1 b 
AB inhibition rate for CaE 0.00108  (nM - hr)-1 b 
AB OP lost enzymes 0   nmol  b 
Initial quantity of AB AChE 1.18826  nmol  b 
 190 
Initial quantity of AB BuChE 5.9413  nmol  b 
Initial quantity of AB CaE 4990.69  nmol  b 
Brain 
Brain ACh Release Rate 0.0761852 nmols/hr 
Brain AChE Homeostatic State 49.4  nmol  c 
Brain AChE Synthesis Rate 0.0014  nmol/hr a 
Brain BuChE 16.9  nmol  b 
Brain CaE 780  nmol  b 
Brain ACh Homeostatic State 0.100  nmol  c 
Brain OP lost AChE 0   mg 
Brain OP lost BuChE 0   mg 
Brain OP lost CaE 0   mg 
Brain OP lost Metab 0   mg 
Free brain AChE 49.4  nmol  b 
Inhibited Brain AChE 0   nmol 
OP in the Brian 0   mg 
Synthesis of Brain CaE 15.6  nmol 
Synthesis of Brain BuChE 0.169  nmol 
Synaptic Brain ACh 0.100  nmol  c 
Liver 
Liver ACh Release Rate 0.001237624 nmols/hr 
Liver AChE Homeostatic State 1.5  nmol  c 
 191 
Liver AChE Synthesis Rate 0.053  nmol/hr a 
Liver BuChE 12  nmol  b 
Liver CaE 68250  nmol  b 
Liver ACh Homeostatic State 0.100  nmol  c 
Liver OP lost AChE 0   mg 
Liver OP lost BuChE 0   mg 
Liver OP lost CaE 0   mg 
Liver OP lost Metab 0   mg 
Free liver AChE 1.5  nmol  b 
Inhibited liver AChE 0   nmol 
OP in liver 0   mg 
Synthesis of liver CaE 136.5  nmol 
Synthesis of liver BuChE 0.24  nmol 
Synaptic liver ACh 0.100  nmol 
Kidney 
Kidney ACh Release Rate 0.0010022492 nmols/hr 
Kidney AChE Homeostatic State 0.13322  nmol  c 
Kidney AChE Synthesis Rate 0.053  nmol/hr a 
Kidney BuChE 0.84  nmol  b 
Kidney CaE 4620  nmol  b 
Kidney ACh Homeostatic State 0.100  nmol  c 
Kidney OP lost AChE 0   mg 
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Kidney OP lost BuChE 0   mg 
Kidney OP lost CaE 0   mg 
Kidney OP lost Metab 0   mg 
Free kidney AChE 0.13322  nmol  b 
Inhibited kidney AChE 0   nmol 
OP in kidney 0   mg 
Synthesis of kidney CaE 4620  nmol 
Synthesis of kidney BuChE 0.84  nmol 
Synaptic kidney ACh 0.100  nmol 
Richly Perfused Tissues 
RP ACh Release Rate 0.008005465 nmols/hr 
RP AChE Homeostatic State 8.32  nmol  c 
RP AChE Synthesis Rate 0.053  nmol/hr a 
RP BuChE 205.92  nmol  b 
RP CaE 443040  nmol  b 
RP ACh Homeostatic State 0.100  nmol  c 
RP OP lost AChE 0   mg 
RP OP lost BuChE 0   mg 
RP OP lost CaE 0   mg 
RP OP lost Metab 0   mg 
Free RP AChE 8.32  nmol  b 
Inhibited RP AChE 0   nmol 
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OP in RP 0   mg 
Synthesis of RP CaE 88.608  nmol 
Synthesis of RP BuChE 205.92  nmol 
Synaptic RP ACh 0.100  nmol 
Fat 
OP in Fat 0   mg 
Slowly Perfused Tissues 
SP ACh Release Rate 0.013998 nmols/hr 
SP AChE Homeostatic State 233.87  nmol  c 
SP AChE Synthesis Rate 0.053  nmol/hr a 
SP BuChE 200.46  nmol  b 
SP CaE 76843  nmol  b 
SP ACh Homeostatic State 0.100  nmol  c 
SP OP lost AChE 0   mg 
SP OP lost BuChE 0   mg 
SP OP lost CaE 0   mg 
Free SP AChE 233.87  nmol  b 
Inhibited SP AChE 0   nmol 
OP in SP 0   mg 
Synthesis of SP CaE 76843  nmol 
Synthesis of SP BuChE 200.46  nmol 
Synaptic SP ACh 0.100  nmol 
 194 
Diaphragm 
Diaphragm ACh Release Rate 0.0117162 nmol/hr 
Diaphragm AChE Homeostatic State 1.065  nmol 
Diaphragm AChE Synthesis Rate 0.053  nmol/hr 
Diaphragm BuChE 2.343  nmol 
Diaphragm CaE 617.7  nmol 
Diaphragm ACh Homeostatic State 0.100  nmol 
Diaphragm OP lost AChE 0   mg 
Diaphragm OP lost BuChE 0   mg 
Diaphragm OP lost CaE 0   mg 
Free Diaphragm AChE 1.065  nmol 
Inhibited Diaphragm AChE 0   nmol 
OP in Diaphragm 0   mg 
Synthesis of Diaphragm CaE 617.7  nmol 
Synthesis of Diaphragm BuChE 2.343  nmol 
Synaptic Diaphragm ACh 0.100  nmol 
Venous Blood Flow 
Initial quantity of VB AChE 3.85416  (nM - hr)-1 a 
Initial quantity of VB BuChE 19.2708  (nM - hr)-1 b 
Initial quantity of VB CaE 161187.47 (nM - hr)-1 b 
VB inhibition rate for AChE 0.4248  nmol  b 
VB inhibition rate for BuChE 0.01416  nmol  b 
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VB inhibition rate for CaE 0.00108  nmol  b 
VB OP lost enzymes 0   nmol  b 
Bronchial 
OP in bronchial tissue 0   mg 
Bronchial BFC 0.0417  Unitless e 
Bronchial Vol 0.17484  l  e 
Dermal 
OP in the skin 0   mg 
Skin BFC 0.058  Unitless d 
Vol of skin 2.2  l  d 
 
a. Gearhart, 1994 
b. Gentry, 2002 
c. Potter, 1970 
d. Poet, 2004 
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